Nova r t i s  In s t i tu te s  fo r  B ioMed i ca l  Re sea r ch
ACZ885
CACZ885X2205
A  mu l t ip le- dose ,  sub jec t-and  inves t iga to r- b l inded ,  
p lacebo- con t ro l led ,  pa ra l le l  des ign  s tudy to  assess  the  
e f f icacy , sa fe ty,  and  to le rab i l i ty  o f  ACZ885  (canak inumab )  
in  pa t ien ts  w i th  pu lmona r y  sa rco idos is
Documen t  type :  AmendedP ro to co lVe r s ion
EUDRACT  numbe r :  2016- 001255- 49
Ve rs ion  numbe r :  v01  ( C lean)
C l in ica l  T r ia l  Phase :  I I
Re lease  da te : 12- Jun- 2017
P rope r ty  o f  Nova r t is
Con f iden t ia l
May  no t  be  used ,  d ivu lged ,  pub l ished ,  o r  o the rw ise  d isc losed
w i thou t  the  consen t  o f  Nova r t is
No va r t i s Con f iden t ia l Page  2
Amended  P ro toco l  Ve rs ion  01  (C lean ) P ro toco l  No .  CACZ885X2205
S i te  Ope ra t ions  Manua l  (SOM )
A  S i t e  Op e r a t ion s  M anu a l  (SOM )  a c comp an i e s  th i s  p ro to co l ,  p rov id ing  th e  op e r a t ion a l  d e t a i l s  
fo r  s tudy  condu c t .
Add i ti ona l  Manua ls
D e t a i l s  f o r  HRCT  a n d  [F- 1 8 ]FDG - PET /CT  im a g i n g  a r e  d e s c r i b e d  i n  t h e  P a r e x e l  Im ag ing  
I n v e s t i g a t o r  SOM .
De t a i l s  on  pu lmon a ry  f u n c t i o n  t e s t i n g  a r e  d e s c r i b e d  i n  t h e  B i om e d i c a l  S y s t em s  C en t r a l i z ed  
Sp i rom e t ry,  DL c o ,  a n d  L u n g  V o l um e s  P r o c e d u r e  M a n u a l.
F o r  d e t a i l s  o n  r e c e i p t ,  s t o r a g e  a n d  h a n d l i n g  o f  s tudy  m ed i c a t ion  p l e a s e  r e f e r  to  t h e  Ph a rm a cy  
M a n u a l .
F o r  t r e a tm e n t  a s s ignm en t  a n d  r a n d om i z a t i o n  p l e a s e  r e f e r  to  C e n d u i t  I n t e r a c t i v e  R e spon s e  
T e chno logy ( IRT )  M anu a l
No t i f ica t ion  o f  se r ious  adve rse  even ts
R e f e r  to  S e c t i o n  9 . 2o f  t h e  p r o t o c o l  f o r  d e f i n i t i o n s  a n d  r e p o r t i n g  r e q u i r em e n t s  f o r  S e r i o u s  
A d v e r s e  E v e n t s  (w i t h i n  2 4  h o u r s  a f t e r  aw a r e n e s s  o f  t h e  SAE  t o  t h e  l o c a l  N o v a r t i s  D r u g  S a f e ty  
and  Ep id em io logy  D ep a r tm en t  and  no t i fy  th e  s tudy  l e ad ) .
C o n t a c t  i n f o rm a t i o n  i s  l i s t e d  i n  t he  S i t e  O p e r a t i o n s  M a n u a l .  Co rpo ra te  Con f iden t ia l  In fo rma t ion
No va r t i s Con f iden t ia l Page  3
Amended  P ro toco l  Ve rs ion  01  (C lean ) P ro toco l  No .  CACZ885X2205
Tab le  o f  con ten ts
S i t e  O p e r a t i o n s  M a n u a l  (SOM ) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .2
N o t i f i c a t i o n  o f  s e r i o u s  a d v e r s e  e v e n t s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2
T a b l e  o f  c o n t e n t s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3
L i s t  o f  t a b l e s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6
L i s t  o f  f i g u r e s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7
L i s t  o f  a b b r e v i a t i o n s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8
P h a rm a c o k i n e t i c  d e f i n i t i o n s  a n d  s ymbo l s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 2
G lo s s a ry o f  t e rm s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 3
P ro to co l  synop s i s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 8
1 I n t r o d u c t i o n. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 1
1 . 1 B a c k g r o u n d. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 1
1 . 2 N o n c l i n i c a l  d a t a. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 4
1 . 2 . 1 T e r a tog en i c i ty and  r ep rodu c t iv e  tox i c i ty  d a t a . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 4
1 . 3 C l i n i c a l  d a t a. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 4
1 . 3 . 1 H um a n  s a f e ty  and  to l e r ab i l i ty  d a t a . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 4
1 . 3 . 2 H um a n  p h a rm a c o k i n e t i c  d a t a . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .2 5
1 . 3 . 3 H um a n  p h a rm a c o dy n am i c  d a t a. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 5
1 . 4 S tudy pu rpo s e . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 5
2 S tudy ob j e c t iv e s  and  endpo in t s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 6
2 . 1 P r im a ry ob j e c t iv e . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 6
2 . 2 S e cond a ry o b j e c t i v e s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 6
2 . 3 Exp lo r a to ry o b j e c t i v e s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 9
3 I n v e s t i g a t i o n a l  p l a n. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 0
3 . 1 S tudy d e s ign . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 0
3 . 2 R a t i o n a l e  f o r  s t u dy  d e s i g n. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 2
3 . 3 R a t i o n a l e  f o r  d o s e / r e g im e n ,  r o u t e  o f  a dm i n i s t r a t i o n  a n d  d u r a t i o n  o f  t r e a tm e n t. . . . 3 2
3 . 4  R a t i o n a l e  f o r  c h o i c e  o f  c om p a r a t o r . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 2
3 . 5 R a t i o n a l e  f o r  c h o i c e  o fb a ckg round  th e r apy. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 3
3 . 6 P u r p o s e  a n d  t im i n g  o f  i n t e r im  a n a ly se s /d e s ign  ad ap t a t ion s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 3
3 . 7 R i s k s  a n d  b e n e f i t s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 3
3 . 7 . 1 B l o o d  s am p l e  v o l um e s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 4
4 Popu l a t ion. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 4
4 . 1 I n c l u s i o n  c r i t e r i a. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 5
4 . 2 E x c l u s i o n  c r i t e r i a. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 5Co rpo ra te  Con f iden t ia l  In fo rma t ion
No va r t i s Con f iden t ia l Page  4
Amended  P ro toco l  Ve rs ion  01  (C lean ) P ro toco l  No .  CACZ885X2205
5 R e s t r i c t ion s  fo r  S tudy S u b j e c t s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 8
5 . 1 C o n t r a c e p t i o n  r e q u i r em e n t s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 8
5 . 2 P r o h i b i t e d  t r e a tm e n t. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 8
5 . 3 D i e t a ry r e s t r i c t ion s  and  smok ing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 8
5 . 4 O t h e r  r e s t r i c t i o n s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 8
6 T r e a tm e n t. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 9
6 . 1 S tudy t r e a tm e n t . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 9
6 . 1 . 1 I n v e s t i g a t i o n a l  t r e a tm e n t  a n d  c o n t r o l  d r u g s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 9
6 . 1 . 2 Add i t ion a l  s tudy t r e a tm e n t . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 9
6 . 2 T r e a tm e n t  a rm s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 9
6 . 3 T r e a tm e n t  a s s i g nm e n t  a n d  r a n d om i z a t i o n . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .3 9
6 . 4 T r e a tm e n t  b l i n d i n g. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 0
6 . 5 T r e a t i n g  t h e  s u b j e c t. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 1
6 . 6 P e rm i t t e d  d o s e  a d j u s tm e n t s  a n d  i n t e r r u p t i o n s  o f  s t u d y t r e a tm e n t . . . . . . . . . . . . . . . . . . . . . . . . . 4 1
6 . 7 Em e rg en cy b r e a k i n g  o f  a s s i g n e d  t r e a tm e n t  c o d e . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 2
6 . 8 T r e a tm e n t  e x p o s u r e  a n d  c om p l i a n c e. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 2
6 . 9 R e c omm e n d e d  t r e a tm e n t  o f  a d v e r s e  e v e n t s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 2
6 . 1 0 R e s c u e  m e d i c a t i o n . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .4 2
6 . 1 1 C o n c om i t a n t  t r e a tm e n t. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 3
7 S tudy comp l e t ion  and  d i s con t inu a t ion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 4
7 . 1 S tudy comp l e t ion  and  po s t - s tudy  t r e a tm e n t . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 4
7 . 2 D i s con t inu a t ion  o f  s tudy t r e a tm e n t . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 4
7 . 3 W i t h d r aw a l  o f  i n f o rm e d  c o n s e n t. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 5
7 . 4 L o s t  t o  f o l l ow- u p . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 5
7 . 5 S tudy S t o p p i n g  r u l e s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 5
7 . 6 E a r ly  s t u d y  t e rm i n a t i o n  b y  t h e  s p o n s o r. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 6
8 P r o c e d u r e s  a n d  a s s e s sm e n t s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 7
8 . 1 A s s e s sm e n t  S c h e d u l e. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 7
8 . 2 I n f o rm e d  c o n s e n t  p r o c e d u r e s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 0
8 . 3 S u b j e c t  s c r e e n i n g . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 0
8 . 4 S u b j e c t  d em o g r a p h i c s / o t h e r  b a s e l i n e  c h a r a c t e r i s t i c s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .5 1
8 . 4 . 1 H e p a t i t i s  s c r e e n ,  H IV  s c r e e n ,  t u b e r c u l o s i s  s c r e e n . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .5 1
8 . 4 . 2   A l c o h o l  t e s t ,  d r u g  s c r e e n ,  u r i n e  c o t i n i n e . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .5 1
8 . 5 E f f i c a cy/P h a rm a c o d y nam i c s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 1
8 . 5 . 1 C l i n i c a l  O u t c om e  A s s e s sm e n t s  (COA s ). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 1
8 . 5 . 2 Im a g i n g. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 3
8 . 5 . 3 S i x- m inu t e  w a l k  t e s t  ( 6MWT ). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 4
No va r t i s Con f iden t ia l Page  5
Amended  P ro toco l  Ve rs ion  01  (C lean ) P ro toco l  No .  CACZ885X2205
8 . 5 . 4 S e rum  IL- 1β . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 5
8 . 5 . 5 Pu lmon a ry fun c t ion  t e s t ing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 5
8 . 6 S a f e ty. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 7
8 . 6 . 1 Phys i c a l  e x am i n a t i o n. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 7
8 . 6 . 2 V i t a l  s i g n s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 7
8 . 6 . 3 H e i g h t  a n d  w e i g h t. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 7
8 . 6 . 4 L abo r a to ry e v a l u a t i o n s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 7
8 . 6 . 5 E l e c t r o c a r d i o g r am  (ECG ). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 8
8 . 6 . 6 P r egn an cy and  a s s e s sm en t s  o f  f e r t i l i ty . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 8
8 . 6 . 7 Immunog en i c i ty  (An t i - ACZ 8 8 5  A n t i b o d i e s ) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .5 8
8 . 6 . 8 L oc a l  t o l e r a b i l i t y  ( s u b c u t a n e o u s  i n j e c t i o n s ). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 9
8 . 7 P h a rm a c o k i n e t i c s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 9
8 . 8 O t h e r  a s s e s sm e n t s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 0
8 . 8 . 1 Exp lo r a to ry b i om a r k e r  a s s e s sm e n t s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 0
8 . 9 U s e  o f  r e s i d u a l  b i o l o g i c a l  s am p l e s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 1
9 S a f e ty  m o n i t o r i n g. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 2
9 . 1 A d v e r s e  e v e n t s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 2
9 . 2 S e r i o u s  a d v e r s e  e v e n t  r e p o r t i n g. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 3
9 . 2 . 1 D e f i n i t i o n  o f  SAE. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 3
9 . 2 . 2 SAE  r e p o r t i n g. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 4
9 . 3 L iv e r  s a f e ty mon i to r ing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 5
9 . 4 R e n a l  s a f e ty  m o n i t o r i n g. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 6
9 . 5 R e p o r t i n g  M e d i c a t i o n  e r r o r s  i n c l u d i n g  m i s u s e / a b u s e. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 6
9 . 6 P r egn an cy r epo r t ing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 7
9 . 7 E a r ly  p h a s e  s a f e ty  m o n i t o r i n g. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 7
1 0D a t a  r e v i ew  a n d  d a t a b a s e  m a n a g em e n t. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 8
1 0 . 1 S i t e  mon i to r ing. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 8
1 0 . 2 D a t a  c o l l e c t i o n . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .6 8
1 0 . 3 D a t ab a s e  m an ag em en t  and  qu a l i ty c o n t r o l . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 9
1 0 . 4 D a t a  M o n i t o r i n g  C omm i t t e e. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 9
1 0 . 5 A d j u d i c a t i o n  C omm i t t e e. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 0
1 0 . 5 . 1 I n f e c t i o n  A d j u d i c a t i o n  C omm i t t e e . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 0
1 0 . 5 . 2 M a l ign an cy Ad jud i c a t ion  Comm i t t e e . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 0
1 1D a t a  an a lys i s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 0
1 1 . 1 An a lys i s  s e t s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 0
1 1 . 2 S u b j e c t  d em o g r a p h i c s  a n d  o t h e r  b a s e l i n e  c h a r a c t e r i s t i c s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .7 0
1 1 . 3 T r e a tm e n t s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 0
No va r t i s Con f iden t ia l Page  6
Amended  P ro toco l  Ve rs ion  01  (C lean ) P ro toco l  No .  CACZ885X2205
1 1 . 4 An a lys i s  o f  th e  p r im a ry  v a r i ab l e ( s ) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 1
1 1 . 4 . 1 V a r i a b l e ( s ). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 1
1 1 . 4 . 2 S t a t i s t i c a l  mod e l ,  hyp o t h e s i s ,  a n d  m e t h o d  o f  a n a l y s i s. . . . . . . . . . . . . . . . . . . . . . . . . . 7 1
1 1 . 4 . 3 H a n d l i n g  o f  m i s s i n g  v a l u e s / c e n s o r i n g / d i s c o n t i n u a t i o n s. . . . . . . . . . . . . . . . . . . . . . . 7 1
1 1 . 4 . 4 S en s i t iv i ty an a l y se s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 1
1 1 . 5 An a lys i s  o f  s e cond a ry  v a r i a b l e ( s ) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 2
1 1 . 5 . 1 E f f i c a cy /  P h a rm a c o d y nam i c s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 2
1 1 . 5 . 2 S a f e ty . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 3
1 1 . 5 . 3 P h a rm a c o k i n e t i c s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 3
1 1 . 5 . 4 P h a rm a c o k i n e t i c / p h a rm a c o d yn am i c  in t e r a c t ion s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 4
1 1 . 5 . 5 O t h e r  a s s e s sm e n t s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 4
1 1 . 6 An a lys i s  o f  exp lo r a to ry  v a r i a b l e s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 4
1 1 . 6 . 1 Exp lo r a to ry b i om a r k e r s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 4
1 1 . 7 S am p l e  s i z e  c a l c u l a t i o n . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .7 4
1 1 . 8 P ow e r  f o r  a n a ly si s  o f  k ey  s e cond a ry  v a r i ab l e s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 5
1 1 . 9 I n t e r im  a n a l y se s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 5
1 2E t h i c a l  c o n s i d e r a t i o n s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 5
1 2 . 1 R egu l a to ry  and  e th i c a l  comp l i an c e. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 5
1 2 . 2 R e s p o n s i b i l i t i e s  o f  t h e  i n v e s t i g a t o r  a n d  IR B / IEC. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 5
1 2 . 3 Pub l i c a t ion  o f  s tudy p r o t o c o l  a n d  r e s u l t s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 6
1 3P r o to c o l  a d h e r e n c e. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 6
1 3 . 1 P r o t o c o l  Am e n dm e n t s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 6
1 4R e f e r e n c e s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 7
1 5App end ix  1 :  Li v e r  E v e n t  d e f i n i t i o n s  a n d  f o l l ow - u p  r e q u i r em e n t s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8 2
1 6A p p en d i x  2 :  S p e c i f i c  R e n a l  a l e r t  c r i t e r i a  a n d  a c t i o n s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8 4
L is t  o f  tab les
T a b l e  5- 1  P r o h i b i t e d  t r e a tm e n t. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 8
T a b l e  6- 1  B l i n d i n g  l e v e l s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 1
T a b l e  9- 1  Summ a ry o f  r e p o r t i n g  r e q u i r em e n t s  f o r  m e d i c a t i o n  e r r o r s . . . . . . . . . . . . . . . . . . . 6 7
T a b l e  1 5- 1  L i v e r  E v e n t  d e f i n i t i o n s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8 2
T a b l e  1 5- 2  A c t i o n s  r e q u i re d  f o r  L i v e r  E v e n t s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8 2
T a b l e  1 5- 3  Ex c lu s ion  o f  und e r lyi n g  l i v e r  d i s e a s e . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8 3
T a b l e  1 6- 1  S p e c i f i c  R e n a l  a l e r t  c r i t e r i a  a n d  a c t i o n s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8 4
T a b l e  1 6- 2  F o l l ow- up  o f  r en a l  ev en t s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8 5
No va r t i s Con f iden t ia l Page  7
Amended  P ro toco l  Ve rs ion  01  (C lean ) P ro toco l  No .  CACZ885X2205
L is t  o f  f igu res
F i g u re  1 - 1  Immunoh i s to ch em i s t ry  s t a i n i n g  o f  s a r c o i d o s i s  l u n g  b i o p s y  t i s s u e. . . . . . . 2 3
F i g u r e  3- 1  S tudy D e s ign  s ch em e . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 0
No va r t i s Con f iden t ia l Page  8
Amended  P ro toco l  Ve rs ion  01  (C lean ) P ro toco l  No .  CACZ885X2205
L is t  o f  abb rev ia t ions
γ - GT G amm a- g l u t amy l t r a n s f e r a s e
6MWT  6 - m i n u t e  w a l k  t e s t
[F - 1 8 ]FDG - PET f l u o r i n e - [ADDRESS_426676] a s p a r t a t e  am i n o t r a n s f e r a s e
ATS /ERS  Am e r i c an  Tho r a c i c  So c i e ty/Eu rop e an  R e sp i r a to ry  So c i e ty
AUC a r e a  u n d e r  t h e  c u r v e
BAL b r o n c h o a l v e o l a r  l a v a g e
BDR b io an a ly t i c a l  d a t a  r e p o r t
BTPS B o dy  t em p e r a t u r e ,  am b i e n t  p r e s s u r e ,  s a tu r a t e d  w i t h  w a t e r  v a p o r
BUN b l o o d  u r e a  n i t r o g e n
CAPS c r y o py r i n - a s so c i a t ed  p e r iod i c  sy nd rom e s
CD- ROM  c om p a c t  d i s c  –r e a d  o n l y  m em o r y
CFR C o d e  o f  F e d e r a l  R e g u l a t i o n
CK c r e a t i n i n e  k i n a s e
cm c e n t im e t e r s
CO2c a r b o n  d i o x i d e
CR c om p l e t e  r e s p o n s e
CRF C a s e  R e p o r t /R e c o r d  F o rm  ( p a p e r  o r  e l e c t r o n i c )
CRO c o n t r a c t  r e s e a r c h  o r g a n i z a t i o n
CT c om p u t e d  t om o g r a p h yCo rpo ra te  Con f iden t ia l  In fo rma t ion
Co rpo ra te  Con f iden t ia l  In fo rma t ion
Co rpo ra te  Con f iden t ia l  In fo rma t ion
No va r t i s Con f iden t ia l Page  9
Amended  P ro toco l  Ve rs ion  01  (C lean ) P ro toco l  No .  CACZ885X2205
CTC Common  Tox i c i ty C r i t e r i a
CV c o e f f i c i e n t  o f  v a r i a t i o n
CXR c h e s t  X - r ay
DL c o  d i f f u s i n g  c a p a c i t y  fo r  c a rbonmonox id e
DAR d o s e  a dm i n i s t r a t i o n  r e c o r d
EC e t h i c s  c omm i t t e e
ECG e l e c t r o c a r d i o g r am
EDC e l e c t r o n i c  da t a  c a p t u r e
EL ISA  e n zy m e- l ink ed  immuno so rb en t  a s s ay
EOS end  o f  s tudy  v i s i t
ePRO e l e c t r o n i c  p a t i e n t  r e p o r t e d  o u t c om e
FCAS f am i l i a l  c o ld  a u to in f l amm a to ry  s y n d r om e
FDA F o o d  a n d  D r u g  A dm i n i s t r a t i o n
FDG f l u o r o d e o x y g l u c o s e
FEF 2 5- 7 5f o r c e d  exp i r a to ry  f l ow  2 5% - 7 5%  FEV 1  f o r c e d  exp i r a to ry  v o l um e  in  1  
s e c o n d
FEV 3 f o r c e d  e x p i r a t o r y  vo lum e  in  3s e c o n d s
FVC f o r c e d  v i t a l  c a p a c i t y
FVC%  f o r c e d  v i t a l  c a p a c i t y  ( e x p r e s s e d  a s  p e r c e n t  o f  n o rm a l  e x p e c t e d  v a l u e )
GCP g o o d  c l in i c a l  p r a c t i c e
h h o u r
HB sA g  h e p a t i t i s  B  s u r f a c e  a n t i g e n
HCV h e p a t i t i s  C  v i r u s
H IV h um a n  imm u n o d e f i c i e n c y  v i r u s
HRCT h i g h  r e s o l u t i o n  c om p u t e d  t om o g r a p h y
i .v . i n t r a v e n o u s
IAC i n f e c t i o n  a d j u d i c a t i o n  c omm i t t e e
IB i n v e s t i g a t o r ' s  b ro chu r e
ICHI n t e r n a t i o n a l  C o n f e r e n c e  o n  H a rmon i z a t ion  o f  T e chn i c a l  R equ i r em en t s  
f o r  R e g i s t r a t i o n  o f  P h a rm a c e u t i c a l s  f o r  H um a n  U s e
IEC i n d e p e n d e n t  e t h i c s  c omm i t t e eCo rpo ra te  Con f iden t ia l  In fo rma t ion
No va r t i s Con f iden t ia l Page  10
Amended  P ro toco l  Ve rs ion  01  (C lean ) P ro toco l  No .  CACZ885X2205
IL i n t e r l e u k i n
IN I n v e s t i g a t o r  N o t i f i c a t i o n
IR B i n s t i tu t ion a l  r e v i ew  b o a rd
IRT i n t e r a c t i v e  r e s p o n s e  t e chno logy
IT F im a g e  t r a n sm i t t a l  f o rm
IU D i n t r a u t e r i n e  d e v i c e
IUS i n t r a u t e r i n e  s y st em
k g k i l o g r am s
LDH l a c t a t e  d e h y dr o g e n a s e
LFT l i v e r  f u n c t i o n  t e s t
LLN l ow e r  l im i t  o f  n o rm a l
MAC ma l ign an cy  a d j u d i c a t i o n  c omm i t t e e
M e dDRA  me d i c a l  d i c t ion a ry  fo r  r egu l a to ry  a c t i v i t i e s
mg m i l l i g r am ( s )
m l m i l l i l i t e r ( s )
MMRC  Mo d i f i e d  M e d i c a l  R e s e a r c h  C o u n c i l
MR I M a g n e t i c  r e s o n a n c e  im a g i n g
MWS M u c k l e  W e l l s  s y n d r om e
PA p o s t e r o a n t e r i o r
PD p h a rm a c o dy nam i c ( s )
PET p o s i t r o n  em i s s i o n  t om o g r a p h y
PFT pu lmon a ry  fun c t ion  t e s t
PK p h a rm a c o k i n e t i c ( s )
PR p a r t i a l  r e s p o n s e
PRO p a t i e n t  r e p o r t e d  o u t c om e
RA r h e um a t o i d  a r t h r i t i s
RBC r e d  b l o o d  c e l l ( s )
REB r e s e a r c h  e t h i c s  b o a r d
RO I r e g i o n  o f  i n t e r e s tCo rpo ra te  Con f iden t ia l  In fo rma t ion
Co rpo ra te  Con f iden t ia l  In fo rma t ion
Co rpo ra te  Con f iden t ia l  In fo rma t ion
No va r t i s Con f iden t ia l Page  11
Amended  P ro toco l  Ve rs ion  01  (C lean ) P ro toco l  No .  CACZ885X2205
RV r e s i d u a l  v o l um e
s . c . s u b c u t a n e o u s
SAE s e r i o u s  a d v e r s e  e v e n t
SAP s t a t i s t i c a l  a n a l y s i s  p l a n
SD s t a n d a r d  d e v i a t i o n
s J I A sy s t em i c  j u v e n i l e  i d i o p a t h i c  a r t h r i t i s
SOM s i t e  o p e r a t i o n s  ma n u a l
S[LOCATION_003]R  s u s p e c t e d  u n e x p e c t e d  s e r i o u s  a d v e r s e  r e a c t i o n
SUVm a x  m a x im um  s t a n d a r d i z e d  u p t a k e  v a l u e
TB t u b e r c u l o s i s
TBL to t a l  b i l i rub in
TLC t o t a l  l u n g  c a p a c i t y
ULN u p p e r  l im i t  o f  n o rm a l
ULQ u p p e r  l im i t  o f  q u a n t i f i c a t i o n
VA a l v e o l a r  v o l um e
VD d e a d  s p a c e  v o l um e  
VT t id a l  vo lum e
WBC w h i t e  b l o o d  c e l l ( s )Co rpo ra te  Con f iden t ia l  In fo rma t ion
No va r t i s Con f iden t ia l Page  12
Amended  P ro toco l  Ve rs ion  01  (C lean ) P ro toco l  No .  CACZ885X2205
Pha rmacok ine t ic  de f in i t ions  and  symbo ls
C    T h e  s e r um  t r o u g h  c o n c e n t r a t i o n  d u r i n g  m u l t i p l e  d o s i n g  [m a s s  /  v o l um e ]
C a v  T h e  o b s e r v e d  a v e r a g e  s e r um  c o n c e n t r a t i o n  f o l l ow i n g  d r u g  a dm i n i s t r a t i o n
CLT h e  sy s t em i c  ( o r  to t a l  body )  c l e a r a n c e  f rom  p l a sm a  ( o r  s e r um  o r  b l o o d )  f o l l ow i n g  
i n t r a v e n o u s  a dm i n i s t r a t i o n  [ v o l um e  /  t im e ]
Cm a xT h e  o b s e r v e d  m ax imum  p l a sm a  ( o r  s e r um  o r  b lood )  c o n c e n t r a t i o n  f o l l ow i n g  d rug  
a dm i n i s t r a t i o n  [m a s s  /  v o l um e ]
V s sT h e  v o l um e  o f  d i s t r ibu t ion  a t  s t e a d y  s t a t e  f o l l ow i n g  i n t r a v e n o u s  adm in i s t r a t ion  
[vo lum e ]
No va r t i s Con f iden t ia l Page  13
Amended  P ro toco l  Ve rs ion  01  (C lean ) P ro toco l  No .  CACZ885X2205
G lossa ry o f  te rms
C o n t r o l  d r u gA  s tudy  d rug  u s e d  a s  a  c om p a r a t o r  to  r e d u c e  a s s e s sm en t  b i a s ,  p r e s e r v e  
b l i n d i n g  o f  inv e s t ig a t ion a l  d r u g ,  a s s e s s  in t e rn a l  s tudy  v a l id i ty ,  a n d / o r  
e v a l u a t e  c om p a r a t i v e  e f f e c t s  o f  t h e  i n v e s t i g a t i o n a l  d r u g .
E n r o l lm e n tP o i n t / t im e  o f  s u b j e c t  en t ry  i n to  th e  s tudy ;  th e  po in t  a t  w h i c h  in f o rm ed  
c o n s e n t  mu s t  b e  ob t a in ed  ( i . e .  p r i o r  to  s t a r t ing  a n y  o f  t h e  p ro c edu r e s  
d e s c r i b e d  i n  t h e  p r o t o c o l ) .
I n v e s t i g a t i o n a l  
d r u gT h e  s tudy  d rug  who s e  p r o p e r t i e s  a r e  b e ing  t e s t e d  in  th e  s tudy ;  th i s  
d e f in i t ion  i s  con s i s t en t  w i th  US  CFR  21  S e c t ion  312 .3  and  i s  sy nony mou s  
w i t h  “ i n v e s t i g a t i o n a l  n ew  d r u g ”  o r  “ i n v e s t i g a t i o n a l  m e d i c i n a l  p r o d u c t ” .
I n v e s t i g a t i o n a l  
t r e a tm e n tA l l  i n v e s t i g a t i o n a l  d r u g ( s )  w h o s e  p r o p e r t i e s  a r e  b e i n g  t e s t ed  in  t h e  s tudy  
a s  w e l l  a s  t h e i r  a s s o c i a t e d  t r e a tm e n t  c o n t r o l s .  Th i s  i n c l u d e s  any  p l a c e b o s ,  
any  a c t i v e  c o n t r o l s ,  a s  w e l l  a s  a p p r o v e d  d rug s  u s e d  o u t s i d e  o f  th e i r  
i n d i c a t i o n / a p p r o v e d  do s ag e  o r  t e s t ed  in  a  f ix ed  c om b i n a t i o n .  
I n v e s t i g a t i o n a l  t r e a tm e n t  g e n e r a l ly  do e s  no t  i n c l u d e  o t h e r  t r e a tm e n t s  
a dm i n i s t e r e d  a s  c o n c om i t a n t  b a c k g r o u n d  t h e r a p y  r e q u i r e d  o r  a l l ow e d  b y  
t h e  p r o t o c o l  w h e n  u s e d  w i t h i n  a p p r o v e d  i n d i c a t i o n / d o s a g e .
M e d i c a t i o n  
n um b e rA  u n i q u e  i d e n t i f i e r  on  th e  l ab e l  o f  e a ch  s tudy  d rug  p a ck ag e  in  s tud i e s  th a t  
d i sp en s e  s tudy  d r u g  u s i n g  a n  IR T  sys t em .
P e r i o dA  m i n o r  subd iv i s ion  o f  t h e  s tudy  t im e l in e ;  d i v i d e s  p h a s e s  in to  sm a l l e r  
f u n c t i o n a l  s e gm e n t s  s u c h  a s  s c r e e n i n g ,  b a s e l i n e ,  t i t r a t i o n ,  w a s h o u t ,  e t c .
P r em a t u r e  
s u b j e c t  
w i t h d r aw a lP o i n t / t im e  w h e n  t h e  s u b j e c t  ex i t s  f r om  t h e  s tudy  p r i o r  to  t h e  p l a n n e d  
c om p l e t i o n  o f  a l l  s tudy  d r u g  a dm i n i s t r a t i o n  and  a s s e s sm e n t s ;  a t  th i s  t im e  
a l l  s tudy  d r u g  adm in i s t r a t ion  i s  d i s c o n t i n u e d  a n d  n o  f u r t h e r  a s s e s sm e n t s  
a r e  p l a n n e d .
R andom i z a t ion  
n um b e rA  u n i q u e  i d e n t i f i e r  a s s i g n e d  t o  e a c h  r a n d om i z e d  s u b j e c t ,  c o r r e s p o n d i n g  t o  
a  s p e c i f i c  t r e a tm e n t  a rm  a s s i g nm e n t
S t a g eAm a j o r  subd iv i s ion  o f  t h e  s tudy  t im e l i n e ;  b eg in s  a n d  e n d s  w i th  m a jo r  
s tudy  m i l e s t o n e s  su ch  a s  e n r o l lm e n t ,  r andom i z a t ion ,  c om p l e t i o n  o f  
t r e a tm e n t ,  e t c .
S tudy comp l e t ionP o i n t / t im e  a t  w h i c h  th e  s u b j e c t  c am e  in  f o r  a  f i n a l  e v a l u a t i o n  v i s i t  o r  
wh en  s tudy d rug w a s  d i s c o n t i n u e d  w h i c h e v e r  i s  l a t e r .
S tudy d rug  
d i s c o n t i n u a t i o nP o i n t / t im e  w h e n  sub j e c t  p e rm a n e n t ly  s top s  t a k i n g  s tudy  d r u g  f o r  a n y  
r e a s o n ;  m ay o r  m ay n o t  a l s o  b e  t h e  p o i n t / t im e  o f  p r em a t u r e  s u b j e c t  
w i t h d r aw a l .
S tudy 
d r u g / t r e a tm e n tAny d r u g  ( o r  comb in a t ion  o f  d r u g s )  a dm i n i s t e r e d  to  t h e  s u b j e c t  a s  p a r t  o f  
t h e  r e q u i r e d  s tudy  p ro c edu r e s ;  i n c l u d e s  i n v e s t i g a t i o n a l  d r u g ,  a c t i v e  d r u g  
r u n - in s  o r  b a ckg round  th e r apy .
No va r t i s Con f iden t ia l Page  14
Amended  P ro toco l  Ve rs ion  01  (C lean ) P ro toco l  No .  CACZ885X2205
S u b j e c tA n  i n d i v i d u a l  w h o  h a s  c o n s e n t e d  to  p a r t i c i p a t e  in  th i s  s tudy .  T h e  t e rm  
S u b j e c t  m ay b e  u s ed  to  d e s c r ib e  e i th e r  a  h e a l thy  v o l u n t e e r  o r  a  p a t i e n t .
S u b j e c t  n um b e rA  n um b e r  a s s i g n e d  to  e a c h  sub j e c t  w h o  en ro l l s  in  t h e  s tudy .  Wh en  
c om b i n e d  w i th  th e  c en t e r  numb e r ,  a  u n i q u e  i d e n t i f i e r  i s  c r e a t e d  f o r  e a c h  
sub j e c t  in  th e  s tudy .
V a r i a b l eI n f o rm a t i o n  u s e d  in  th e  d a t a  an a ly s i s ;  d e r i v e d  d i r e c t ly  o r  ind i r e c t l y  f r om  
d a t a  c o l l e c t e d  u s i n g  s p e c i f i e d  a s s e s sm e n t s  a t  s p e c i f i e d  t im e p o i n t s .
No va r t i s Con f iden t ia l Page  15
Amended  P ro toco l  Ve rs ion  01  (C lean ) P ro toco l  No .  CACZ885X2205
Co rpo ra te  Con f iden t ia l  In fo rma t ion
No va r t i s Con f iden t ia l Page  16
Amended  P ro toco l  Ve rs ion  01  (C lean ) P ro toco l  No .  CACZ885X2205
Co rpo ra te  Con f iden t ia l  In fo rma t ion
No va r t i s Con f iden t ia l Page  17
Amended  P ro toco l  Ve rs ion  01  (C lean ) P ro toco l  No .  CACZ885X2205
Co rpo ra te  Con f iden t ia l  In fo rma t ion
No va r t i s Con f iden t ia l Page  18
Amended  P ro toco l  Ve rs ion  01  (C lean ) P ro toco l  No .  CACZ885X2205
P ro toco l  synops is
P ro toco l  
numbe rCACZ885X2205
T i t le A  mul t ip le -do se ,  sub jec t-and  inves t iga to r - b l inded ,  p lacebo- con t ro l led ,  pa ra l le l  
des ign  s tudy  t o  assess  the  e f f icacy ,  sa fe ty  a nd  to le rab i l i ty  o f  ACZ885  
(canak inumab )  in  pa t ien ts  w i th  pu lmona ry  sa rco idos is
B r ie f  t i t le S tudy  o f  e f f icacy ,  sa fe ty  a nd  to le rab i l i t y  o f  ACZ885  (canak inumab )  in  pa t ien t s  w i th  
pu lmona r y  sa r co ido s i s
Sponso r  and  
C l in ica l  PhaseNo va r t i s
Phase  2
In te rven t ion  
typeD rug
S tudy  type In te rven t iona l  
Pu rpose  and  
ra t iona leThe  pu rpose  o f  th is  s tudy  i s  to  assess  i f  inh ib i t ion  o f  IL - 1β  by A CZ885  w i l l  im p rove  
lung  fun c t ion  in  assoc ia t ion  w i th  reduc t ion  o f  t i s sue  in f lamma t ion  in  pa t ien ts  w i th  
ch ron ic  sa rco idos is .
P r ima ry  
Ob jec t iveTo  compa re  the  e f fec t  o f  ACZ885  ve rsus  p lacebo  on  the  c l in ica l  d isease  ac t iv i ty  o f  
sa rco idos is  pa t ien tsas  measu red  by t he  change  f rom  ba se l ine  in  the  pe rcen t  
p red ic ted  fo rced  v i ta l  capac i ty  (FVC )  a t  week  [ADDRESS_426677] ized  
up take  va lue  (SUVmax )  ( [F -18 ]FDG - PET )  in  nodu les  (noda l  up take  reg ions )  a f te r  
[ADDRESS_426678]  sco r ing .
To  de te rmine  the  e f fec t  o f  ACZ885  ve rsus  p lacebo  on  the  6 -m inu te  wa lk  te s t  
d is tance  o f  pa t ien ts  w i th  sa rco idos is  a t  12  and  24  weeks  compa red  to  base l ine
To  de te rm ine  the  e f fec t  o f  ACZ885  on  add i t iona l  [F- 18 ]FDG- PET  ou tcomes  a f te r  12  
weeks  o f  t rea tmen t  compa red  to  p lacebo
To  assess  the  sa fe ty  a nd  to le rab i l i t y  o f  ACZ885  in  pa t ien t s  wi th  sa rco idos is  a s  
measu red  by  [CONTACT_343838]
S tudy  des ign Th is  i s  a  sub jec t-and  inves t iga to r - b l inded ,  random ized ,  p lacebo- con t ro l led ,  
pa ra l le l- g roup ,  non- con f i rma to ry  s tudy  t o  assess  the  c l in ica l  e f f icacy  o f  ACZ885  
admin is te red  subcu taneous ly  (s .c . )  eve ry  fou r  weeks  fo r  a  to ta l  o f  24  weeks .
No va r t i s Con f iden t ia l Page  19
Amended  P ro toco l  Ve rs ion  01  (C lean ) P ro toco l  No .  CACZ885X2205
Popu la t ion The  s tud y  w i l l  random ize  app rox ima te ly  38  pa t ien t s  w i th  rad io log ica l  ev idence  o f  
pa renchymal lyinvo lve d ,ch ron ic  pu lmona ry  sa rco idos is  o f  ≥1  yea r  du ra t ion  w i th  
pe rs is t ing  ac t iv i ty  a t  base l ine  desp i te  backg round  the rapy .
Inc lus ion  
c r i te r ia Ma le  and  fema le  sub jec ts  ages  18  to  80  yea rs  o f  age  ( inc lus ive )
 Sub jec ts  mus t  we igh  a t  leas t  50  kg  to  pa r t ic ipa te  in  thes tudy
 Ab le  to  commun ica te  we l l  w i th  the  inves t iga to r ,  to  unde rs tand  and  comp ly
w i th  the  requ i remen ts  o f  the  s tudy
 D isease  du ra t ion  o f  ≥1  yea r
 Cl in ica l ly  ac t ive  d isease  demons t ra ted  e i ther  by  a  b iopsy  (any  o rgan )  o r  by
b ronchoa lveo la rlavage  ( lymphocy tos is  >15% ,  CD4+/CD8+ra t io  >3 .5 ,
CD103+CD4+/CD4+ra t io  <0 .2 ) .  Pa t ien ts  mus t  a lso  have  a l l  o f  the  fo l low ing
c r i te r ia :
o Mod i f ied  Med ica l  Resea rch  Counc i l  (MMRC )  dyspnea  sca le  ≥  1
o Th resho ld  FVC  50  -90%  o f  p red ic ted
o Ev idence  o f  pa renchyma l  lung  invo lvemen t  by  [CONTACT_343839] t  sc reen ing
o r  by  h is to r ica l  rad io log ica l  ev idence
Exc lus ion  
c r i te r ia D iagnos is  o f  pu lmona ry  hype r tens ion  requ i r ing  t rea tmen t
 Cu r ren t  inha led  use  o f  tobacco  p roduc ts(u r ine  co t in ine  leve l  >  500
nanog rams /mL )  a t  sc reen ing
 H i s to r y  o f  b leed ing  d iso rde r
 Ex t ra- pu lmona ry  sa rco idos is  as  p r ima ry t rea tmen t  ind ica t ion  (e .g . ,  invo lv ing
b ra in ,  hea r t ,  eye  and  rena l  d isease  w i th  s ign i f ican t  hype rca lcem ia )
 Any  cond i t ions  o r  s ign i f ican t  med ica l  p rob lems ,  wh ich  in  the  op in ion  o f  the
inves t iga to r ,  immuno - comp romises  the  pa t ien t  and /o r  p laces  the  pa t ien t  a t
unaccep tab le  r isk  fo r  immunomodu la to ry  the rapy ,  such  as :
o Abso lu te  neu t roph i l  coun t  (ANC )  <  lowe r  l im i t  o fno rma l  (LLN )
(1 ,500 /μ l )
o P la te le ts  <  LLN  –75 .0  x  109/L
o Any  ac t ive  o r  recu r ren t  bac te r ia l ,  funga l  (w i th  excep t ion  o f
onychomy cos is )  o r  v i ra l  in fec t ion
o P resence  o f  human  immunode f ic iency  v i rus  (H IV )  in fec t ion ,  a c t i ve
hepa t i t is  B  o r  hepa t i t is  C  in fec t ions  based  on  sc reen ing  lab  resu l t
o P resence  o f  ac t ive  o r  la ten t  tube rcu los is  (TB )  C l in ica l  ev idence  o r
h is to ry  o f  mu l t ip le  sc le ros is  o r  o the r  demyel ina t ing  d iseases ,  o r  Fe l ty ’s
sy nd rome
L ive  vacc ina t ions  w i th in  3  mon ths  p r io r  tosc reen ing
Cu r ren t  seve re  p rog ressive  o r  uncon t ro l led  d isease  wh ich  in  the  judgmen t  o f  the
c l in ica l  inves t iga to r  rende rs  the  pa t ien t  unsu i tab le  fo r  the  t r ia l
Two  t rea tmen t  a rmsin  a  ra t io  o f  1 :1 :  canak inumab  ( ACZ885)ve rsus  p lacebo -
con t ro l led  dose  g roup
No va r t i s Con f iden t ia l Page  20
Amended  P ro toco l  Ve rs ion  01  (C lean ) P ro toco l  No .  CACZ885X2205
E f f icacy /PD  
assessmen tsPu lmona r y  f unc t ion  t es t ing
[F -18 ]FDG - PET /CT
HRCT
S i x-m inu te  wa lk  t es t  (6MWT )
Se rum  IL- 1β
Sa fe ty  
assessmen tsPhy sica l  exam ina t ion ,  inc lud ing  v i ta l  s igns  and  he igh t /we igh t
Hema to logy ,  c l in ica l  chem is t ry,  u r ina lys is
Loca l  to le rab i l i ty  o f  subcu taneous(s .c . )in jec t ions  o f  canak inumab /ACZ885
E lec t roca rd iog ram  (ECG )
O the r  
assessmen ts
Da ta  ana lys is The  p r ima ry  va r iab le  fo r  the  assessmen t  o f  e f f icacy  w i l l  be  the  change  f rom  
ba se l ine  in  the  pe rcen t  p red ic ted  FVC .  I t  w i l l  be  ana lyzed  us ing  a  Baye s ian  mode l  
fo r  repea ted  measu remen ts .  The  mode l  w i l l  inves t iga te  e f fec ts  fo r  ba se l ine  by t ime  
in te rac t ion ,  t rea tm en t  by t im e  in te rac t ion  and  PET  pos i t iv i ty  (y es /no )  p r io r  to  
random iza t ion .  Un in fo rma t ive  p r io rs  w i l l  be  u t i l ized  to  ob ta in  the  pos te r io r  
es t ima tes .  The  pos te r io r  p robab i l i ty  tha t  ACZ885  i s  be t te r  than  p lacebo  in  te rms  o f  
change  f rom  ba se l ine  in  pe rcen t  p red ic ted  FVC  a t  24  weeks  w i l l  be  ca lcu la ted .  I f  i t  
i s  a t  leas t  90% ,  i t  w i l l  be  cons ide red  a  s ign  o f  e f f i ca c y  o f  ACZ885  inc reas ing  FVC  
a f te r  24  weeks  o f  t rea tmen t  in  th is  pa t ien t  popu la t ion .
Key  wo rds Pu lmona ry  sa rco idos is ,  [F-18 ]FDG - PET /CT ,  IL- 1β ,  canak inumabCo rpo ra te  Con f iden t ia l  In fo rma t ion
No va r t i s Con f iden t ia l Page  21
Amended  P ro toco l  Ve rs ion  01  (C lean ) P ro toco l  No .  CACZ885X2205
1  In t roduc t ion
1 .1  Backg round
Ch ron ic  sa rco idos is
C h r o n i c  s a r co ido s i s  i s  a  sy s t em i c  d i s e a s e  c h a r a c t e r i z e d  by  d e v e l o pm e n t  o f  g r anu lom a s ,  
i n f l amm a t i o n  a n d  a c comp any ing  f i b r o t i c  t i s s u e  r e a c t i o n s  ( C h e n  and  M o l l e r 2 0 1 1 ) .  
A l t h o u g ha n y  o rg an  c an  b e  a f f e c t e d ,  mo s t  c omm o n  d i s e a s e  m an i f e s t a t ion s  a r e  found  in  lung ,  
sk in ,  a n d  ey e  t i s s u e s .  Ch ron i c  s a r co ido s i s  i s  a n  o r p h a n  d i s e a s e  w i th  a n  ov e r a l l  p r e v a l e n c e  in  
US  p o p u l a t i o n s  o f  8 /10 ,000 .  T h e r e  ex i s t  e t h n i c  d i f f e r e n c e s  in  d is e a s e  f r equ en cy  a n d  s e v e r i t y . 
T h ed i s e a s e  i s  mo r e  s ev e r e  a n d  f r equ en t  in  A f r i c a n  Am e ri c an s  th an  in  t h o s e  o f  
N o r t h e r nE u r o p e a n  d e s c en t  ( 2 . 4%  v s  0 .85%  l i f e t im e  r i s k )  w i th  r i s k  o f  d e a t h  u p  to  8% ;  
( Sw i g r i se ta l2 0 1 1 ) .
T h e r e  a r e  n o  a p p r o v e d  t h e r a p i e s  fo r  s a r co ido s i s .  C o r t i c o s t e r o i d  u s e  h a s  l o n g  c om p r i s e d  th e  
s t a n d a r d  o f  c a r e ,  w i th  d i v e r s e  a n d  un app rov ed ,  s e cond a ryimm u n o s u p p r e s s i v e  u s ag e  
( e . g . ,m e t h o t r e x a t e ,  a z a t h i o p r i n e )  a s  n e ed ed ,  a l l  o f  w h ich  a r e  a c c om p a n i e d  by  
t r e a tm e n t - r e l a t e d , s ev e r e  adv e r s e  r e a c t ion s ( B aughm an  and  Nun e s  2 0 1 2 ;  
P a r amo th aya ne ta l2 0 0 8) .  C l i n i c a l  t r i a l s  in  s a r co ido s i s  w i th  b i o l o g i c a l  t h e r a p i e s  t a r g e t i n g  th e  
a d a p t i v e  imm u n e  r e s p o n s e  h av e  no t  m e t  exp e c t a t ion s .  T h e  ty p i c a l  c l in i c a l  c o u r s e  fo r  c h r o n i c ,  
a c t i v e  s a r c o i d o s i s  p a t i en t s  i s  c h a r a c t e r i z e d  by  p r o g r e s s i v e  a n d  d e b i l i t a t i n g  d e c l i n e s  in  lung  
f u n c t i o n ,  w i th  t h e  p r im a ry  c au s e s  o f  mo rb id i ty a n d  m o r t a l i ty  in c lud ing  pu lmon a ry  
hy p e r t e n s i o n  a n d  f i b r o s i s  ( B a u g hm a na n dL ow e r2 0 1 1 ) .  T h u s  t h e r e  i s  a n  unm e t  m e d i c a l  n e ed  
in  p a t i e n t s  w i th  c h r o n i c ,  a c t i v e  s a r co ido s i s  fo r  a  d i s e a s e  mod i fying  a g e n t  t h a t  indu c e s  
r e s o l u t i o n  o f  g r a n u l om a s  a n d  p r e v e n t s  d e t e r i o r a t i o n  o r  im p r o v e s  l u n g  f u n c t i o n .
T h e  p a t h o p hy sio logy  o f  s a r c o i d o s i s  r em a in s  poo r ly  u nd e r s tood  bu t  i s  s u s p e c t e d  to  b e  a  ho s t  
imm u n o l o g i c a l  r e s p o n s e  to  a n  a n t i g e n i c  expo su r e .  T h e  r o l e  o f  T- ly mpho cyt e s  in  r e cogn i t ion  
o f  s p e c i f i c  a n t i g e n s  and  in  th eam p l i f i c a t i o n  o f  in f l amm a to ry  r e spon s e s  h a s  b e e n  w e l l  
e s t a b l i s h e d .  H ow e v e r ,  T -c e l l  t a r g e t e d  th e r ap eu t i c s  h a v e  no t  d em o n s t r a t e d  s u b s t a n t i a l  c l i n i c a l  
b e n e f i t s .  T h e r e f o r e ,  a l t e r n a t i v e  t h e r a p e u t i c  t a rg e t s  a n d  d i s e a s e  m e ch an i sm s  mu s t  b e  
c o n s i d e r e d  i n  t h i s  d i s e a s e .
A  ro le  fo r  IL -1βin  sa rco idos is
IL - 1β  i s  a  p r o - in f l amm a to ry  c y to k i n e  p rodu c ed  by  a  v a r i e t y  o f  c e l l  ty p e s ,  p a r t i c u l a r ly  
mononu c l e a r  ph ago cyt e s ,  in  r e spon s e  to  in ju ry ,  in f e c t ion  and  in f l amm a t ion .  In  s a r co ido s i s ,  th e  
IL - 1β  h a s  b e en  s h ow n  to  b e  a n  impo r t a n t  con t r ibu to r  to  m a i n t a i n i n g  m a c r o p h a g e  a n d  Tc e l l  
a l v e o l i t i s  a n d  e p i t h e l i o i d  c e l l  g r a n u l om a  fo rm a t ion  ( H u n n i n g h a k e1 9 8 4 ) .  Ep i th e l io idc e l l s ,  t h e  
p r e d om i n a n t  c e l l  ty p e  w i th in  s a r c o i d  g r a n u l om a s ,  h av e  b e en  shown  to  s t r o n g l y  e x p r e s s  IL - 1β  
( D e v e r g n ee ta l1 9 9 2 ) .  I n  a d d i t i o n ,  7 0 - 9 5%  o f  b r o n c h o a l v e o l a r  l a v a g e  (BAL )  m a c r o p h a g e s  
f r om  s a r co ido s i s  p a t i en t s  d em o n s t r a t e  cy top l a sm i c  s t a i n i n g  o f  IL - 1β  ( Ch i lo s ie ta l1 9 8 8 ) .  
C l in i c a l  r e l ev an c e  i s  sugg e s t ed  by s t u d i e s  s h ow i n g  t h a t  t h e  d e g r e e  o f  s a r c o i d o s i s  i n f l amm a t i o n  
m e a s u r e d  by  g a l l ium  s c a n  and  ly mpho cyt i c  a lv eo l i t i s  c o r r e l a t e s  w i th  s p o n t a n e o u s  and  
s t im u l a t e d  IL - 1β  r e l e a s e  by  a lv eo l a r  m a c r o p h a g e s  ( Hunn ingh ak e1 9 8 4 ;  S t e f f e ne ta l1 9 9 3 ;  
Y am a g u c h ie ta l1 9 8 8 ;  B a r t he ta l1 9 8 9 ) .  F in a l ly,IL - 1β  i s  known  to  indu c e  a n d  enh an c e  
No va r t i s Con f iden t ia l Page  22
Amended  P ro toco l  Ve rs ion  01  (C lean ) P ro toco l  No .  CACZ885X2205
g r a n u l om a  f o rm a t i o n  in  v i t r oa n d  in  v i v o  a n d  to  b e  i n v o l v e d  i n  a s s o c i a t e d  a n e r g y  
( Kob aya s h ie ta l1 9 8 5 ;  K a s a h a r ae ta l1 9 8 9 ;  T e r a oe ta l1 9 9 3 ) .  T h u s ,  IL - 1β  r ep r e s en t s  a  
p o t e n t i a l  t h e r a p e u t i c  t a r g e t  f o r  s a r c o i d o s i s .
The rapeu t ic  ta rge t ing  o f  IL -1β  and  the  in f lammasome
ACZ 8 8 5  ( c a n a k i n um a b )  i s  a  h igh  a f f in i ty ,  fu l ly  h um an ,  mono c lon a l  a n t i - h um a n  IL - 1β  
a n t ibody  o f  t h e  IgG1 /κ  i so ty p e  t h a t  i s  d e s i g n e d  to  b ind  to  h um a n  IL - 1β ,  b l o c k i n g  th e  
i n t e r a c t i o n  o f  th i s  cy tok in e  to  i t s  r e c ep to r s ,  thu s  fun c t ion a l ly  n e u t r a l i z i n g  t h e  b i o a c t i v i ty  o f  
th i s  cy t o k i n e .
C a n a k i n um a b  i s  cu r r en t ly  m a r k e t e d  u n d e r  t h e  n am e  I l a r i s®f o r  t r e a tm e n t  o f  a d u l t s  and  
c h i l d r e n  ag ed  4  y ea r s  and  o l d e r  t h a t  h av e  a  cond i t ion  k n ow n  a s  c ry opy r i n - a s s o c i a t e d  p e r iod i c  
sy n d r om e s  (CAPS ) ,  i n c l u d i n g  f am i l i a l  c o l d  a u t o i n f l amm a to ry  s y n d r om e  (FCAS )  and  
M u c k l e- W e l l s  sy nd rom e  (MWS ) .  I l a r i s®i s  a l s o  a p p r o v e d  f o r  th esy mp tom a t i c  t r e a tm e n t  o f  
a c u t e  g o u ty  a r t h r i t i s  a t t a c k s  a n d  f o r  th e  t r e a tm e n t  o f  a c t i v e  sy s t em i c  juv en i l e  id iop a th i c  
a r t h r i t i s  ( s J I A )  in  c h i l d r e n  2  y e a r s  o f  a g e  a n d  o ld e r .  F o r  f u r t h e r  d e t a i l s  p l e a s e  r e f e r  to  t h e  
i n v e s t i g a t o r s ’b r o c h u r e  ( IB ) .
IL - 1β  i s  r e c o g n i z ed  a s  o n e  o f  t h e  p r i n c i p a l  p r o - in f l amm a to ry  c y tok in e s  in  a  v a r i e ty  o f  
in f l amm a to ry  c ond i t ion s  ( D i n a r e l l oe ta l2 0 1 2 ) ,  i n c l u d i n g  t h o s e  i n v o l v i n g  au to in f l amm a t ion  
a n d  t h e  i n f l amm a s om e .
T h e  i n f l amm a s om e  i s  a  mu l t ip ro t e i n  o l i g om e r  t h a t  i s  e x p r e s s e d  in  mye l o i d  c e l l s  a s  a  
c om p o n e n t  o f  t h e  inn a t e  imm u n e  sy s t em .  I n f l amm a som e s  c a n  b e  t r i g g e r e d  by  a  v a r i e t y  o f  
a c t i v a t o r s  a n d  p ro c e s s e s ,  r e s u l t i n g  in  a n  in f l amm a to ry  c a s c a d e  th a t  in c lud e s  c l e a v a g e  by  
c a s p a s e - 1  o f  p r o - IL - 1β  andp r o - IL -1 8  in to  th e i r  a c t i v e  f o rm s ,  a l o n g  w i th  t r igg e r ing  o f  o th e r  
in f l amm a to ry  p ro c e s s e s .  O v e r  t h e  l a s t  f ew  y ea r s ,  t h e r e  h a s  b e en  a n  i n c r e a s i n g  body  o f  
l i t e r a t u r e  a b o u t  t h e  e f f i c a cy  o f  t a r g e t i n g  IL - 1β  in  a  w i d e  s p e c t r um  o f  a u t o i n f l amm a t o r y  
c o n d i t i o n s .  A u to in f l amm a to ry  d i s o r d e r s  c an  b e  d i s t i n g u i s h e d  f r om  a u t o imm u n e  d i s o r d e r s  by  
d i s e a s e  m e ch an i sm s  i n v o l v i n g  i n n a t e  imm u n e  r e g u l a t i o n  o f  cy tok in e s  a n d  n eu t roph i l i c  
i n f l amm a t i o n  r a t h e r  th an  a d a p t i v e  imm u n e  r e spon s e s  invo lv ing  an t ibod i e s  a n d  ly mpho cyt e s .  
I n f l amm a s om e - m ed i a t ed  d i s e a s e s  i n c l u d e  r a r e  o rph an  d i s e a s e s  c l a s s i f i e d  t o g e t h e r  w i th in  th e  
c o n d i t i o n  o f  h e r ed i t a ry  p e r i o d i c  f e v e r s .  A n o t h e r  d i s e a s e  in  wh i ch  t h e  in f l amm a som e  p l ay s  a  
k ey  r o l e  i s  g o u ty  a r th r i t i s .  T h e s e  c o n d i t i o n s  h av e  in  c omm o n  e i th e r  cond i t ion s  o r  mu t a t ion s  
t h a t  r e s u l t  in  i n c r e a s e d  i n f l amm a s om e  a c t i v a t i o n ,  r e s u l t i n g  in  ch ron i c a l ly  r e c u r r i n g  
i n f l amm a t i o n .
Sa rco idos is  as  an  in f lammasome -med ia ted  d isease
U s i n g  unb i a s ed ,  m o l e c u l a r  p r o f i l i n g  a p p r o a c h e s  g u i d e d  by  p a thw ay  s i g n a t u r e s  f r om  r e c en t  
c a n a k i n um a b  t r i a l s  in  o th e r  d i s e a s e s ,  w e  d i s c o v e r e d  u n a n t i c i p a t e d  e v i d e n c e  fo r  s ign i f i c an t  
i n v o l v em e n t  o f  t h e  i n f l amm a s om e  a s  a  g en e r a to r  o f  IL - 1β  in  s a r co ido s i s ;  a  d i s e a s e  h e r e t o f o r e  
p r im a r i ly  r e g a r d e d  a s  d r i v e n  l a r g e l y  by  c e l l - m e d i a t e d  imm u n e  p r o c e s s e s .  Con f i rm a to ry
s t u d i e s  e x am i n i n g  l u n g  a n d  sk in  l e s i o n a l  t i s s u e s  o r  e x  v i v oc e l l s  f r om  p a t i e n t s  w i th  c h r o n i c  
s a r c o i d o s i s  p r o v i d e d  f u r t h e r  e v i d e n c e  f o r  in f l amm a som e  a n d  IL - 1β  a c t iv a t ion  in  d i s e a s e d  
t i s s u e s .  I n  t h e  r ep r e s en t a t iv e  F i g u r e  1 - 1b e low ,  s e r i a l  s e c t i o n s  f r om  a n  u n t r e a t e d  s a r co ido s i s  
p a t i e n t  w i th  h igh ly  a c t iv e ,  mu l t i- o r g a n  d i s e a s e  d em o n s t r a t e  s t r o n g ,  c o - lo c a l i z ing  s t a i n i n g  o f  
pu lmon a ry  g r anu lom a s  f o r  m a c r o p h a g e s  (CD 6 8+ ) ,  a c t i v a t e d  i n f l amm a s om e  
No va r t i s Con f iden t ia l Page  23
Amended  P ro toco l  Ve rs ion  01  (C lean ) P ro toco l  No .  CACZ885X2205
( c l e a v e dc a s p a s e - 1 )  a n d  i t s  d ow n s t r e am  p r o d u c t  IL - 1β .  F u n c t i o n a l  a s s ay s  w i th  e x  v i v oBAL  
c e l l s  f r om  s a r c o i d o s i s  p a t i e n t s  a n d  n o rm a l  h e a l t h yc o n t r o l s  r e v e a l e d  e l ev a t ed  n o n - s t im u l a t e d  
a n d  s t im u l a t e d  IL - 1β  l ev e l s  in  s a r co ido s i s - d e r i v e d  s p e c im e n s  w i th  co r r e l a t ion s  to  d i s e a s e  
a c t iv i ty .  F in a l ly,  n eu t roph i l s ,  a n  im p o r t a n t  c om p o n e n t  o f  au to in f l amm a to ry  d i s o r d e r s ,  a l so  
p l ay  a  r o l e  in  s a r co ido s i s  p a thophy s io logy .  N eu t roph i l  ch emo t ax i s ,  ph ago cy to s i s  a n d  numb e r s  
in  s a r c o i d o s i s  p a t i e n t s  h a v e  b e en  s h ow n  to  c o r r e l a t e  to  d i s e a s e  a c t iv i ty  a n d  p rogno s i s  
( Z ie g e n h a g e ne ta l2 0 0 3 ;  T u t o r- Ur e t ae ta l2 0 0 6;  S c hm e k e le ta l1 9 8 5 ;  D r e n te ta l1 9 9 9 ;  
T u r n e r- W a rw i cke ta l1 9 8 6 ) .  A d d i t i o n a l  i n d i c a t o r s  o f  n e u t r o p h i l  a c t i v i t y ,  s u c h  a s  IL - 8  and  
e s t e r a s e  a r e  a l s o  e l e v a t e d  in  s a r c o i d o s i s  p a t i e n t s  w i th  c o r r e l a t i o n s  to  d i s e a s e  a c t i v i t y  
( C a re ta l1 9 9 4 ;  L o z ae ta l2 0 1 1 ;  H i n de ta l1 9 8 8 ) .
Th e  abov e  ev id en c e  suppo r t s  th a t  in f l amm a som e  a c t iv i ty  i s  up r egu l a t ed  in  s a r co ido s i s  p a t i en t s  
and  m ay  p l ay  a  ro l e  in  d i s e a s e  a c t iv i ty .  Thu s ,  IL - 1β  p a thw ay  in t e r rup t ion  w i th  c an ak inum ab  i s  
a n t i c i p a t e d  t o  c o n f e r  t h e r a p e u t i c  b e n e f i t .
F igu re  1 -1  Immunoh is tochem is t ry  s ta in ing  o f  sa rco idos is  lung  b iopsy t issue
Rep resen ta t ive  s ta in ing  in  se r ia l  sec t ions  o f  b iopsy  t i ssue  f rom  a  sa rco idos is  pa t ien t  w i th  h igh ly  ac t ive  
d isease  in  need  o f  immune  supp ress ive  t rea tmen t .  CD68  is  a  ma rke r  fo r  mac rophages .  C leaved  
caspase - 1  is  ind ica t ive  o fin f lammasome  ac t iva t ion .  Pos i t ive  s ta in ing  rep resen ted  by  [CONTACT_343840] r  b rown .
No va r t i s Con f iden t ia l Page  24
Amended  P ro toco l  Ve rs ion  01  (C lean ) P ro toco l  No .  CACZ885X2205
1 .2  Nonc l in ica l  da ta
1 .3  C l in ica l  da ta
1 .3 .1 Human  sa fe ty and  to le rab i l i ty  da ta
A s  o f  3 0  Jun e  2 0 1 6 ,  a n  e s t im a t e d  1 0 , 9 0 0p a t i e n t s  h a v e  r e c e i v e d  c an ak inum ab  t r e a tm e n t  in  6 6  
No v a r t i s - spon so r ed  i n v e s t i g a t i o n a l  c l i n i c a l  t r i a l s  a n d  1 7i n v e s t i g a t o r - i n i t i a t e d  t r i a l s  in  a  w id e  
s p e c t r um  o f  IL - 1β  d r iv en  d i s e a s e s  s u c h  a s  CAPS ,  m i ld  a s t hm a ,  p s o r i a s i s ,  w e t  a g e - r e l a t ed  
m a c u l a r  d e g e n e r a t i o n ,  gou ty  a r th r i t i s ,  ty p e  2  d i ab e t e s  m e l l i tu s ,  r h e um a to id  a r t h r i t i s  (RA ) ,  a n d  
s J I A .  H e a l th  a u t h o r i t y  a p p r o v a l s  fo r  I l a r i s®h av e  b e en  g r a n t e d  fo r  CAPS ,  g o u ty  a r t h r i t i sand  
s J I A .  Th e  p o s t-m a r k e t i n g  c um u l a t i v e  p a t i en t  e x p o s u r e  s i n c e  t h e  f i r s t  l aun ch  o f  t h e  p r o d u c t  i s  
e s t im a t e d  to  b e  a p p r o x im a t e l y  8 , 5 8 8p a t i e n t  t r e a tm e n t - y e a r s .  T h e  d o s e s  a dm i n i s t e r e d  i . v .  
r a n g e d  f r om  0 . 3  mg /kg  to  1 0  m g / k g  o r  a  f ix ed  d o s e  o f  6 0 0  m g ,  a n d  f r om  0 . 5  m g / k g  to  
9m g / k g  s . c .  o r  f i x e d  d o s e s  o f  5  m g  to  3 0 0  m g  s . c .T h e  f r equ en cy  o f  d o s i n g  r a n g e d  f r om  a  
s i n g l e  d o s e  to  w e ek ly r e p e a t e da dm i n i s t r a t i o n .  Ev e ry f o u r  w e e k s  s . c .  d o s i n g  o f  4  mg/ k g  u p  to  Co rpo ra te  Con f iden t ia l  In fo rma t ion
No va r t i s Con f iden t ia l Page  25
Amended  P ro toco l  Ve rs ion  01  (C lean ) P ro toco l  No .  CACZ885X2205
3 0 0  m g  i s  a p p r o v e d  b y  t h e  FDA  in  s J I A .  C an ak inum ab  h a s  a  l o n g  h a l f - l i f e ,  av e r ag ing  
app rox im a t e ly  4  w e ek s  in  m a n  and  h a s  b e en  w e l l- t o l e r a t e d  by  p a t i en t s  a t  a l l  do s e  l ev e l s  
i n v e s t i g a t e d .  So  f a r  t h e  du r a t ion  o f  expo su r e  to  c a n a k i n um a b  i s  m o r e  t h a n  4y ea r s  fo r  t h e  f i r s t  
4  MWS  p a t i e n t s  e n r o l l e d  in  th e  CACZ 8 8 5A 2 1 0 2  t r i a l .  F in a l  and  p r e l im in a ry  d a t a  f rom  
c om p l e t e d  c l i n i c a l  s tud i e s  d em o n s t r a t e  e f f i c a cy  a s  w e l l  a s  g o o d  s a f e t y  in  p a t i en t s  w i th  CAPS ,  
s J I A ,RA  and  g o u ty  a r th r i t i s .  T h e  d e t a i l s  o f  th e  SAE s  a n d  AE s  o f  t h e  comp l e t ed  s t u d i e s  and  
r e l e v a n t  d e t a i l s  o f  th e  SAE s  o f  th e  ongo ing  s tud i e s  a r e  summ a r i z ed  in  th e  l a t e s t  v e r s ion  o f  th e  
IB .  A d v e r s e  e v e n t s  in  u n b l i n d e d  s t u d i e s  r a n g e d  f r om  m i ld  to  m o d e r a t e  in  s e v e r i ty  and  
i n c l u d e d  u p p e r  r e sp i r a to ry  t r a c t  in f e c t ion s ,  n a soph a ry ng i t i s  a n d  o t i t i s ,  h e a d a c h e ,  n au s e a ,  
d i a r r h e a ,  a n d  a s t h e n i c  c o n d i t i o n s .
Immunog en i c i ty  h a s  no t  p r o v e d  to  b e  a  s ign i f i c an t  c o n c e r n  fo r  c an ak inum ab .  C an ak inum ab  
s t u d i e s  a c r o s s  mu l t ip l e  i n d i c a t i o n s  a n d  do s ing  r e g im e n s  h av e  d em o n s t r a t e d  t h a t  th e  in c id en c e  
o f  t r e a tm e n t - em e r g e n t  ADA  d e v e l o pm e n t  r em a in s  v e ry  l ow ,  in  t h e  r ang e  o f  0 . 3%  to  2 . 9% .  
F u r t h e rm o r e ,  t h e r e  h a v e  b e e n  n o  c l i n i c a l  c o n s e q u e n c e s  e v i d e n t  f o r  t h e s e  d e t e c t e d  a n t i b o d i e s .
1 .3 .2   Human  pha rmacok ine t ic  da ta
C a n a k i n um a b  h a s  t h e  e x p e c t e d  p h a rm a c o k i n e t i c s  o f  a n  I gG 1- ty p e  an t ibody  w i th  a  low  vo lum e  
o f  d i s t r ibu t ion  (VSS= 6 . 0  L )  a n d  l ow  c l e a r an c e  t h a t  i s  d e p e n d e n t  o n  body  w e i g h t  ( e .g . ,  
CL= 0 . 1 7 4  L /d ay i n  a  a  CAPS  p a t i e n t  o f  body  w e i g h t  7 0  k g ,  0 . 1 1  L /d ay  i na  S J IA  p a t i e n t  o f  
body  w e i g h t  3 3  kg  a n d  0 . 2 3  L /d ay  i n  a  g o u t  p a t ie n t  o f  body  w e i g h t  9 3  k g ) .  H a l f- l i v e s  v a ry  
b e tw e en  21  and  30  d ay s .  W i th in  th e  do s e  r ang e  s tud i ed ,  th e  ph a rm a cok in e t i c s  o f  c an ak inum ab  
w e r e  l i n e a r .  T h e  sy s t em i c  e x p o s u r e  p a r am e t e r s ,  AUC  a n d  Cm ax ,  i n c r e a s e  in  p r o p o r t i o n  to  
d o s e  o v e rt h e  do s e  r a n g e  o f  0 . 3 0  to  1 0 . 0mg /kg  g i v e n  a s  i .v .  i n f u s i o n  and  f r om  1 5 0m g  to  
3 0 0m g  wh en  a dm i n i s t e r e d  a s  a n  s . c .  in j e c t ion .  T h eab so lu t e  b io av a i l ab i l i ty  o f  s . c .  
c a n a k i n um a b  i s  7 0% .  A  m a t h em a t i c a l  m o d e l  to  c h a r a c t e r i z e  t h e  b i n d i n g  k i n e t i c s  o f  
c a n a k i n um a b  to  IL - 1β  h a s  b e e n  c r e a t e d .  Th e  m o d e l  s u c c e s s f u l l y  f i t s  t h e  p a t i e n t  d a t a  and  
a l l ow s  e s t im a t i o n  o f  c a n a k i n um a b  c l e a r a n c e  a n d  v o l um e s  o f  d i s t r i b u t i o n ,  t o g e t h e r  w i th  IL - 1β  
r a t e  o f  r e l e a s e  a n d  h a l f - l iv e s .
1 .3 .3 Human  pha rmacodynam ic  da ta
C an ak inum ab  b ind s  to  and  in a c t iv a t e s  IL- 1β  and  b lo ck s  down s t r e am  ev en t s  o f  IL - 1β  s ign a l ing ,  
i n c l u d i n g  IL - 1β  p rodu c t ion ,  IL - 1β  p a thw ay - r e l a t ed  g e n e  a c t iv a t ion ,  e l ev a t ion  o f  a c u t e  ph a s e  
p r o t e i n s ,  a n d  C -r e a c t i v e  p r o t e in  (CRP ) ,  a n d  mob i l i z a t ion  o f  
n e u t r o p h i l s  a n d  p l a t e l e t s  f r om  b o n e  m a r r ow .
No rm a l ly u nd e t e c t ab l e ,  s e r um  IL - 1β  b e c om e s  d e t e c t a b l e  in  hum an s  wh en  c om p l e x e d  w i th  
c a n a k i n um a b .  T h e s e  IL - 1β / c a n a k i n um a b  comp l ex e s  a r e  b i o l o g i c a l ly  in a c t iv e  a n d  h a v e  b e en  
u t i l i z ed  ina l l  c l i n i c a l  s tud i e s  a s  a  su r rog a t e  PD  m a r k e r  b e c au s e  th e i r  in c r e a s e  r e f l e c t s  th e  
r e d u c t i o n  o f  f r e e  IL - 1β  l e v e l s  c a u s e d  by  b i n d i n g  t o  c a n a k i n um a b .
1 .4  S tudy  pu rpose
Th i s  s tudy  i s  d e s ign ed  a s  a  p roo f - o f - c o n c e p t  s tudy  to  a s s e s s  i f  inh ib i t ion  o f  IL - 1β  by  
c a n a k i n um a b  w i l l  im p r o v e  l u n g  f u n c t i o n  in  a s s o c i a t i o n  w i th  a t t e n u a t i o n  o f  t i s s u e  
i n f l amm a t i o n  in  p a t i e n t s  w i th  c h r o n i c  s a r c o i d o s i s ,  t h e r e f o r e  a l l ow i n g  f u r t h e r  d e v e l o pm e n t  o f  
t h e  c om p o u n d  f o r  t r e a tm e n t  o f  t h i s  d i s e a s e  p o p u l a t i o n .Co rpo ra te  Con f iden t ia l  In fo rma t ion
No va r t i s Con f iden t ia l Page  26
Amended  P ro toco l  Ve rs ion  01  (C lean ) P ro toco l  No .  CACZ885X2205
2  S tudy ob jec t ives  and  endpo in ts
2 .1  P r ima ry  ob jec t ive
P r ima ry  ob jec t iveEndpo in tsre la ted  to  
p r ima ry  ob jec t ive
T o  c om p a r e  t h e  e f f e c t  o f  ACZ 8 8 5  v e r s u s  p l a c e b o  o n  t h e
c l i n i c a l  d i s e a s e  a c t i v i t yo f  s a r c o i d o s i s  p a t i e n t s  a s  m e a s u r e d  by
t h e  c h a n g e  f r om  b a s e l i n e  i n  t h e  p e r c e n t  p r e d i c t e d  f o r c e d  v i t a l
c ap a c i ty  (FVC )  a t  w e ek  24C h a n g e  f r om
b a s e l i n e  i n  p e r c e n t
p r e d i c t e d  FVC  a t
w e e k  2 4
Ra t iona le  fo r  P r ima ry  Ou tcome
FVC  h a s  b e e n  shown  in  s a r c o i d o s i s  p a t i e n t s  to  c o r r e l a t e  w i th  mo r t a l i ty r i sk  a n d  i s  t h e  mo s t  
o f t e n  u s e d  f u n c t i o n a l  o u t c om e  in  s a r c o i d o s i s  s t u d i e s ,  p r o v i d i n g  a  b e n c hm a r k  f o r  comp a r i son  
a g a i n s t  p r ev iou s ly  t e s t ed  a g e n t s  ( B a u g hm a ne ta l2 0 1 2 ) .  B a s e d  o n  p u b l i s h e d  r e s u l t s  w i t h  
c o r t i c o s t e r o i d s ,  s ign i f i c an t  c l i n i c a l  r e s p o n s e s  b y  sp i rom e t ry  i n  s a r co ido s i s  p a t i e n t s  c a n  b e  
d e t e c t e d  a s  e a r ly  a s  2 4  w e e k s ,  w i th  m ax imum  e f f e c t  s h ow n  by  5 2  w e ek s  
( B a u g hm a ne ta l2 0 1 3 ) .
2 .2  Seconda ry ob jec t ive s
Seconda ry  ob jec t ivesEndpo in tsre la ted  to  
seconda ry  ob jec t ives
T o  d e t e rm i n e  t h e  e f f e ct  o f  ACZ 8 8 5  o n  d e c r e a s i n g  t h e
m a x im um  s t a n d a r d i z e d  u p t a k e  v a l u e  (SUVm a x )  [F -1 8 ]FDG-
PET  i n  n o d u l e s  ( n o d u l a r  u p t a k e  r e g i o n s )  a f t e r  1 2  w e e k s  o f
t r e a tm e n t ,  c om p a r e d  t o  p l a c e b o .P e r c e n t  c h a n g e  f r om
in i t i a l  s c an  in  [F -
1 8 ]FDG - PET  SUVm ax
a t  w e e k  1 2
T o  d e t e rm i n e  t h e  e f f e c t  o f  ACZ 8 8 5  v e r s u s  p l a c e b o  o n  o t h e r
p a r am e t e r s  o f  p u lm o n a r y  f u n c t i o n  t e s t i n g  ( i . e . ,  a b s o l u t e
FVC ,  FEV 1 ,  FEV 1 /FVC ,  FEV 3 ,FEF 2 5- 7 5 ,  FEV 3 /FVC ,
FEV 6 ,  TLC ,  RV ,  RV /TLC ,  DLc o  a n d  p o s t - b ron chod i l a to r
FEV1 / r ev e r s ib i l i ty)  i n  p a t i e n t s  w i t h  s a r c o i d o s i s  a t  2 4  w e e k s
c om p a r e d  t o  b a s e l i n eL u n g  f u n c t i o n  t e s t i n g
r e s u l t s  a t  2 4  w e e k s
c om p a r e d  t o  b a s e l i n e
T o  d e t e rm i n e  t h e  e f f e c t  o f  ACZ [ADDRESS_426679]  s c o r i n gHRCT  r e s u l t s  a t  [ADDRESS_426680]
s c o r i n g
T o  d e t e rm i n e  t h e  e f f e c t  o f  ACZ 8 8 5  v e r s u s  p l a c e b o  o n  t h e  6 -
m i n u t e  w a l k  t e s t  ( 6MWT )  d i s t a n c e  o f  p a t i e n ts  w i t h
s a r c o i d o s i s  a t  1 2  a n d  2 4  w e e k s  c om p a r e d  t o  b a s e l i n e6MWT  r e s u l t s  a t  w e e k
1 2  a n d  2 4  c om p a r e d  t o
b a s e l i n e
No va r t i s Con f iden t ia l Page  27
Amended  P ro toco l  Ve rs ion  01  (C lean ) P ro toco l  No .  CACZ885X2205
Seconda ry  ob jec t ivesEndpo in tsre la ted  to  
seconda ry  ob jec t ives
T o  d e t e rm i n e  t h e  e f f e c t  o f  ACZ 8 8 5  o n  a d d i t i o n a l  [F-
1 8 ]FDG - PET  o u t c om e s  ( i . e . ,  SUVm e a n ,  SUV p e a k  a n d
v o l um e  o f  t h e  l e s i o n s )  a f t e r  1 2  w e e k s  o f  t r e a tm e n t  c om p a r e d
t o  p l a c e b oP e r c e n t  c h a n g e  f r om
i n i t i a l  s c a n  i n
add i t ion a l  [F - 1 8 ]FDG
PET  o u t c om e s  a t  w e e k
1 2
T o  a s s e s s  t h e  s a f e ty  a n d  t o l e r a b i l i t y  o f  ACZ 8 8 5  i n  p a t i e n t s
w i t h  s a r c o i d o s i s  a s  m e a s u r e d  by  a d v e r s e  e v e n t s  (AE s )A d v e r s e  e v e n t s  i n
p a t i e n t s  t a k i n g
ACZ [ADDRESS_426681]  and  FDG  PET /CT  in  sc reen ing  and /o r  
seconda ry ou tcomes
H i g h  r e s o l u t i o n  compu t ed  t om o g r a p h y  (HRCT )  i s  u s e d  in  t h i s  s tudy  f o r  bo th  s c r e e n i n g  and  
f o r  c l i n i c a l  o u t c om e  m e a s u r em e n t s .  S t a n d a r d  p l a in  c h e s t  r a d i o g r a p h i c  v i ew s  a r e  f r e q u e n t l y  
u s e d  in  th e  d i a g n o s t i c  a n d  s t a g i n g  p ro c e s s e s  fo r  s a r co ido s i s  p a t i e n t s .  H ow e v e r ,  th e  ch e s t  
r a d i o g r a p h i c  s c o r e s  (S c a d d i n g  s t ag e s  0 -IV )  h av e  l im i t ed  v a l u e  in  p r ed i c t ing  s e v e r i t y  o f  
pu lmon a ry  i n v o l v em e n t  a n d  a r e  r e l a t i v e l y  in s en s i t iv e  a s  a  d i s e a s e  m a r k e r  in  t h e r a p e u t i c  t r i a l s .  
HRCT  (w i t h o u t  con t r a s t  a g e n t )  p rov id e s  sup e r io r  r e s o l u t i o n  o f  lung  mo rpho logy w h en  
c om p a r e d  to  ch e s t  r a d i o g r a p h y  o r  ev en  conv en t ion a l  CT .  HRCT  c an  d e t e c t  p a r e n c hyma l  
d i s e a s e  in  p a t i e n t s  w i th  n o rma l  c h e s t  r a d i o g r a p h s  o r  d em o n s t r a t e  m o r e  ex t en s iv e  d i s e a s e  in  
p a t i e n t s  h a v i n g  on ly  f o c a l  a b n o rm a l i t i e s  o n  c h e s t  r a d i o g r a p h s  ( B a t r a1 9 9 3;  D r e n te ta l2 0 0 3 ) .  
Typ i c a l  HRCT  f e a t u r e s  o f  s a r c o i d  p a r e n c hyma l  a b n o rm a l i t i e s  in c lud e  n o d u l a r  d en s i t i e s ,  
p a t c hy  a r e a s  o f  g r o u n d  g l a s s  op a c i t i e s ,  i r r egu l a r  l in e a r  op a c i t i e s ,  e n d - s t a g e  f i b r o s i s  and  
hon ey comb  a p p e a r a n c e .  T h e  n o d u l e s  f o u n d  o n  HRCT  h a v e  b e e n  shown  to  l ik e ly  r ep r e s en t  
c o n f l u e n t  in t e r s t i t i a l  g r a n u l om a s .  S ign s  o f  d i s to r t ion  o n  HRCT  a r e  c o n s i s t e n t  w i th  th e  
d e v e l o pm e n t  o f  f i b r o s i s .  S e q u e n t i a l  HRCT s  h av e  s h ow n  th a t  nodu l e s  and  p a t c hy  g r o u n d  g la s s  
d e n s i t i e s  a r e  r ev e r s ib l e ,  w h e r e a s  hon ey c om b i n g  a n d  lung  d i s to r t ion  s u g g e s t  i r r ev e r s ib l e  
f i b r o s i s .  M o r e o v e r ,  HRCT  a b n o rm a l i t i e s  h av e  b e e n  r e p o r t e d  to  c o r r e l a t e  b e t t e r  th an  
r a d i o g r a p h i c  s t ag e  to  pu lmon a ry  f un c t ion a l  p a r am e t e r s  a n d  s e r um  b i om a r k e r s .  O f  p a r t i cu l a r  
n o t e ,  r e l a t i o n s h i p s  h a v e  b e e n  n o t e d  b e tw e e n  HRCT  f i n d i n g s  a n d  BAL  n eu t roph i l  n um b e r s ,  a
m a r k e r  o f  d i s e a s e  a c t iv i ty .  HRCT  c o r r e l a t i o n s  w i th  o t h e r  s a r c o i d o s i s  d i s e a s e  a c t iv i ty  m a rk e r s  
h a v e  a l s o  b e e n  f o u n d ,  i n c l u d i n g  BAL t o t a l  c e l l  c o u n t  a n d  s e r um  l e v e l s  o f  s I L- 2R .
Th i s  s tudy  w i l l  u s e  h igh ly  s e n s i t i v e  [F - 1 8 ]FDG- PET /CT  im a g i n g  to  p rov id e  e a r l y  ev id en c e  
f o r  e f f e c t i v e  d e c r e a s e  in  IL -1β - d r iv en  i n f l amm a t i o n o n  ACZ 8 8 5  t r e a tm en t .  
[F - 1 8 ]FDG - PET /CT  d e t e c t s  i n c r e a s e d  in f l amm a t ion - a s s o c i a t e d  m e t abo l i c  a c t iv i ty  i n  
s a r c o i d o s i s  w i th  s en s i t iv i ty  o f  9 0 - 1 0 0% ,  a n d  d e c r e a s e s  in  [F - 1 8 ]FDG- PET /CT  a t  2 4  w e e k s  
c om p a r e d  to  b a s e l i n e  h av e  b e e n  c o r r e l a t e d  w i th  imp rov em en t s  in  FVC  ov e r  th i s  t im e  p e r iod  
( K e i j s e r se ta l2 0 0 8 ;  M i lm ane ta l2 0 1 2 ;  A d am se ta l2 0 1 4 )  w i th  ev id en c e  o f  im p r o v em e n t  by  [CONTACT_343841] f iden t ia l  In fo rma t ion
No va r t i s Con f iden t ia l Page  28
Amended  P ro toco l  Ve rs ion  01  (C lean ) P ro toco l  No .  CACZ885X2205
s e r i a l  [F - 18 ]FDG - PET  d e t e c t e d  in  s a r c o i d  p a t i en t s  r e p o r t e d  a s  e a r l y  a s  1 - 2  mon th s  
( B r u d i ne ta l1 9 9 4 ;  B r a u ne ta l2 0 0 8 ;  Im p e r i a l ee ta l2 0 1 3 ) .  I n  a dd i t ion ,  e v i d e n c e  s u g g e s t s  th a t  
l ow  d o s e  p r e d n i s o n e  t h e r a p y  d o e s  no t  app r e c i ab ly  a l t e r  [F - 1 8 ]FDG- PET  t r a c e r  up t ak e  
e v a l u a t e d  in  a  s e c o n d ,  fo l low  u p  sc a n  w h i l e  h igh  d o s e  ( e . g . ,  4 0  m g / d )  d o e s  r e s u l t  in  PET  
s i g n a l  r e d u c t i o n  ( B r u d i ne ta l1 9 9 4 ) .  W e  p o s t u l a t e  r a p i d  r e d u c t i o n  in  i n f l amm a s om e  a c t i v i t y  
upon  ACZ885  t r e a tm en t ,  and  a  t empo r a l ly  a s so c i a t ed  d e c r e a s e  in  [F - 1 8 ]FDG - PET  i s  exp e c t ed  
by  1 2  w e e k s .  H ow e v e r ,  d e t e c t a b l e  c l i n i c a l  s i g n s  o f  im p r o v em e n t  in  pu lmon a ry  f u n c t i o n  a r e  
a n t i c i p a t e d  to  r e q u i r e  a d d i t i o n a l  t im e  a f t e r  c e s s a t i o n  o f  t i s s u e  in f l amm a t ion  by  t h e  
e x p e r im e n t a l  t r e a tm e n t .  H e n c e ,  t h e  e n d p o i n t  r e l a t e d  to  pu lmon a ry  f un c t ion  a s s e s sm e n t  o c c u r s  
l a t e r  a t  2 4  w e e k s .  I n  c on s id e r a t ion  o f  ev id en c e  s u g g e s t i n g  th a t  p a t i en t s  w i th  FDG  PET  t r a c e r  
u p t a k e  in  p a r e n c hyma l  lung  t i s s u e s  h av e  a c t i v e  d i s e a s e  m o r e  l i k e l y  to  imp rov e  w i th  e f f e c t i v e  
i n t e r v e n t i o n  v e r su s  n o  c h a n g e s  in  p a t i e n t s  w i th  n e g a t i v e  PET  f i n d i n g s  ( K e i j s e r se ta l2 0 1 1 ;  
V o r s e l a a r se ta l2 0 1 5 ) ,  p a t i en t s  in  th i s  s tudy  w i l l  und e rgo  s t r a t i f i c a t ion  a t  r andom i z a t ion  b a s ed  
o n  b a s e l i n e  FDG  PET /CT  r e s u l t s .  I n  a d d i t i o n ,  l a t e r  an a ly s e s  fo r  th i s  s tudy  w i l l  a l s o  s t r a t i fy  
p a t i e n t s  f o r  t h e  p r e s e n c e  o f  l u n g  p a r e n c h y m a l  PET  t r a c e r  u p t a k e  a t  b a s e l i n e .
Ra t iona le  fo r  o the r  seconda ry ou tcomes
F u l l  pu lmon a ry  f un c t ion  t e s t s  i n c l u d e  s p i r om e t r y  (FVC ,  FEV 1 ,  FEV 1 /FVC,  FEF 2 5- 75 ,  
FEV 3 /FVC ,  FEV 6 ,lung  v o l um e s  (TLC ,  RV ,  RV /TLC )  a n d  g a s  d i f fu s ion  (DL c o )  to  a l low  
f u r t h e r  c h a r a c t e r i z a t i o n  o f  th e  p a t i e n t s ’  r e s p o n s e  to  t r e a tm e n t .  Em e rg ing  e v i d e n c e  sugg e s t s  
th a t  s a r co ido s i s  invo lv e s  a  compon en t  o f  sm a l l  a i rw ay s  d i s e a s e  c au s ed  b y  c o n s t r i c t i o n  b y  p e r i-
b r o n c h i o l a r  g r anu lom a tou s  i n f l amm a t i o n  ( D a v i e se ta l2 0 0 0 ) .  Th e r e fo r e ,t h e  fo l low ing  
sp i rom e t ry  m e a s u r e s :  FEV 3 ,  FEV3 /FVC ,  1 - (FEV 3 /FVC )  w i l l  b e  p e r fo rm ed  to  a s s e s s  sm a l l  
a i rw ay  d i s e a s e .  ( B u r g e le ta l2 0 1 1 ) .  T h e  I n v e s t i g a t o r  n e ed s  to  p ay  s p e c i a l  a t t en t ion  to  c a p t u r e  
t h e  FEV 3  d a t a  (no t  a lw ay s  c a p t u r e d  by  t r ad i t ion a l  s o f tw a r e ;  m ay b e  c a p t u r e d  by  s a v i n g  th e  
f l ow  v o l um e  l o o p ) .
Th e  6MWT  ( in c lud ing  d i s t an c e  w a lk ed ,  ch ang e s  in  oxyg en a t ion ,  and  Bo rg  Q u e s t i o n n a i r e)  i s  a  
p r a c t i c a l  a n d  s imp l e  a s s e s sm en t  o f  f u n c t i o n a l  c ap a c i ty ,  r e f l e c t i v e  o f  a c t i v i t i e s  o f  d a i ly  l iv ing  
( E n r i g h t2 0 0 3 )  t h a t  h a s  b e e ni n c r e a s i n g l y  app l i ed  to  a s s e s s  v a r i o u s  l u n g  d i s e a s e s ,  i n c l u d i n g  
i n t e r s t i t i a l  l u n g  d i s e a s e s  o t h e r  th an  s a r co ido s i s  wh e r e  i t  h a s  p rov ed  u s e fu l  fo r  bo th  p r ed i c t ing
mo r t a l i ty a n d  mon i to r ing  r e s p o n s e  to  th e r apy .  I t s  a p p l i c a t i o n  in  s a r co ido s i s  s t u d i e s  h a s  b e en  
m o r e  l im i t ed  ( B a u g hm a ne ta l2 0 0 7 )  a n d  r e su l t s  s h o u l d  b e  i n t e r p r e t e d  in  r e c o g n i t i o n  o f  th e  
mu l t i- f a c t o r i a l  n a t u r e  o f  t h e  d i s e a s e  ( B aughm an  and  Low e r  2 0 1 1) .
No va r t i s Con f iden t ia l Page  29
Amended  P ro toco l  Ve rs ion  01  (C lean ) P ro toco l  No .  CACZ885X2205
2 .3  Exp lo ra to ry ob jec t iv es
Co rpo ra te  Con f iden t ia l  In fo rma t ion
No va r t i s Con f iden t ia l Page  30
Amended  P ro toco l  Ve rs ion  01  (C lean ) P ro toco l  No .  CACZ885X2205
3  Inves t iga t iona l  p lan
3 .1  S tudy  des ign
F igu re  3 -1  S tudy Des i gn  schemeCo rpo ra te  Con f iden t ia l  In fo rma t ion
No va r t i s Con f iden t ia l Page  31
Amended  P ro toco l  Ve rs ion  01  (C lean ) P ro toco l  No .  CACZ885X2205
Th i s  i s  a  3 2 -w e e k ,  sub j e c t -a n d  inv e s t ig a to r - b l i n d e d ,  r andom i z e d ,  p l a c e b o- con t ro l l ed ,  
p a r a l l e l - g roup ,  non - con f i rm a to ry  s tudy  to  a s s e s s  th e  c l in i c a l  e f f i c a cy  o f  ACZ885  adm in i s t e r ed  
s u b c u t a n e o u s l y  ( s . c . )  in  6  i n j e c t i o n s  g i v e n  28  d ay s  a p a r t  ( F i g u r e  3 -1 ) .  T h es tudy  w i l l  
r a n d om i z e  a p p r o x im a t e l y  3 8  p a t i e n t s  ( t a r g e t i n g  30  c om p l e t e r s )  w i th  ev id en c e  o f  p a r en chy m a l  
i n v o l v em e n t  a n d  h i s to log i c a l ly  p r o v e n ,  c h r o n i c  pu lmon a ry  s a r co ido s i s  o f  ≥1  y e a r  du r a t ion  
w i th  p e r s i s t i n g  a c t iv i ty  a t  b a s e l i n e  d e s p i t e  b a c k g r o u n d  th e r apy  a s  d e t e rm i n e d  by  c l in i c a l  
h i s to ry ,  r a d i o l o g i ce v i d e n c e  ( e . g .HRCT,  MR Io r  c h e s t  x - r ay ) ,  sp i rom e t ry  a n d  MMRC  
dy spn e a  s c a l e  a s s e s sm en t s .  R andom i z a t ion  w i l l  b e  s t r a t i f i e d  by  p o s i t iv e  PET  p a r e n c hyma l  
t r a c e r  up t ak e  (y e s /no ) .  A c c e p t a b l e  b a ckg round  t h e r a p y  i n c l u d e s  a  s t a b l e  r eg im en  o f  
p r e d n i s o n e  ≤ 1 5  mg/d ay  a n d / o r  no  mo r e  t h a n  o n e  immun e  s u p p r e s s i v e  ag en t  
( i . e . ,m e t h o t r e x a t e ,  a z a t h i o p r i n e ,  l e f l u n om i d e  o r  hy d r o xy c h l o r o q u i n e ) .
R e- s c r e e n i n g  o f  s u b j e c t s  m ay b e  a l low ed  w i th  t h e  c o n s u l t a t i o n  o f  th e  S p o n s o r ’ s  m ed i c a l  
e x p e r t .
F o r  e a c h  s u b j e c t ,  t h e r e  w i l l  b e  a  m ax imum  4 0 - d ay  s c r e e n i n g  p e r i o d .  S c r e e n i n g  i s  v a l i d  f o r  
4 0d ay s  f r om  t h e  t im e  o f  t h e  f i r s t  s c r e e n i n g  a s s e s sm en t .  [F - 1 8 ]FDG - PET /CT  s c a n s  o b t a i n e d  
l o c a l ly  a t  t h e  s tudy  s i t e  w i th in  8  w e e k s  o f  r andom i z a t ion  w i l l  b e  a c c e p t a b l e  f o r  b a s e l in e  
a s s e s sm e n t  p r i o r  to  r e c e i v i n g  t h e  f i r s t  i n j e c t i o n  o f  ACZ 8 8 5 .  How ev e r ,  a n y  p r i o r  [F - 1 8 ]FDG -
PET /CT  im a g i n g  mu s t  a l s o  h a v e  b e e n  don e  w i thou t  c h a n g e s  in  t r e a tm e n t  d u r i n g  t h e  
s u b s e q u e n t  p e r i o d  l e a d i n g  u p  t o  s t u d y  r a n d om i z a t i o n .
S u b j e c t s  w h o  m e e t  th e  e l ig ib i l i ty  c r i t e r i a  a t  s c r e e n i n g  w i l l  u n d e r g o  e v a l u a t i o n  o f  f u l l  b a s e l in e  
c l i n i c a l  a n d  b i om a r k e r  a s s e s sm en t s  p r i o r  to  in j e c t ion .  B a s e l i n e  a s s e s sm en t s  i n c l u d i n g  s a f e t y  
l abo r a to rye v a l u a t i o n s  and  pu lmon a ry  f un c t ion  t e s t s  w i l l  no t  b e  a v a i l a b l e  p r i o r  to  d o s i n g  and  
f o r  tho s e  m e a s u r e s  e l ig ib i l i ty  c r i t e r i a  w i l l  b e  d e t e rm i n e d  b a s ed  o n  th e  s c r e e n i n g  r e su l t s .  
En ro l l ed  sub j e c t s  w i l l  b e  r andom i z ed  a t  a  1 :1  r a t io  to  r e c e iv e  t r e a tm en t  w i th  e i th e r  ACZ885  o r  
p l a c e b o .  O n  D ays1 ,  2 9 ,  5 7 ,  8 5 ,  1 1 3a n d  1 4 1p a t i e n t s  w i l l  b e  a dm i n i s t e r e d  s . c .  d o s i n g  w i th  
ACZ 8 8 5  a t  3 0 0  mgo r  c o r r e s p o n d i n g  p l a c e b o  t r e a tm en t .  A l l  p a t i e n t s  w i l l  r e t u r n  to  th e  s tudy  
c e n t e r  f o r  s a f e t y  a n d  p h a rm a c o k i n e t i c  (PK )  ch e ck s  o n  a n  e v e r y  fou r  w e e k  b a s i s  a t  w h i c h  t im e  
th ey  w i l l  r e c e i v e  e i t h e r  s tudy  t r e a tm e n t s  d e p e n d i n g  o n  t r e a tm e n t  a rm .  Add i t ion a l ly,  p a t i en t s  
w i l l  u n d e r g o  c l i n i c a l  a s s e s sm en t s  t h a t  i n c l u d e  pu lmon a ry  f un c t ion  t e s t s  w i th  l u n g  v o l um e s ,  
DLCO,  6MWT ,  a n d  c l i n i c a l  o u t c om e  a s s e s sm e n t s  a s  o u t l i n e d  i n  t h e  A s s e s sm e n tS c h e d u l e.
A t  w e e k  1 2 ,  a  s e cond  [F - 1 8 ]FDG- PET /CT  w i l l  b e  ob t a in ed .  I n  a d d i t i o n ,  f u n c t i o n a l  c l in i c a l  
m e a s u r e s   w i l l  t ak e  p l a c e  a t  th i s  t im e  po in t .  Th ef i n a l  d o s i n g  w i l l  
t a k e  p l a c e  o n  w e e k  [ADDRESS_426682]  
a s s e s sm e n t .  P a t i e n t s  r e t u r n  f o r  t h e  e n d  o f  s t u d y  (EOS )  v i s i t  a t  w e e k  3 2 .
A  f o l l ow - u p  v i s i t  o r  p h o n e  c a l l  f o r  SAE s  mu s t  b e  p e r f o rm e d  3 0  d ay s  f o l l ow i n g  e a r l y  
d i s c o n t i n u a t i o n ,  o r  8  w e e k s  a f t e r  l a s t  in j e c t ion  o f  s tudy  d r u g ,  wh i ch ev e r  i s  l a t e r .  
I fa n a p h y la c t i c  r e a c t ion s  o c c u r  a f t e r  in j e c t ion ,  tw o  m o r e  imm u n o g e n i c i t y  s amp l e s  ( a t  t h e  t im e  
o f  th e  ev en t  and  8  w e ek s  l a t e r )  n e ed  to  b e  t ak en .  Any  p a t i en t  who  d i s con t inu e s  th e  s tudy  e a r ly  
w i l l  c om p l e t e  t h e  W e ek  [ADDRESS_426683]  a s s e s sm e n t  a t  t h i s  v i s i t ,  a s  a s s e s s e do n  a  c a s e - by - c a s e  b a s i s  by  t h e  S p o n s o r .Co rpo ra te  Con f iden t ia l  In fo rma t ion
Co rpo ra te  Con f iden t ia l  In fo rma t ion
Co rpo ra te  Con f iden t ia l  In fo rma t ionCo rpo ra te  Con f iden t ia l  In fo rma t ion
No va r t i s Con f iden t ia l Page  32
Amended  P ro toco l  Ve rs ion  01  (C lean ) P ro toco l  No .  CACZ885X2205
3 .2  Ra t iona le  fo rs tudy  des ign
A  r a n d om i z e d ,  p l a c e b o - c o n t r o l l e d ,  s u b j e c t  a n d  i n v e s t i g a t o r  b l i n d e d  a p p r o a c h  i s  u s e d  to  
e l im i n a t e  p o t e n t i a l  b i a s  in  r e p o r t i n g  s a f e t y  a n d  c l i n i c a l  e f f i c a cy  d a t a  in  th i s  f i r s t  exp lo r a to ry  
s tudy  i n  s a r c o i d o s i s  p a t i e n t s .
T h e  p a t i e n t  ex c lu s ion  c r i t e r i a  o f  b a c k g r o u n d  p r e d n i s o n e  d o s i n g  > 1 5  mg /d ay i s  j u s t i f i e d
b e c a u s e  c h r o n i c  h igh  do s e  s t e r o i d s  ( e .g . ,  4 0  mg/d ay )  h av e  b ee n  r epo r t ed  to  a t t e n u a t e  th e  
[F - 1 8 ]FDG - PET  s i g n a l  w h i l e  l ow  d o s e  s t e r o i d s  d o  n o t  h a v e  t h i s  e f f e c t  (B r u d i ne ta l1 9 9 4 ) .
3 .3  Ra t iona le  fo r  dose / reg imen ,  rou te  of  adm in is t ra t ion  and  du ra t ion  
o f  t rea tmen t
T h e  d o s e  o f  ACZ 8 8 5  ( c a n a k i n um a b )  s e l e c t e d  fo r  t h e  c u r r e n t  p r o o f - o f - con c ep t  t r i a l  i s  3 0 0mg  
s . c .  ev e ry  f o u r  w e e k s .  Th i s  d o s e  w i l l  e n s u r e  o p t im a l  t i s s u e  p e n e t r a t i o n  f o r  s u p p r e s s i n g  th e
e s t a b l i s h e d  g r a n u l om a t o u s  i n f l amm a t ion  ov e r  t im e  and  a l low  fo r  t i s su e  r ep a i r  and  r e cov e ry  o f
o r g a n  fun c t ion a l i ty .  Th e  c u r r e n t  l ab e l  fo r  c an ak inum ab  ( I l a r i s®)  ind i c a t e s  a  s t a n d a r d  s t a r t ing
d o s a g e  o f  2  o r  4  mg/kg  up  to  1 5 0  m g  s . c .ev e ry  8  w e e k s  and  a l l ow s  fo r  ev e ry  8  w e e k s  do s ing
u p  to  8mg/kg  f o r  CAPS  p a t i e n t s  ≤ 4 0  kg  and  u p  to  6 0 0mg s . c .  fo r  tho s e  p a t i en t s  > 4 0k g  i f  a
s a t i s f a c to ry  c l in i c a l  r e spon s e  h a s  no t  b e en  a ch i ev ed  7  d ay s  a f t e r  t r e a tm en t  s t a r t .  Ev e ry4w e e k
s . c .  d o s i n g  u p  to  3 0 0  mg i s  ind i c a t ed  fo r  p a t i en t s  w i th  sy s t em i c  juv en i l e  i d i o p a t h i c  a r th r i t i s .
RA  p a t i e n t s ,  a  r e l a t i v e l y  c om p a r a b l e  p a t i e n t  popu l a t ion  to  s a r c o i d o s i s  in  t e rm s  o f  a g e  r a n g e
a n d  in f l amm a to ry  l ev e l s ,  h a v e  b e e n  t r e a t e d  w i th  3 0 0  mg  s . c .  u p  to  1 8 4  w e e k s
( s t u d i e sCACZ 8 8 5A 2 2 0 1 ,  E 1  &  E2 )  a t  ev e ry  2  w e ek s  fo r  t h e  f i r s t  12  w e e k s  a n d  e v e r y
4w e e k s  th e r e a f t e r .  Th i s  d o s i n g  r eg im en  w a s  w e l l- t o l e r a t e d ,  w i thou t  d o s e - d e p e n d e n t
d i f f e r e n c e s  i n  AE  i n c i d e n c e  c om p a r e d  t o  e v e r y  4  w e e ksd o s i n g  o f  1 5 0  m g  s . c .
ACZ 8 8 5  a dm i n i s t e r e d  s . c .  h a s  a n  a p p r o x im a t e  b io av a i l ab i l i ty  o f  70%  c om p a r e d  to  i . v .  
a dm i n i s t r a t i o n .  H ow e v e r ,  t h e r e  a r e  l ik e ly  t o  b e  d i f f e r en t i a l ,  o r g a n- d ep end en t  t i s s u e  l e v e l s  o f  
ACZ 8 8 5 ,  w i th  lung  t i s s u e  p e n e t r a t i o n  exp e c t ed  to  b e  1 0 - 15%  o f  t h e  sy s t em i c  expo su r e  
( W ange ta l2 0 0 8 ,  S h a he ta l2 0 1 2 ,  S h a he ta l2013) .  A n a ly si s  o f  a  r e c en t  f a i l e d  t r i a l  o f  th e  
TNF- α  inh ib i to r  g o l im um a b  in  c h r o n i c  s a r co ido s i s  p a t i e n t s  s u g g e s t e d  i n s u f f i c i e n t  d o s i n g  m ay  
h a v e  b e en  a  f a c t o r  ( Jud sone ta l2 0 1 4 ) .  T h u s ,  h igh e r  d o s i n g  o f  ACZ 8 8 5  i s  d e s i r e d  f o r  in i t i a l  
c l i n i c a l  t e s t i n g  o f  IL - 1β  b lo ck ad e ,  a  n o v e l  t h e r a p e u t i c  t a r g e tf o rt h i s  d i s e a s e  p r o c e s s .
T h e  du r a t ion  o f  ev e ry  4 -w e e k  d o s i n g  to  w e e k  20  i s  b a s e d  on  t h e  exp e c t ed  t im e  o f  2 4w e e k s  
r e q u i r e d  fo r  d e t e c t ing  fun c t ion a l  im p r o v em e n t  in  t h e  c l i n i c a l  ou t com e  o f  c h a n g e  in  p e r c en t  o f  
p r e d i c t e d  FVC  f o r  t h i s  p a t i e n t  p o p u l a t i o n .
I n  s umm a ry ,  in  o r d e r  to  op t im a l ly  a s s e s s  t h e  p o t e n t i a l  f o r  ACZ 8 8 5  in  i t s  f i r s t  t r i a l  in  
s a r c o i d o s i s  p a t i e n t s ,  a n  ev e ry  4 -w e e k  d o s i n g  a t  3 0 0  m g  s . c .  i s  j u s t i f i e d  to  r e a c h  ad equ a t e  
c i r c u l a t i n g  a n d  t i s su e  l ev e l s  w i th in  th e  t a rg e t  o rg an s  fo r  th e  an t i c ip a t ed  du r a t ion  r equ i r ed  fo r  a  
m e a n i n g f u l  c h a n g e  i n  t h e  l u n g  i n f l amm a t i o n  a n d  i n  t h e  s u b s eq u e n t  c l i n i c a l  o u t c om e s .
3 .4  Ra t iona le  fo r  cho ice  o f  compa ra to r
I n  t h i s  s t u d y ,  t h e  p l a c e b o  t o  ACZ 8 8 5  w i l l  b e  u s e d  a s  c om p a r a t o r  t o  p r o v i d e  o b j e c t i v e  e v i d e n c e  
o f  p o t e n t i a l  AE s  a n d  o th e r  s a f e t y  d a t a  a s  w e l l  a s  c l i n i c a l  e f f i c a cy  g e n e r a t e d  f rom  p a t i e n t s  
expo s ed  toACZ 8 8 5 .
No va r t i s Con f iden t ia l Page  33
Amended  P ro toco l  Ve rs ion  01  (C lean ) P ro toco l  No .  CACZ885X2205
3 .5  Ra t iona le  fo r  cho ice  o f  backg round  the rapy
P a t i e n t s  w i l l  c o n t i n u e  on  s t a b l e  b a c k g r o u n d  th e r apy  a s  e s t ab l i sh ed  p r io r  to  s tudy  e n t ry ,  
t h e r e b y  ju s t i fy ing  po t en t i a l  t r e a tm e n t  w i th  p l a c e b o .  S u b j e c t s  w i l l  b e  m a i n t a i n e d  o n  t h e i r  
p r e - ex i s t ing  s t ab l e  m ed i c a l  r e g im e n  fo r  t r e a tm en t  o f  p r e ex i s t ing  m ed i c a l  cond i t ion s ,  in c lud ing  
s a r c o i d o s i s .
3 .6  Pu rpose  and  t im ing  o f  in te r im  ana lyses /des ign  adap ta t ions
3 .7  R isks  and  bene f i ts
ACZ 8 8 5  h a s  no t  b e en  p r ev iou s ly  a dm i n i s t e r e d  w i th  t h e r a p e u t i c  i n t e n t  to  p a t i en t s  w i th  a c t iv e ,  
c h r o n i c  s a r c o ido s i s .  T h e r e f o r e ,  n o  s t a t em e n t  c an  b e  m a d e  a t  th i s  t im e  o n  t h e  a c t u a l  c l in i c a l  
b e n e f i t s  o f  ACZ 8 8 5  in  th i s  p a t i e n t  p o p u l a t i o n .  H ow e v e r ,  g i v e n  th e  m e ch an i sm  o f  a c t ion  o f  
ACZ 8 8 5  a n d  t h e  r e l ev an t  in f l amm a to ry  p a thw ay s  i n v o l v i n g  IL - 1β  a s  d i s c u s s e d  in  t h e  
b a ckg r o u n d  ( S e c t ion  1 . 1 ) ,  t h e r e  i s  a  r e a s o n a b l e  e x p e c t a t i o n  t h a t  a  th e r ap eu t i c  r e s p o n s e  c an  b e  
a c h i e v e d  w i t h  t h e  c om p o u n d  i n  s a r c o i d o s i s .
O v e r a l l ,  t h e  d e v e l o pm e n t  p r o g r am  w i th  ACZ 8 8 5  h a s  d em o n s t r a t e d  a  g o o d  s a f e t y  and  
to l e r ab i l i ty  p ro f i l e  a s  e v i d e n c e d  by  a  l ow  numb e r  o f  s tudy  d i s con t inu a t ion s  f o r  AE s ,  
p r edom in an t ly  m i ld  i n j e c t i o n  s i t e  r e a c t i o n s  a n d  n o  s p e c i f i c  t a r g e t  o rg an  tox i c i ty .  T h e  AE s  
p r o f i l e  i s  c h a r a c t e r i z e d  b y  non - sp e c i f i c  g a s t ro in t e s t in a l  and  c en t r a l  n e rvou s  sy s t e m  ev en t s ,  and  
i n f e c t i o n s  p r edom in an t ly  o f  th e  upp e r  r e sp i r a to ry  t r a c t ,  in  s om e  i n s t a n c e s  s e r i o u s ,  w i th  a l l  
i n f e c t i o n s  r e s p o n d i n g  t o  s t a n d a r d  t h e r a p y .
T h e  a v a i l a b l e  t o x i c o l o g y ,  e f f i c a cy ,  s a f e t y ,  to l e r ab i l i ty ,  l a c k  o f  d e t e c t a b l e  imm u n o g e n i c i t y  and  
e f f i c a cy  d a t a  in  MWS ,  RA ,  s J I A  and  g o u ty  a r th r i t i s ,  f u r t h e r  suppo r t  t h e  c l i n i c a l  d ev e lopm en t  
o f  c a n a k i n um a b  in  d i s e a s e s  in  w h i c h  IL - 1β  i s  l ik e ly  t o  h a v e  a  p r e d om i n a n t  ro l e .  
H ow e v e r ,s i n c e  p r e v e n t i n g  IL - 1β  r e c e p t o r  s i g n a l i n g  m ay a l t e r  immuno log i c  r e s p o n s i v e n e s s  in  
u n a n t i c i p a t e d  w ays ,  p a t i en t s  r e c e i v i n g  ACZ 8 8 5  w i l l  b e  c lo s e ly  m on i to r ed  f o r  c l i n i c a l  and  
l abo r a to ry  i n d i c a t o r s  o f  imm u n e  s u p p r e s s i o n  and  imm u n e  dy s r egu l a t ion ,  s u c h  a s  in f e c t ion  
i n c l u d i n g  oppo r tun i s t i c  i n f e c t i o n s  ( r e cogn i z ing  th a t  b l o c k i n g  IL - 1β  m ay m a s k  f ev e ra n d  b lun t  
t h e  in f l amm a to ry  r e spon s e  to  in f e c t ion ) ,  b l o o d  c e l l s  coun t  a b n o rm a l i t i e s  
( i n c l u d i n gn eu t rop en i a ) ,  a n d  d e v e l o pm e n t  o f  m a l i g n a n c i e s ,  a u t o imm u n e  m a n i f e s t a t i o n s  and  
hy p e r s en s i t iv i ty  r e a c t ion s .Co rpo ra te  Con f iden t ia l  In fo rma t ion
No va r t i s Con f iden t ia l Page  34
Amended  P ro toco l  Ve rs ion  01  (C lean ) P ro toco l  No .  CACZ885X2205
T h e  to t a l  r a d i a t i o n  w h o l e  body  e f f e c t iv e  d o s e  in  th i s  p r o t o c o l  w i l l  b e  l e s s  t h a n  2 5mS v ;  
[ADDRESS_426684]  s c a n n i n g  a n d  1 1  mSv  f r om  [F - 1 8 ]FDG - PET /CT  s c a n s ,  i n c l u d i n g  
a t t e n u a t i o n  c o r r e c t i o n  s c a n s .  I n  l a rg e rp a t i e n t s ,  a  h i g h e r  i n j e c t e d  [F - 1 8 ]FDG  a c t iv i ty  m ay  b e  
r e q u i r e d  bu t  t h e  to t a l  r a d i a t i o n  e x p o s u r e  in  t h e s e  p a t i e n t s  w i l l  no t  e x c e e d  3 0  mS v .  
T h i sam o u n t  o f  r ad i a t ion  i s  c o n s i d e r e d  to  b e  a  m o d e r a t e  r i s k ,  c a t ego ryI I I  ( I CRP6 2 )  a n d  i s  
b a l a n c e d  ag a in s t  t h e  s u b s t a n t i a l  s o c i e t a l  b e n e f i t  g a i n e d  f rom  t h e  t r i a l .I f  p a t i en t s  h a v e  a  
h i s t o r i c a l  [F - 1 8 ]FDG - PET /CT  s c a n  t h a t  c a n  b e  u s e d  a s  b a s e l i n e  s c a n ,  t h e non ly  t h e  f o l l ow  u p  
s c a n  w i l l  b e  c o n d u c t e d  a s  p a r t  o f  t h e  c l i n i c a l  p r o t o c o l .
A s  p a r t  o f  th e  s p i rom e t ry  a s s e s sm e n t  a t  V i s i t s  1 0 1  a n d  1 0 7 ,  a  s ing l e  do s e  o f  s h o r t - a c t i n g  
b r o n c h o d i l a t o r s  (SABA )  s a l b u t am o l / a l b u t e r o l  w i l l  b e  a dm i n i s t e r e d .  F o r  m o r e  in fo rm a t ion  
p l e a s e  r e f e r  t o  p r o d u c t  i n f o rm a t i o n  (SmPC /USP I ) .
Wom en  o f  c h i l d  b e a r ing  p o t e n t i a l  s h o u l d  b e  in fo rm ed  t h a t  t ak ing  t h e  s t udy  d r u g  m ay i nvo lv e  
u n k n ow n  r i sk s  to  th e  f e tu s  i f  p r egn an cy  w e r e  to  o c cu r  du r ing  th e  s tudy  a nd  ag r e e  th a t  in  o rd e r  
to  p a r t i c i p a t e  in  t h e  s tudy  t h ey  m u s t  adh e r e  to  t h e  c o n t r a c e p t i o n  r equ i r em en t  f o r  t h e  du r a t ion  
o f  t h e  s tudy .  I f  t h e r e  i s  any  q u e s t i o n  t h a t  t h e  s u b j e c t  w i l l  no t  r e l i ab ly  c omp ly ,  th ey  s h o u l d  no t  
b e  e n t e r e d  i n  t h e  s t u d y .
Th e r e  m ay b e  u n k n ow n  r i s k s  o f  ACZ 8 8 5  w h i c h  m a y  b e  s e r i o u s  a n d  u n f o r e s e e n .
3 .7 .1 B lood  samp le  vo lumes
A  m ax imum  o f  3 5 0  mL  o f  b l o o d  i s  p l a n n e d  t o  b e  c o l l e c t e d  o v e r  a  p e r iod  o f  a p p r o x im a t e l y  
3 8w e e k s ,  f r om  e a c h  s u b j e c t  a s  p a r t  o f  t h e  s tudy .  A d d i t i o n a l  s am p l e s  f o r  m o n i t o r i n g  o f  a n y  
s a f e t y  f i n d i n g s  w o u l d  b e  in  a d d i t i o n  to  th i s .  Th i s  i s  no t  c o n s i d e r e d  to  b e  a  r i s k  fo r  th i s  
p o p u l a t i o n .
T im i n g s  o f  b l o o d  s am p l e  c o l l e c t i o n  a r e  o u t l i n e d  i n  t h e  A s s e s sm e n t  S c h e d u l e ,S e c t i o n8 . 2.
A  summ a ry  b lood  l o g  i s  p r o v i d e d  in  t h e  S i t e  O p e r a t i o n s  M a n u a l ,  t o g e t h e r  w i th  i n s t r u c t i o n s  
f o r  a l l  s am p l e  c o l l e c t i o n ,  p r o c e s s i n g ,  s t o r a g e  a n d  s h i pm e n t  i n f o rm a t i o n .
S e e  S e c t i o n  8 . 9r e g a r d i n g  t h e  p o t e n t i a l  u s e  o f  r e s i d u a l  s am p l e s .
4  Popu la t ion
Th i s  s tudy  w i l l  r e c r u i t  p a t i e n t s  w i th  c h r o n i c  a c t i v e  pu lmon a ry  s a r co ido s i s  a s  d e f i n e d  b y  
d i s e a s e  d u r a t i o n  ≥1  y ea r  w i th  e v i d e n c e  o f  p e r s i s t en t  o r  p r o g r e s s i v e  p a r en chy m a l  c h a n g e s  a s  
c h a r a c t e r i z e d  by  r a d i o l o g i c a l  e v i d e n c e .  A  to t a l  o f  app rox im a t e ly  3 8  p a t i e n t s  w i l l  b e  
r a n d om i z e d  to  p a r t i c i p a t e  in  t h e  s tudy .  Th e  s amp l e  s i z e  w i l l  b e  r e - e s t im a t e d  a t  th e  in t e r im  
a n a l y si s  a n d  n um b e r  o f  r a n d om i z e dp a t i en t s  m ay  b e  i n c r e a s e d  u p  t o  a  m a x im um  o f  9 0 .
T h e  i n v e s t i g a t o r  mu s t  e n s u r e  t h a t  a l l  sub j e c t s  b e i n g  c o n s i d e r e d  f o r  th e  s tudy  m e e t  th e  
fo l low ing  e l ig ib i l i ty  c r i t e r i a .
No va r t i s Con f iden t ia l Page  35
Amended  P ro toco l  Ve rs ion  01  (C lean ) P ro toco l  No .  CACZ885X2205
S u b j e c t  s e l e c t i o n  i s  to  b e  e s t a b l i s h e d  by  c h e ck ing  t h r o u g h  a l l  in c lu s ion / ex c lu s ion  c r i t e r i a  a t  
s c r e e n i n g  a n d  f i r s t  b a s e l i n e  p r i o r  to  t h e  f i r s t  i n j e c t i o n .  S a f e ty l abo r a to ry  e v a lu a t ion s  and  
pu lmon a ry  f un c t ion  t e s t s  t a k e n  a t  f i r s t  b a s e l i n e  w i l l  no t  b e  a v a i l a b l e  p r i o r  to  f i r s t  i n j e c t i o n ,  
a n d  s c r e e n i n g  v a l u e s  s h o u l d  b e  u s e d  f o r  i n c l u s i o n  in  t h e  s tudy .  A  r e l e v a n t  r e co rd  
( e . g . ,c h e c k l i s t )  o f  t h e  e l ig ib i l i ty  c r i t e r i a  mu s t  b e  s t o r e d  w i th  t h e  sou r c e  do cum en t a t ion  a t  th e  
s tudy  s i t e .
D e v i a t i o n  f r om  a ny  e n t r y  c r i t e r i o n  e x c l u d e s  a  s u b j e c t  f r om  e n r o l lm e n t  i n t o  t h e  s t u d y .
4 .1  Inc lus ion  c r i te r ia
Pu lmon a ry s a r co ido s i s  p a t i e n t s  e l i g i b l e  f o r  in c lu s ion  in  t h i s  s tudy  m u s t  f u l f i l l  a l lo f  t h e  
f o l l ow i n g  c r i t e r i a :
1 .W r i t t e n  i n f o rm e d  c o n s e n t  m u s t  b e  o b t a i n e d  b e f o r e  a n y a s s e s sm en t  i s  p e r fo rm ed .
2 .M a l e  a n d  f em a l e  s u b j e c t s  a g e s  1 8  t o  8 0  y e a r s  o f  a g e  ( b o t h  i n c l u s iv e )
3 .S u b j e c t s  m u s t  w e i g h  a t  l e a s t  5 0  k g  t o  p a r t i c i p a t e  i n  t h e  s t u d y
4 .A b l e  t o  c omm u n i c a t e  w e l l  w i t h  t h e  i n v e s t i g a t o r  a n d  t o  u n d e r s t a n d  a n d  c om p l y w i t h  t h e
r e q u i r em e n t s  o f  t h e  s t u d y .
5 .D i s e a s e  d u r a t i o n  o f  ≥1  y e a r
6 .Cl in i c a l ly  a c t i v e  d i s e a s ed em o n s t r a t e d  e i t h e rby  a  b iop sy  ( a n y  o r g a n )  o r  by
b r o n c h o a l v e o l a r  l a v a g e( l ympho cy to s i s  >15% ,  CD4+/CD8+r a t i o  > 3 . 5 ,
CD 1 0 3+CD 4+/CD4+r a t i o  < 0 . 2 )( H e ron  e t  a l  2008) .  P a t i e n t sm u s t  a l s o  h a v ea l l  o f  t h e
f o l l ow i n g  c r i t e r i a :
MMRC  dys p n e a  s c a l e  ≥1
T h r e s h o l d  FVC  5 0  -9 0 %  o f  p r e d i c t e d  (P e l l e g r i n oe ta l2 0 0 5 ,  V o r s e l a a r se ta l2 0 1 5 )
E v i d e n c e  o f  p a r e n c hyma l  lung  invo lv em en t  by  [CONTACT_343839] t  s c r e e n i n g  o r  b y  h i s t o r i c a l
r a d i o l o g i c a l  e v i d e n c e( e .g .  CT ,  MR Io r  x- r ay )
4 .2  Exc lus ion  c r i te r ia
Pu lmon a ry s a r c o i d o s i s  p a t i e n t s  f u l f i l l i n g  any  o f  t h e  f o l l ow i n g  c r i t e r i a  a r e  n o te l i g i b l e  fo r  
in c lu s ion  in  th i s  s tudy :
1 .H i s to ry o f  known  hy p e r s en s i t iv i ty  to  c an ak inum ab
2 .C u r r e n t  i n h a l e d  u s e  o f  t o b a c c o  p r o d u c t s( u r i n e  c o t i n i n e  l e v e l  >5 0 0  n anog r am s/ mL )a t
s c r e e n i n g
3 .U s e  o f  o t h e r  i n v e s t i g a t i o n a l  d r u g s  a t  t h e  t im e  o f  e n r o l lm e n t ,  o r  w i t h i n  5  h a l f - l i v e s  o f
e n r o l lm e n t ,  o r  u n t i l  t h e  e x p e c t e d  PD  e f f e c t  h a s  r e t u r n e d  t o  b a s e l i n e ,  w h i c h e v e r  i s  l o n g e r ,
o r  l o n g e r  i f  r e q u i r e d  by  [INVESTIGATOR_48085] c a l  r e g u l a t i o n s
4 .P r e v i o u s  e x p o s u r e  t o  c o n c om i t a n t  t r e a tm e n t  a c c o r d i n g  t o  t h e  f o l l ow i n g  c r i t e r i a :
a .P r e d n i s o n e  > 15  mg /d ay  o r  c h a n g e s  i n  p r e d n i s o n e  d o s e  i n  t h e  8  w e e k s  p r i o r  t o  s c r e e n i n g
b .M o r e  t h a n  o n e  imm u n e- m o d u l a t o r  ( i . e . ,  m e t h o t re x a t e ,  a z a t h i o p r i n e ,  l e f l u n om i d e ,
hy d r o xy ch l o r o q u i n e )  o r  c h a n g e s  i n  t h e i r  d o s i n g  l e v e l s  w i t h i n  1 2  w e e k s  o f
r a n d om i z a t i o n .  R e f e r  t oS e c t i o n  5 . 2,  'P r o h i b i t e d  t r e a tm e n t s '  f o r  a d d i t i o n a l  d e t a i l s
c .Myc o p h e n o l a t e  u s e  w i t h i n  1 2  w e e k s  o f  r a n d om i z a t i o n
No va r t i s Con f iden t ia l Page  36
Amended  P ro toco l  Ve rs ion  01  (C lean ) P ro toco l  No .  CACZ885X2205
[ADDRESS_426685] e r
8 .Ex t r a- pu lmon a ry  s a r co ido s i s  a s  p r im a ry  t r e a tm e n t  i n d i c a t i o n  ( e . g . ,  i n v o l v i n g  b r a i n ,  h e a r t ,
ey e  and  r en a l  d i s e a s e  w i th  s ign i f i c an t  hy p e r c a l c em i a )
9 .Any c o n d i t i o n s  o r  s i g n i f i c a n t  m e d i c a l  p r o b l em s  w h i c h  i n  t h e  o p i n i o n  o f  t h e  i n v e s t i g a t o r
immun e - c om p r om i s e  t h e  p a t i e n t  a n d / o r  p l a c e s  t h e  p a t i e n t  a t  u n a c c e p t a b l e  r i s k  f o r
immunomodu l a to ry  th e r apy ,  s u c h  a s :
A b s o l u t e  n e u t r o p h i l  c o u n t  (ANC )  <LLN  ( 1 , 5 0 0 /μ l )
Th rombo cyt o p e n i a  CTCAE  v 4 . 0 3  G r a d e  1 :  P l a t e l e t s  <LLN  ( 7 5 . 0  x  1 09/L )
Any a c t i v e  o r  r e c u r r e n t  b a c t e r i a l ,  fung a l  (w i th  ex c ep t ion  o f  ony chom y c o s i s )  o r  v i r a l
i n f e c t i o n
P r e s e n c e  o f  h um a n  i mmunod e f i c i en cy v i r u s  (H IV )  i n f e c t i o n ,  a c t i v e  he p a t i t i s  B  o r
h e p a t i t i s  C  i n f e c t i o n sb a s e d  o n  s c r e e n i n g  l a b  r e s u l t s
P r e s e n c e  o f  a c t i v e  o r  l a t e n t  t u b e r c u l o s i s  (TB ).  I f  h i s to r i c a l  T b  r e s u l t  i s  a v a i l a b l e ,  T b
s t a t u s  n e e d s  t o  b e  c o n f i rm e d  p r e - r a n d om i z a t i o n  a s  d e t e rm i n e d  b y  s c r e e n i n g  l a b o r a t o r y
m e a s u r em e n t s.
C l i n i c a l  e v i d e n c e  o r  h i s t o r y o f  m u l t i p l e  s c l e r o s i s  o r  o t h e r  d em y e l i n a t i n g  d i s e a s e s ,  o r
F e l ty ’ s  sy n d r om e
1 0 .L i v e  v a c c i n a t i o n s  w it h i n  3  m o n t h s  p r i o r  t o  s c r e e n i n g
1 1 .C u r r e n t  s e v e r e  p r o g r e s s i v e  o r  u n c o n t r o l l e d  d i s e a s e ,  w h i c h  i n  t h e  j u d gm e n t  o f  t h e  c l i n i c a l
i n v e s t i g a t o r  r e n d e r s  t h e  p a t i e n t  u n s u i t a b l e  f o r  t h e  t r i a l
1 2 .I n ab i l i ty  o r  u nw i l l i n g n e s s  t o  u n d e r g o  r e p e a t e d  v e n i p u n c t u r e  ( e . g . ,  b e c a u s e  o f  p o o r
to l e r ab i l i ty  o r  l a c k  o f  a c c e s s  t o  v e i n s )
1 3 .D o n a t i o n  o r  l o s s  o f  b l o o d  ( am o u n t  d e p e n d i n g  o n  a g e  a n d  w e i g h t ,  1 0- 2 0%  o r  m o r e  o f
v o l um e ,  w i t h i n  8  w e e k s  p r i o r  t o  f i r s t  d o s i n g ,  o r  l o n g e r  i f  r e q u i r e d  by  l o c a l  r e g u l a t i o n
1 4 .H i s to ry o f  m a l ign an cy  o f  any  o rg an  sy s t em  ( o t h e r  t h a n  l o c a l i z e d  b a s a l  c e l l  c a r c i n om a  o f
t h e  s k i n ) ,  t r e a t e d  o r  u n t r e a t e d ,  w i t h i n  t h e  p a s t  5  y ea r s ,  r e g a r d l e s s  o f  w h e t h e r  t h e r e  i s
e v i d e n c e  o fl o c a l  r e c u r r e n c e  o r  m e t a s t a s e s
1 5 .C o n t r a i n d i c a t i o n s  t o  FDG- PET  s c a n  i n v e s t i g a t i o n s ,  s u c h  a s  s e v e r e  c l a u s tr o p h o b i a  o r
u n c o n t r o l l e d  d i a b e t e s
1 6 .P r e g n a n t  o r  n u r s i n g  ( l a c t a t i n g )  w om e n ,  w h e r e  p r e g n a n c y i s  d e f i n e d  a s  t h e  s t a t e  o f  a  f em a l e
a f t e r  c o n c e p t i o n  a n d  u n t i l  t h e  t e rm i n a t i o n  o f  g e s t a t i o n ,  c o n f i rm e d  b ya  po s i t iv e  hCG
l abo r a to ry  t e s t
No va r t i s Con f iden t ia l Page  37
Amended  P ro toco l  Ve rs ion  01  (C lean ) P ro toco l  No .  CACZ885X2205
1 7 .W om e n  o f  c h i l d- b e a r i n g  p o t e n t i a l ,  d e f i n e d  a s  a l l  w om e n  p h y s io log i c a l ly  c a p a b l e  o f
b e com ing  p r egn an t ,  un l e s s  th ey  a r e  u s i n g  b a s i c  m e t h o d s  o f  c o n t r a c e p t i o n  d u r i n g  d o s i n g  o f
i n v e s t i g a t i o n a l  d r u g .  Ba s i c  con t ra c ep t ion  m e thod s  in c lud e :
T o t a l  a b s t i n e n c ef r om  h e t e r o s e x u a l  i n t e r c o u r s e  (w h e n  t h i s  i s  i n  l i n e  w i t h  t h e  p r e f e r r e d
a n d  u s u a l  l i f e s t y le  o f  t h e  s u b j e c t ) .  P e r i o d i c  a b s t i n e n c e  ( e . g . , c a l e n d a r ,  o v u l a t i o n ,
sy m p t o t h e rm a l ,  p o s t -o v u l a t i o n  m e t h o d s )  a n d  w i t h d r aw a l  a r e  n o t  a c c e p t a b l e  m e t h o d s
o f  c o n t r a c e p t i o n
F em a l e  s t e r i l i z a t i o n  ( h a v e  h a d  s u r g i c a l  bi l a t e r a l  o o p h o r e c t om y  w i t h  o r  w i t h o u t
hy s t e r e c t om y ) ,  t o t a l  hy st e r e c tomy  o r  t u b a l  l i g a t i o n  a t  l e a s t  6w e e k s  b e f o re  t a k i n g
i n v e s t i g a t i o n a l  d r u g .  I n  c a s e  o f  o o p h o r e c t om y  a l o n e ,  o n l y  w h e n  t h e  r e p r o d u c t i v e
s t a t u s  o f  t h e  w om a n  h a s  b e e n  c o n f i rm e d  b y  f o l l ow  u p  h o r m o n e  l e v e l  a s s e s sm e n t
M a l e  s t e r i l i z a t i o n  ( a t  l e a s t  6  m o n t h s  p r i o r  t o  s c r e e n i n g ) .  F o r  f em a l e  s u b j e c t s  o n  t h e
s tudy ,  t h e  v a s e c t om i z e d  m a l e  p a r t n e r  s h o u l d  b e  t h e  s o l e  p a r t n e r  f o r  t h a t  s u b j e c t .
B a r r i e r  m e t h o d s  o f  c o n t r a c e p t i o n :  c o n d om  o r  oc c l u s i v e  c a p  ( d i a p h r a gm  o r
c e r v i c a l / v a u l t  c a p s ) .  F o r  [LOCATION_006] :  w i t h  s p e rm i c i d a l  f o am / g e l / f i lm / c r e am / v a g i n a l
suppo s i to ry
U s e  o f  o r a l ,  i n j e c t e d  o r  im p l a n t e d  h o rm o n a l  m e t h o d s  o f  c o n t r a c e p t i o n  o r  o t h e r  f o rm s
o f  h o rm o n a l  c o n t r a c e p t i o n  t h a t  h a v e  c om p a r a b l e  e f f i c a c y  ( f a i l u r e  r a t e  < 1% ) ,  f o r
e x am p l e  h o rm o n e  v a g i n a l  r i n g  o r  t r a n s d e rm a l  h o rm o n e  c o n t r a c e p t i o n  o r  p l a c em e n t  o f
a n  i n t r a u t e r i n e  d e v i c e  ( IUD )  o r  i n t r a u t e r i n e  s y st em  ( IUS )
I n  c a s e  o f  u s e  o f  o r a l  c o n t r a c e p t i o n  w om e n  s h o u l d  b e  s t a b l e  o n  t h e  s am e  p i l l  f o r  a  
m in imum  o f  3  m o n t h s  b e f o r e  t a k i ng  s t u dy  d r u g
W om e n  a r e  c o n s i d e r e d  p o s t- m e n o p a u s a l  a n d  n o t  o f  c h i l d  b e a r i n g  p o t e n t i a l  i f  t h e y h a v e  
h a d  1 2  m o n t h s  o f  n a t u r a l  ( s p o n t a n e o u s )  am e n o r r h e a  w i t h  a n  a p p r o p r i a t e  c l i n i c a l  p r o f i l e  
( e . g . , ag e  app rop r i a t e ,  h i s to ry  o f  v a s om o t o r  s ymp t om s )  o r  h a v e  h a d  s u r g i c a l  b i l a t e r a l  
o o p h o r e c t omy  (w i t h  o r  w i t h o u t  h y s t e r e c tomy ) ,  to t a l  hy s t e r e c t om y  o r  t u b a l  l i g a t i o n  a t  l e a s t  
s i x  w e e k s  a g o .  I n  t h e  c a s e  o f  o o p h o r e c t om y  a lon e ,  on ly  w h e n  t h e  r e p r o d u c t i v e  s t a t u s  o f  
t h e  w om a n  h a s  b e e n  c o n f i rm e d  b y  f o l l ow  u p  h o rm o n e  l e v e l  a s s e s sm e n t  i s  s h e  c o n s i d e r e d  
n o t  o f  c h i l d  b e a r i n g  p o t e n t i a l .
1 8 .H i s to ry o f  d r u g  o r  a l c o h o l  a b u s e  w i t h i n  t h e  1 2  m o n t h s  p r i o r  t o  d o s i n g ,  o r  e v i d e n c e  o f  s u c h
a b u s e  a s  i n d i c a t e d  b y  t h e  l a b o r a t o r y  a s s a y s
No  a d d i t i o n a l  e x c l u s i o n s  m a y  b e  app l i ed  by  t h e  i n v e s t i g a t o r ,  i n  o r d e r  t o  e n s u r e  t h a t  t h e  s t u d y  
p o p u l a t i o n  w i l l  b e  r e p r e s e n t a t i v e  o f  a l l  e l i g i b l e  p a t i e n t s .
No va r t i s Con f iden t ia l Page  38
Amended  P ro toco l  Ve rs ion  01  (C lean ) P ro toco l  No .  CACZ885X2205
5  Res t r ic t ions  fo r  S tudy Sub jec ts
D u r i n g  r e c r u i tm e n t ,  s c r e e n i n g / i n f o rm e d  c o n s e n t  r e v i ew ,  a n d  b a s e l i n e  v is i t ,  t h e  s u b j e c t s  m u s t  
b e  i n f o rm e d  a n d  r em i n d e d  o f  t h e  f o l l ow i n g  r e s t r i c t i o n s :
5 .1  Con t racep t ion  requ i remen ts
P l e a s e  r e f e r  to  ex c lu s ion  c r i t e r i a  (S e c t ion  4 .2)  fo r  d e t a i l s  o f  con t r a c ep t ion  r equ i r em en t s  fo r  th e  
s tu dy .
5 .2  P roh ib i ted  t rea tmen t
U s e  o f  t h e  t r e a tm e n t s  d i sp l ay ed  in  t h e  t a b l e  b e low  a r e  NOT  a l low ed  d u r i n g  t h e  s c r e en ing  
p e r i o d  o r  a f t e r  th e  s t a r t  o f  s tudy  t r e a tm e n t  d u e  t h e  c o n c e r n  f o r  i n c r e a s e d  po t en t i a l  
imm u n o s u p p r e s s a n t - r e l a t ed  cond i t ion s .  Th e s e  a r e  p roh ib i t edfo r  th e  du r a t ion  o f  th e  s tudy  un t i l  
30  d ay s  a f t e r  th e  l a s t  s tudy  v i s i t .
Tab le  5 -1  P roh ib i ted  t rea tmen t
Med ica t ion Ac t ion  to  be  taken
B io log i c  d rug s  ta rge t ing  the  s y s tem i c  immune  s y s tem  (e .g . ,  
TNF- α  b lo c ke r s ,  ana k in ra ,  r i tu x imab ,  aba ta cep t ,  to c i l i zumab )D i s con t inue  s tud y  d rug
L i ve  va c c ine s  (w i th in  90  da y s  o f  s tud y  d rug  do s ing )  D i s con t inue  s tud y  t rea tmen t ;  i f  l i ve  va c c ine s  
a re  g i ven  a f te r  s c reen ing  bu t  p r io r  to  s tud y  d rug  
adm in i s t ra t ion ,  the  sub je c t  ma y  be  en ro l led  
a f te r  90  da y s  ha ve  pa s sed  s in ce  va c c ine  
adm in i s t ra t ion  i f  the  sub je c t  con t inue s  to  mee t  
e l ig ib i l i t y  c r i te r ia  upon  re -sc reen ing
S y s tem i c  immune  supp re s s i ve  d rug s ,  e x cep t  fo r  the  fo l low ing :  
p redn isone  ≤15  mg /d  and /o r  no  mo re  than  one  o f  the  fo l low ing  
c y to to x i c  d rug s :  me tho t re xa te ,  a za th iop r ine ,  le f lunom ide  o r  
h yd ro x y ch lo roqu ine ,  p ro v ided  do s ing  o f  the se  l i s ted  
med i ca t ion s  ha s  rema ined  un changed  ina  12wee k  pe r iod  p r io r  
to  random i za t ion  and  rema in s  un changed  th roughou t  s tud y  
pe r iodAn y  a cu te  do s ing  o f  immune  supp re s s i ve  d rug s  
ma y  requ i re  d i s con t inua t ion  o f  s tud y  t rea tmen t  
and  pa r t i c ipa t ion  and  w i l l  ha ve  to  beeva lua ted  
w i th  Sponso r  on  a  case- b y  ca se  ba s i s
5 .3  D ie ta ry res t r ic t ions  and  smok ing
T h er e  a r e  n o  s p e c i f i c  d i e t a ry  r e s t r i c t i o n s  e x c e p t  f o r  t h o s e  r e q u i r e d  wh en  p r e p a r i n g  fo r  PET  
s c a n n i n g .  S u b j e c t s  a r e  n o t  a l l ow e d  t o  p a r t i c i p a t e  i n  t h e  t r i a l  i f  t h e y  sm o k e .
5 .4  O the r  res t r ic t ions
On  s tudy d ay s  wh en  sp i rom e t ry  w i l l  b e  p e r f o rm e d ,  p a t i e n t s  s h o u l d  r e f r a i n  f r om  t h e  f o l l ow i n g :
U s i n g  o f  b r o n c h o d i l a t o r s  f o r  a t  l e a s t  6  h o u r s  f o r  s h o r t -a c t i n g  β - 2  a g o n i s t  a n d  a t  l e a s t  4 8
h o u r s  f o r  l o n g - a c t i n g  β - 2  agon i s t  p r io r  to  sp i rom e t ry  t e s t ing
D r i n k i n g  a l c o h o l  f o r  4  h o u r s  p r i o r  t o  s p i r om e t r y t e s t ing
P a r t i c i p a t i n g  i n  s t r e n uou s  a c t iv i ty  fo r  30  m in  p r io r  to  sp i rom e t ry  t e s t ing
W e a r ing  c lo th e s  th a t  sub s t an t i a l ly r e s t r i c t  f u l l  c h e s t  a n d  a b d om i n a l  e x p a n s i o n
E a t i n g  a  l a r g e  m e a l  w i t h i n  2  h o u r s  o f  t e s t i n g
No va r t i s Con f iden t ia l Page  39
Amended  P ro toco l  Ve rs ion  01  (C lean ) P ro toco l  No .  CACZ885X2205
On  s tudy d ay s  wh en  [F - 18 ]FDG -PET /CT  s c a n  i s  p e r f o rm e d ,  p a t i e n t s  s h o u l d :
R e f r a i n  f r om  a l c o h o l  c o n s um p t i o n  a n d  v i g o r o u s  s p o r t s  a c t i v i t i e s  2 4  h o u r s  p r i o r  t o  t h e
m e a s u r em e n t
B e  w e l l- hy d r a t e d  a n d  f a s t e d  4  h o u r s  p r i o r  t o  a dm i n i s t r a t i o n  o f  r a d i o t r a c e r
H a v e  a  b l o o d  g l u c o s e  l e v e l  b e l ow  1 1  mm o l /L ( 2 0 0  m g / dL )
6  T rea tmen t
6 .1  S tudy  t rea tmen t
D et a i l s  o n  t h e  s t o r a g e  and  m a n a g em e n t  o f  s tudy  m e d i c a t i o n ,  r andom i z a t ion  a n d  i n s t r u c t i o n s  
f o r  p r e s c r i b i n g  a n d  t a k i n g  s tudy  t r e a tm e n t  a r e  o u t l i n e d  in  S e c t i o n  3  o f  t h e  S i t e  Op e r a t ion s  
M a n u a l .
6 .1 .1 Inv es t iga t iona l  t rea tmen t  and  con t ro l  d rugs
T h e  i n v e s t i g a t i o n a l  d rug ,  ACZ 8 8 5  ( c a n a k i n um a b )  1 5 0  m g /  1mL  a n d  m a t c h i n g  p l a c e b o  l iqu id  
in  v i a l s  w i l l  b e  p r ep a r ed  by  [CONTACT_343842] a r t i s  and  supp l i ed  to  th e  I n v e s t i g a t o r  a s  b l i n d e d  s u b j e c t  p a c k s .
6 .1 .2 Add i t iona l  s tudy t rea tmen t
[F - 1 8 ] f l u o r o d e o x y g l u c o s e  ( [F - 18 ]FDG )  PET  t r a c e rw i l l  b e  p r o d u c e d  u n d er  GMP .
[F - 1 8 ]FDG  PET  h a s  a p p r o v e d  N ew  D r u g  A p p l i c a t i o n  i n  t h e  US  a n d  m a r k e t i n g  a u t h o r i t i e s
i n  t h e  EU  f o r  c e r t a i n  i n d i c a t i o n s .  [F - 1 8 ]FDG  w i l l  b e  s o u r c e d  l o c a l ly .
S a l b u t am o l /A l b u t e r o l  w i l l  b e  u s e d  d u r i n g  t h e  s p i r om e t r y t e s t i n g  a n d  w i l l  b e  s o u r c e d
lo c a l ly .
6 .2  T rea tmen t  a rms
S u b j e c t s  w i l l  b e  a s s ign ed  to  o n e  o f  t h e  f o l l ow i n g  tw o  t r e a tm e n t  a rm s  in  a  r a t i o  o f  1 :1 .  
S tudyt r e a tm e n t s  a r e  d e f i n e d  a s :
D o s e s  o f  3 0 0  m g  ACZ 8 8 5  s . c .  e v e r y  f o u r  w e e k s
D o s e s  o f  p l a c e b o  t o  m a t c h  t h e  3 0 0  m g  ACZ 8 8 5  s . c .  e v e r y f o u r  w e e k s
6 .3  T rea tmen t  ass ignmen t  and  random iza t ion
A l l  e l i g i b l e  s u b j e c t s  w i l l  b e  r a n d om i z e d  v i a  I n t e r a c t i v e  R e s p o n s e  T e chno logy ( IRT )  to  o n e  o f  
t h e  t r e a tm e n t  a rm s .  Th e  i n v e s t i g a t o r  o r  h i s /h e r  d e l e g a t e  w i l l  c o n t a c t  th e  IRT  a f t e r  con f i rm ing  
t h a t  t h e  s u b j e c t  f u l f i l l s  a l l  t h e  i n c l u s i o n / e x c l u s i o n  c r i t e r i a .  S u b j e c t s  w i l l  u n d e r g o  s t r a t i f i c a t i o n  
b a s e d  o n  b a s e l i n e  [F - 18 ]  FDG- PET /CT  r e s u l t s .  Th e  IR T  w i l l  a s s i g n  a  r andom i z a t ion  n um b e r  
to  t h e  s u b j e c t ,  wh i ch  w i l l  b e  u s e d  to  l ink  th e  sub j e c t  to  a  t r e a tm e n t  a rm  a n d  w i l l  sp e c i fy  a  
u n i q u e  m e d i c a tion  numb e r  fo r  th e  f i r s t  p a ck ag e  o f  inv e s t ig a t ion a l  t r e a tm en t  to  b e  d i sp en s ed  to  
t h e  s u b j e c t .  T h e  r a n d om i z a t i o n  n um b e r  w i l l  n o t  b e  c omm u n i c a t e d  t o  t h e  c a l l e r .
T h e  r a n d om i z a t i o n  n um b e r s  w i l l  b e  g e n e r a t e d  u s ing  t h e  f o l l ow i n g  p r o c e d u r e  to  e n s u r e  th a t  
t r e a tm e n t  a s s i g nm e n t  i s  u n b i a s e d  a n d  c o n c e a l e d  f rom  s u b j e c t s  and  i n v e s t i g a t o r  s t a f f .  
As u b j e c t  r a n d om i z a t i o n  l i s t  w i l l  b e  p r o d u c e d  b y  t h e  IR T  p r o v i d e r  u s ing  a  v a l i d a t e d  sy s t em  
t h a t  a u t om a t e s  t h e  r a n d om  a s s i g nm e n t  o f  t r e a tm e n t  a rm s  to  r a n d om i z a t i o n  n um b e r s .O n c e  a  
No va r t i s Con f iden t ia l Page  40
Amended  P ro toco l  Ve rs ion  01  (C lean ) P ro toco l  No .  CACZ885X2205
p a t i e n t  i s  d e em e d  e l i g i b l e  f o r  e n r o l lm e n t  in to  t h e  s tudy  a n d  r e a d y  fo r  d o s i n g ,  t h e  n ex t  l ow e s t  
a v a i l a b l e  r a n d om i z a t i o n  n um b e r  w i l l  b e  a s s ign ed .  T h e s e  r a n d om i z a t i o n  n um b e r s  a r e  l i n k e d  to  
t h e  d i f f e r e n t  t r e a tm e n t  a rm s ,  w h i c h  in  t u r n  a r e  l i n k e d  to  m e d i c a t i o n  numb e r s .  A  s ep a r a t e  
m e d i c a t i o n  l i s t  w i l l  b e  p r o d u c e d  by  o r  und e r  th e  r e spon s ib i l i ty  o f  Nov a r t i s  D r u g  Supp ly  
M a n a g em e n t  u s ing  a  v a l id a t ed  sy s t em  t h a t  a u t om a t e s  t h e  r a n d om  a s s ignm en t  o f  m ed i c a t ion  
n um b e r s  t o  p a c k s  c o n t a i n i n g  t h e  i n v e s t i g a t i o n a l  d r u g .
6 .4  T rea tmen t  b l ind ing
Th i s  i s  a  s u b j e c t -a n d  i n v e s t i g a t o r - b l i n d e ds tudy ;  sub j e c t s ,  i n v e s t i g a t o r  s t a f f ,  a n d  p e r son s  
p e r f o rm i n g  th e  a s s e s sm en t s  w i l l  r em a i n  b l ind  to  th e  id en t i ty  o f  s tudy  t r e a tm en t s  a c c o r d i n g  to  
t h e  s p e c i f i c a t i o n s  p r o v i d e d  i n  T a b l e  6- 1 .
T h e  id en t i ty  o f  th e  t r e a tm en t s  w i l l  b e  con c e a l ed  by  [CONTACT_3433] e  u s e  o f  s tudy  d rug s  th a t  a r e  a l l  id en t i c a l  
i n  p a c k a g i n g ,  l a b e l i n g ,  s c h e d u l e  o f  a dm i n i s t r a t i o n ,  a p p e a r a n c e ,  t a s t e  a n d  o d o r .
R andom i z a t ion  d a t a  a r e  k e p t  s t r i c t ly  c on f id en t i a l ,  a n d  a r e  a c c e s s i b l e  on ly  t o  au tho r i z ed  
p e r s o n n e l ,  un t i l  u n b l i n d i n g  o f  t h e  t r i a l  a s  d e s c r i b e d  in  t h e  b l i n d i n g  t a b l e  ( T a b l e  6 - 1 ) .  
T h ec l i n i c a l  t e am  m ay c omm u n i c a t e  unb l ind ed  i n t e r im  an a ly s i sr e su l t s  ( e . g . ,  in fo rm a t ion  
n e e d e d  fo r  p l ann ing /mod i fy ing  a n o t h e r  s tudy )  to  r e l e v a n t  Nov a r t i s  t e am s  f o r  in fo rm a t ion ,  
c o n s u l t i n g  a n d / o r  d e c i s i o n  p u r p o s e s .  
N o  f u r t h e r  d i s s em i n a t i o n  o f  i n t e r im  r e s u l t s  s h o u l d  o c c u r ,  in  p a r t i c u l a r  no t  w i th  i n d i v i d u a l s  
i n v o l v e din  t r e a t ing  th e  s tudy ' s  s u b j e c t s  o r  a s s e s s i n g  c l i n i c a l  d a t a  ( e . g . ,ECG s ,  im ag e s ,  
sy mp tom s )  ob t a in ed  in  th e  s tudy.
U n b l i n d i n g  w i l l  o c c u r  in  t h e  c a s e  o f  p a t i e n t  em e r g e n c i e s  ( s e e  S e c t ion  6 . 7 ) ,  a t  t h e  t im e  o f  
i n t e r im  a n a l y si s  and  a t  th e  con c lu s ion  o f  th e  s tudy .
S i te  s ta f f
U n b l i n d i n g  a  s i n g l e  s u b j e c t  a t  s i t e  f o r  s a f e t y  r e a son s  (n e c e s s a ry  f o r  sub j e c t  m a n a g em e n t )  w i l l  
o c c u r  v i a  a n  em e r g e n c y  sy s t em  in  p l a c e  a t  th e  s i t e  ( s e eS e c t i o n  6 . 7) .
Sponso r  s ta f f
T h e  f o l l ow i n g  u n b l i n d e d  s p o n s o r  r o l e s  a r e  r e q u i r e d  f o r  t h i s  s t u d y:
U n b l i n d e d  s am p l e  a n a ly st ( s )  (PK /PD / I G )
T h e  s am p l e  a n a l y st s  w i l l  r e c e i v e  a  c o p y  o f  t h e  r a n d om i z a t i o n  s c h e d u l e  ( v i a  r e q u e s t  to  th e  
R andom i z a t ion  O f f i ce ) ,  to  f a c i l i t a t e  an a ly s i s  o f  th e  s am p l e s .  T h e  s am p l e  an a ly s t s  w i l l  p r o v i d e  
t h e  s am p l e  d a t a  t o  t h e  s t u d y  t e am  u n d e r  b l i n d e d  c o n d i t i o n s  u n l e s s  o t h e rw i s e  a l l ow e d .
T h e  s tudy  s t a t i s t i c i an  w i l l  b e  a b l e  to  a c c e s s  th e  r andom i z a t ion  l i s t  f o r  in t e r im  a n a l y se s  a n d  i s  
a l l ow e d  to  s h a r e  u n b l i n d e d  i n f o rm a t i o n  w i th  t h e  r e s t  o f  t h e  c l i n i c a l  t e am  a s  a p p r o p r i a t e  fo r  
i n t e r n a l  d e c i s i o n  pu rpo s e s ,  a s  o u t l i n e d  in  T ab l e  6 - 1 .  F o r  e x am p l e ,  u n b l i n d e d  s umm a r i e s  and  
u n b l i n d e d  i n d i v i d ua l  d a t a  c a n  b e  s h a r e d  w i t h  t h e  t e am  f o r  i n t e r im  a n a l y s e s .
S tudy p r o g r amm e r s  and  o t h e r  p e r sonn e l  i n v o l v e d  in  s tudy  d a t a  a n a l y si s  ( e . g . ,b iom a rk e r  
e x p e r t )  a r e  a l low ed  to  a c c e s s  t r e a tm e n t  a s s ignm en t  i n f o rm a t i o n  f o r  t h e  p u r p o s e  o f  condu c t ing  
i n t e r im  a n a l y se s .
No va r t i s Con f iden t ia l Page  41
Amended  P ro toco l  Ve rs ion  01  (C lean ) P ro toco l  No .  CACZ885X2205
Tab le  6 -1  B l ind ing  leve ls
Ro leT ime  o r  Even t
Random i za t ion  
l is t  gene ra tedT rea tmen t  
a l loca t ion  &  
dos ingSa fe ty even t  
(s ing le  sub jec t  
unb l inded )In te r im  
Ana lysis  &  
dose  esca la t ion
Sub je c t s /Pa t ien t s B B U I B
S i te  s ta f f B B U I B
Unb l inded  s i te  s ta f f  ( see  te x t  fo r  
de ta i ls )  NA NA NA NA
D rug  Supp l y  and  Random i za t ion  
O f f iceU I U I U I U I
Unb l inded  spon so r  s ta f f  ( see  te x t  
fo r  de ta i ls )U I U I U I U I
S ta t is t ic ian /s ta t is t ica l  
p rog ramme r /da ta  ana l y s t sB B U I U I
Independen t  comm i t tee s  u sed  fo r  
a s se s s ing  in te r im  re su l t sNA NA NA NA
A l l  o the r  spon so r  s ta f f  no t  
iden t i f ied  abo veB B U I U I
B  Rema in s  b l inded
NA  No t  app l i cab le
U I  A l lowed  to  be  unb l inded  on  ind i v idua l  pa t ien t  le ve l
6 .5  T rea t ing  the  sub jec t
ACZ 8 8 5  w i l l  b e  a dm i n i s t e r e d  to  t h e  s u b j e c t  v i a  t h e  f o l l ow i n g  r o u t e  o f  a dm i n i s t r a t i o n  ( s . c .
i n j e c t i o n )a t  t h e  i n v e s t i g a t i o n a l  s i t e .  S e e  t h e  S i t e  O p e r a t i o n s  M a n u a l  f o r  f u r t h e r  d e t a i l s .
S p o n s o r  q u a l i f i e d  m ed i c a l  p e r s o n n e l  w i l l  b e  r e ad i ly  a v a i l a b l e  to  adv i s e  o n  t r i a l - r e l a t ed  
m e d i c a l  q u e s t i o n s  o r  p r o b l em s .
6 .6  Pe rm i t ted  dose  ad jus tmen ts  and  in te r rup t ions  o f  s tudy t rea tmen t
S c h e d u l e d  d o s i n g  o f  s tudy  d r u g  m ay b e  d e l ay ed  by  u p  to  5  d ay s  i f  s u b j e c t s  p r e s e n t  w i th  
c o n d i t i o n s  t h a t  r equ i r e  w i t h h o l d i n g  o f  s tudy  d r u g ,  e .g . ,  ev id en c e  f o r  a c t i v e  in f e c t ion  
( t r e a t e do r  un t r e a t ed )  o r  a c u t e  a b dom in a l  p a in .  Ou t s id e  o f  th i s  5- d ay  w indow ,  th e  do s e  w i l l  b e  
c o n s i d e r e d  m i s s e d .  T h e s e  c h a n g e s  mu s t  b e  r e c o r d e d  o n  th e  D o s a g e  Adm in i s t r a t ion  R e c o r d  
CRF .  T h e  5 - d ay  w indow  f o r  t h o s e  sub j e c t s  r e q u i r i n g  s tudy  d r u g  to  b e  w i thh e l d  un t i l  
r e s o l u t i o n  i si n  a d d i t i o n  to  t h e  d e f i n e d  + /- [ADDRESS_426686] h e  f i r s t  d o s e  a dm i n i s t r a t i o n .
S u b j e c t s  a r e  a b l e  to  m i s s  n o  m o r e  t h a n  on e  d o s e  adm in i s t r a t ion .  A l l  m i s s e d  d o s e  
a dm i n i s t r a t i o n s  mu s t  b e  d i s c u s s e d  w i th  t h e  Spon so r  to  d e t e rm i n e  i f  th e  s u b j e c t  s h o u l d  b e  
d i s c o n tinu e d  f r om  f u r t h e r  s t u d y  t r e a tm e n t .
No va r t i s Con f iden t ia l Page  42
Amended  P ro toco l  Ve rs ion  01  (C lean ) P ro toco l  No .  CACZ885X2205
6 .7  Eme rgency b reak ing  o f  ass igned  t rea tmen t  code
Em e rg en cy t r e a tm e n t  cod e  b r e a k s  mu s t  on ly  b e  u n d e r t a k e n  wh en  i t  i s  r e q u i r e d  to  in  o r d e r  to  
t r e a t  t h e  s u b j e c t  s a f e ly .  Mo s t  o f t e n ,  s tudy  t r e a tm en t  d i s c o n t i n u a t i o n  a n d  k n ow l e d g eo f  th e  
p o s s i b l e  t r e a tm e n t  a s s i g nm e n t s  a r e  s u f f i c i e n t  to  t r e a t  a  s tudy  s ub j e c t  who  p r e s e n t s  w i th  an  
em e rg en cy  c ond i t ion .  Em e rg en cy t r e a tm e n t  cod e  b r e a k s  a r e  p e r fo rm ed  u s i n g  t h e  IR T .  
Wh enth e  inv e s t ig a to r  con t a c t s  th e  sy s t em  to  b r e ak  a  t r e a tm en t  cod e  fo r  a  sub j e c t ,  h e / sh e  mu s t  
p r o v i d e  t h e  r e q u e s t e d  sub j e c t  id en t i fy ing  in fo rm a t ion  a n d  c o n f i rm  t h e  n e c e s s i ty  t o  b r e a k  th e  
t r e a tm e n t  c o d e  f o r  t h e  sub j e c t .  T h e  i n v e s t i g a t o r  w i l l  t h e n  r e c e i v e  d e t a i l s  o f  t h e  i n v e s t i g a t i o n a l  
d r u g  t r e a tm e n t  f o r  t h e  s p e c i f i e d  s u b j e c t  a n da  f ax  o r  em a i l  c o n f i rm i n g  th i s  in fo rm a t ion .  
T h esy s t em  w i l l  au tom a t i c a l ly  i n fo rm  t h e  s tudy  m o n i t o r  f o r  t h e  s i t e  a n d  t h e  s tudy  t e am  th a t  
t h e  c o d e  h a s  b e e n  b r o k e n .
I t  i s  th e  i n v e s t i g a t o r ’ s  r e spon s ib i l i ty  t o  e n s u r e  th a t  t h e r e  i s  a  d ep end ab l e  p r o c e d u r e  in  p l a c e  to  
a l l ow  a c c e s s  t o  t h e  IRT  i n  c a s e  o f  em e r g e n c y .  T h e  i n v e s t i g a t o r  w i l l  n e e d  t o  p r o v i d e :
p r o t o c o l  n um b e r
s tudy  d r u g  n am e  ( i f  a v a i l a b l e )
s u b j e c t  n um b e r
T h e  i n v e s t i g a t o r  mu s t  p r o v i d e  o r a l  a n d  w r i t t e n  i n f o rm a t i o n  to  i n f o rm  t h e  s u b j e c t  h ow  to  
c o n t a c t  h i s / h e rb a c k u p  in  c a s e s  o f  em e rg en cy  w h e n  h e / s h e  i s  u n a v a i l a b l e  to  e n s u r e  t h a t  u n -
b l ind in g  c a n  b e  p e r fo rm ed  a t  a n y  t im ea n d  in s t ru c t ion s  f o r  c o n t a c t i n g  t h e  lo c a l  Nov a r t i s  CPO  
( o r  a n y  en t i ty  t o  wh i ch  i t  h a s  d e l e g a t e d  r e spon s ib i l i ty  f o r  em e rg en cy  c o d e  b r e a k s )  to  th e  
s u b j e c t  in  c a s e  a n  em e rg en cy  t r e a tm e n t  c o d e  b r e ak  i s  r e q u i r e d  a t  a  t im e  wh en  t h e  inv e s t ig a to r  
a n d  b a c k u p  a r e  u n a v a i l a b l e .
6 .8  T rea tmen t  exposu re  and  comp l iance
P h a rm a c o k i n e t i c  p a r am e t e r s  (m e a s u r e s  o f  t r e a tm e n t  e x p o s u r e )  w i l l  b e  d e t e rm i n e d  in  a l l  
s u b j e c t s  t r e a t e d  w i t h  ACZ 8 8 5 ,  a s  d e t a i l e d  i n  S e c t ion  8 .7.
6 .9  Recommended  t rea tmen t  o f  adve rse  even ts
T h e r e  i s  no  t r e a tm en t  th a t  c an  r e v e r s e  th e  a c t iv i ty  o f  ACZ885 .  G iv en  th a t  ACZ 8 8 5  i s  a n  IgG1  
i so ty p e  m o n o c l o n a l  an t ibody ,  p l a sm a p h e r e s i s  m a y  b e  o f  v a l u e  in  r em o v i n g  ACZ 8 8 5  f r om  th e  
body .  Po t en t i a l  adv e r s e  ev en t s  shou ld  th e r e fo r e  b e  t r e a t ed  sy m p t om a t i c a l ly  a t  th e  d i s c r e t ion  o f  
t h e  I n v e s t i g a t o r .  M ed i c a t ion  u s e d  to  t r e a t  AE s  mu s t  b e  r e c o r d e d  on  t h e  con com i t an t  
m e d i c a t i o n s / s i g n i f i c a n t  n o n- d r u g  t h e r a p i e s  eCRF .
6 .10 Rescue  med ica t ion
I n  t h e  con t ex t  o f  th i s  s tudy ,  r e s c u e  m ed i c a t ion s  a r e  d e f i n e d  a s  t h o s e  m ed i c a t ion s  u s e d  a c u t e l y  
to  d i r e c t ly  m a n a g e  m e d i c a l  s i g n s  o r  sy mp tom s  r e l a t e d  to  t h e  s u b j e c t ’ s  u n d e r ly in g  s a r co ido s i s .  
Add i t ion  o r  a l t e r a t i o n  o f  imm u n o s u p p r e s s a n t  o r  c o r t i c o s t e r o i d  t h e r a p y  fo r  o r  by  a  p a t i en t  
d u r i n g  t h e  s tudy  a r e  no t  a l l ow e d  a n d  m ay r e q u i r e  h i s  o r  h e r  t e rm in a t ion  f r om  s tudy  
p a r t i c i p a t i o n .  I f  a  p a t i en t  i s  w i t h d r aw n  f r om  t h e  s tudy ,  t h e  W e e k  3 2  EOS  v i s i t  s h o u l d  b e  
c om p l e t e d .
No va r t i s Con f iden t ia l Page  43
Amended  P ro toco l  Ve rs ion  01  (C lean ) P ro toco l  No .  CACZ885X2205
Non- sa rco idos is  f la res  (b ronch i t is )
P a t i e n t s  w i t h  s a r c o i d o s i s  m a y exp e r i en c e  ep i sod e s  o f  b ron ch i t i s  th a t  do  no t  ind i c a t e  wo r s en ing  
o f  t h e i r  d i s e a s e .  P rodu c t ion  o f  y e l l ow - g r e e n  spu tum  i s  a  ch a r a c t e r i s t i c  o f  b ron ch i t i s .  
T r e a tm e n t  d e t a i l s  a r e  a t  t h e  d i s c r e t i o n  o f  t h e  i n v e s t i g a t i n g  phy s i c i a n .  F i r s t  l i n e  t r e a tm e n t  i s  
ty p i c a l ly  w i th  an t ib io t i c s .  U n r e s p o n s i v e  p a t i e n t s  m ay r e q u i r e  th e  a d d i t i o n  o f  a  s h o r t  c o u r s e  o f  
c o r t i c o s t e r o i d s .  Th i s  m ay r e s u l t  in  th e  p a t i en t  b e i n g  w i t h d r aw n  f rom  t h e  t r i a l  (S e eT ab l e  5 - 1 )  
i n  w h i c h  c a s e  t h e  W e e k  3 2  EOS  v i s i t  s h o u l d  b e  c om p l e t e d .
Acu te  pu lmona ry  exace rba t ions  o f  sa rco idos is  (APES )
APES  a r e  d e f i n e d  a s  a cu t e  w o r s e n i n g  o f  pu lmon a ry  s ig n s  and  sy mp tom s  in  p a t i e n t s  w i th  
k n ow n  s a r c o i d o s i s  n o t  e x p l a i n e d  by  a no th e r  c a u s e ,  c om b i n e d  w i th  a  d e c l i n e  in  s p i r om e t r y  
( ≥ 1 0%  d e c r e a s e  f rom  p r e v i o u s  b a s e l i n e  FVC  and /o r  FEV 1 ,  p r e s e n t  f o r  a t  l e a s t  o n e  m o n t h  
( P a n s e l i n a s  and  J u d s o n  2 0 1 2 ) .  P a t i e n t s ’  s ign s  a n d  sy mp tom s  o fAPES  ty p i c a l ly  r e spond  
toc o r t i c o s t e r o i d s .  Th i s  m ay r e s u l t  in  th e  p a t i e n t  b e i ng  w i t h d r aw n  f rom  t h e  t r i a l  
(S e eT a b l e5 - 1 )  i n  w h i c h  c a s e  t h e  W e e k  3 2  EOS  v i s i t  s h o u l d  b e  c om p l e t e d .
U s e  o f  r e s c u e  m ed i c a t ionmu s t  b e  r e c o r d e d  on  t h e  c o n c om i t a n t  m e d i c a t i o n s / s i g n i f i c a n t  
n o n d r u g  t h e r a p i e s  CRF .
6 .11 Concom i tan t  t rea tmen t
T h e  i n v e s t i g a t o r  mu s t  i n s t r u c t  t h e  s u b j e c t  to  n o t i f y  t h e  s tudy  s i t e  a b o u t  any  n ew  m ed i c a t ion s  
h e / s h e  t a k e s  a f t e r  t h e  s u b j e c t  w a s  e n r o l l e d  i n t o  t h e  s t u dy .
Common  po t en t i a l  con com i t an t  m ed i c a t ion s  in  th i s  s tudy popu l a t ion  a r e  an t i c ip a t ed  to  in c lud e  
t o p i c a l  c o r t i c o s t e r o i d s  o r  sy s t em i c  c o r t i c o s t e r o i d s  a t  ≤ 1 5  m g / d  p r e d n i s o n e  o r  e q u i v a l e n t ,  
a n d / o r  u p  to  o n e  o f  t h e  f o l l ow i n g  sy s t em i c  immun e - m o d u l a t i n g  d r u g s :  me tho t r ex a t e ,  
a z a t h i o p r i n e ,  l e f l u n om i d e  o r  h y d r o xy c h l o r o q u i n e .
A l l  p r e s c r i p t i o n  m ed i c a t ion s ,  o v e r - th e - c o u n t e r  d r u g s  a n d  s i g n i f i c a n t  non - d r u g  th e r ap i e s  
( i n c l u d i n g  phy s i c a l  th e r apy  a n d  b l o o d  t r a n s f u s i o n s )  a dm i n i s t e r e d  o r  t a k e n  w i th in  t h e  
t im e f r am e  d e f in ed  in  t h e  en t ry  c r i t e r i a  p r io r  to  th e  s t a r t  o f  t h e  s tudy  a nd  du r ing  th e  s tudy  mu s t  
b e  r e c o r d e d  o n  t h e  c o n c om i t a n t  m e d i c a t i o n s / s i g n i f i c a n t  n o n - d r u g  t h e r a p i e s  CRF .
M e d i c a t i o n  en t r i e s  s h o u l d  b e  s p e c i f i c  to  t r a d e  n am e ,  t h e  s i n g l e  do s e  a n d  un i t ,  t h e  f r e q u e n c y  
a n d  r o u t e  o f  a dm i n i s t r a t i o n ,  t h e  s t a r t  a n d  d i s c o n t i n u a t i o n  d a t e  a n d  t h e  r e a s o n  f o r  t h e r a p y .
No va r t i s Con f iden t ia l Page  44
Amended  P ro toco l  Ve rs ion  01  (C lean ) P ro toco l  No .  CACZ885X2205
[ADDRESS_426687]  ex am  shou ld  a l so  b e  in c lud ed  
a s  a s s e s s e d  o n  a  c a s e - by - c a s e  b a s i s  by  [CONTACT_3433] e  Spon so r .
I f  a  s u b j e c t  d i s con t inu a t ion  o c c u r s  f o r  a n y  r e a son ,  t h e  I n v e s t ig a to r  mu s t  m a k e  ev e ry  e f fo r t  to  
d e t e rm i n e  th e  p r im a ry  r e a s o n  fo r  a  sub j e c t ’ s  d i s con t inu a t ion  f r om  th e  s tudya n d  r e c o r d  th i s  
i n f o rm a t i o n  o n  t h e  CRF .
T h e  i n v e s t i g a t o r  s h o u l d  d i s c o n t i n u e  s tudy  t r e a tm e n t  f o r  a  g i v e n  s u b j e c t  o r  d i s c o n t i n u e  t h e  
s u b j e c t  f r om  s tudy  i f ,  on  b a l a n c e ,  h e / s h e  b e l i e v e s  t h a t  c o n t i n u a t i o n  w o u l d  b e  d e t r im e n t a l  to  
t h e  s u b j e c t ’ s  w e l l - b e i n g .
I f  a  l i v e r  o r  r e n a l  ev en t  o c c u r s ,  f o l l ow  g u i d e l i n e s  o u t l i n e d  in  A p p e n d i x1a n d  A p p e n d i x2
r e g a r d i n g  d i s c o n t i n u a t i o n  o f  s t u d y  t r e a tm e n t .
S tudy t r e a tm e n t  m u s t  b e  p e rm a n e n t l y  d i s c o n t i n u e d  u n d e r  t h e  f o l l ow i n g  c i r c um s t a n c e s :
S u b j e c t  w i t h d r aw s  c o n s e n t
P r egn an cy
S e v e r e  a l l e r g i c  r e a c t i o n  o r  a n a p hy la x i s  f o l l ow i n g  a dm i n i s t r a t i o n  o f  t h e  s t u d y  d rug
N o n- c om p l i a n c e  a s  d e f i n e d  b y  m i s s i n g  m o r e  t h a n  o n e  d o s e  a dm i n i s t r a t i o n
Em e r g e n c e  o f  t h e  f o l l ow i n g  a d v e r s e  e v e n t s :
S e r i o u s  i n f e c t i o n s  c om b i n e d  w i t h  n e u t r o p e n i a  CTCAE  v 4 . 0 3  g r a d e s  ≥1  (ANC< 1 . 5x
1 09/L )
C o n f i rm e d  d i a g n o s i s  o f  l a t e n t  o r  a c t i v e  TB
O n s e t  o f  a ny  m a l i g n a n c y
No va r t i s Con f iden t ia l Page  45
Amended  P ro toco l  Ve rs ion  01  (C lean ) P ro toco l  No .  CACZ885X2205
Any o f  th e  fo l low ing  l abo r a to ry  a b n o rm a l i t i e sc o n f i rm e d  t o  b e  s u s t a i n e d  b y  r ep e a t
a s s e s sm e n t  w i th in7  d ay s  a f t e r  i n i t i a l  l a b  a s s e s sm e n t :
N e u t r o p e n i a  CTCAE  v 4 . 0 3  g r a d e s  ≥2
Th rombo cyt o p e n i a  CTCAE  v 4 . 0 3  g r a d e  4
U s e  o f  p r o h i b i t e d  t r e a tm e n t  a s  p e r  T ab l e5 - 1 .
Any o t h e r  p r o t o c o l  d e v i a t i o n  t h a t  r e s u l t s  i n  a  s i g n i f i c a n t  r i s k  t o  t h e  p a t i e n t ’ s  s a f e t y
T h e  a p p r o p r i a t e  p e r s o n n e l  f r om  t h e  s i t e  a n d  N o v a r t i s  w i l l  a s s e s s  w h e t h e r  s tudy  t r e a tm e n t  
s h o u l d  b e  d i s c o n t i n u e d  f o r  a n y  sub j e c t  w h o s e  t r e a tm en t  c o d e  h a s  b e en  b roke n  i n a d v e r t e n t l y  
f o r  a n y  r e a s o n .
S u b j e c t s  w h o  d i s c o n t i n u e  s tudy  t r e a tm e n t  s h o u l d  NOT  au tom a t i c a l ly  b e  con s id e r ed  
w i t h d r aw n  f r om  th e  s tudy .  S e e  S e c t ion  8f o r  th e  r e q u i r e d  a s s e s sm en t s  o f  t h e s e  sub j e c t s  a f t e r  
d i s con t inu a t ion  o f  s tudy  t r e a tm e n t .
7 .3  W i thd rawa l  o f  in fo rmed  consen t
S u b j e c t s  m ay v o l u n t a r i ly  w i t h d r aw  con s en t  to  p a r t i c i p a t e  in  th e  s tudy  f o r  a n y  r e a s o n  a t  a n y  
t im e .
W i t h d r aw a l  o f  c o n s e n t  o c c u r s  on ly  w h en  a  s u b j e c t  d o e s  no t  w a n t  t o  p a r t i c i p a t e  in  t h e  s tud y  
any mo r e  andd o e s  no t  w a n t  a n y  f u r t h e r  v i s i t s  o r  a s s e s sm e n t s  andd o e s  no t  w a n t  any  f u r th e r  
s tudy - r e l a t e d  c o n t a c t  andd o e s  n o t  a l l ow  a n a ly si s  o f  a l r e ady  o b t a i n e d  b i o l o g i c  m a t e r i a l .
I f  a  s u b j e c t  w i t h d r aw s  c o n s e n t ,  t h e  i n v e s t i g a t o r  mu s t  m a k e  e v e r y  e f fo r t  to  d e t e rm i n e  t h e  
p r im a ry  r e a son  f o r  th i s  d e c i s i o n  a n d  r e c o r d  th i s  i n f o rm a t i o n .  S tudy t r e a tm e n t  mu s t  b e  
d i s c o n t i n u e d  a n d  n o  f u r t h e r  a s s e s sm e n t s  c o n d u c t e d .  A l l  b i o l o g i c a l  m a t e r i a l  t h a t  h a s  no t  b e en  
a n a l y ze d  a t  t h e  t im e  o f  w i t h d r aw a l  mu s t  no t  b e  u s e d .  F u r t h e r  a t t emp t s  to  c o n t a c t  t h e  sub j e c t  
a r e  n o t  a l l ow e d  u n l e s s  s a f e t y  f i n d i n g s  r e q u i r e  c omm u n i c a t i n g  o r  f o l l ow - u p .
7 .4  Los t  to  fo l low- up
Fo r  sub j e c t s  who s e  s t a tu s  i s  un c l e a r  b e c au s e  th ey f a i l  to  app e a r  fo r  s tudy  v i s i t s  w i thou t  s t a t ing  
a n  in t en t ion  to  w i t h d r aw ,  t h e  i n v e s t i g a t o r  s h o u l d  show  " d u e  d i l ig en c e "  by  d o c um e n t i n g  in  th e  
s o u r c e  d o c um e n t s  s t e p s  t ak en  to  c o n t a c t  t h e  sub j e c t ,  e . g . ,  d a t e s  o f  t e l e p h o n e  c a l l s ,  r eg i s t e r ed  
l e t t e r s ,  e t c .  A  sub j e c t  shou ld  no t  b e  con s id e r ed  lo s t  to  fo l low - up  un t i l  h i s /h e r  s ch edu l ed  end  o f  
s tud y  v i s i t  w o u l d  h a v e  o c c u r r e d .
7 .5  S tudy  S topp ing  ru les
A l l  s u b j e c t s  w i l l  u n d e r g o  r e g u l a r  m o n i t o r i n g  a t  s c h e d u l e d  v i s i t s  f o r  s a f e ty  a n d  t o l e r a b i l i ty ,  
i n c l u d i n g  a d v e r s e  ev en t s ,  t h r o u g h o u t  th e  du r a t ion  o f  t h e  s tudy .  I f  s ign i f i c an t  r i s k  to  t h e  s tudy  
sub j e c t s  i s  id e n t i f i ed ,  th e  s tudy  m ay  b e  pu t  on  ho ld  o r  t e rm in a t ed  b a s ed  on  a  fu l l  s a f e ty  r e v i ew .
T h e  s tudy  w i l l  b e  s topp ed  i f  a n y  o f  t h e  f o l l ow i n g  c r i t e r i a  a r e  m e t ,  and  n o  f u r t h e r  do s ing  
p e n d i n g  a  f u l l  s a f e t y  r ev i ew :
A n  o v e r t  c h a n g e  i n  t h e  r a t e  o f  i n c i d e n c e  o f  e x p e c t e d  d rug - r e l a t e d  s e r i o u s  a d v e r s e  e v e n t s
s u c h  a s  i n f e c t i o n s ,  o p p o r t u n i s t i c  i n f e c t i o n s ,  h y p e r s en s i t iv i ty ,  w h i t e  b l o o d  c e l l  (WBC )  o r
p l a t e l e t  c o u n t  d e c r e a s e s  a s  c om p a r e d  t o  t h e  r a t e s  d e s c r i b e d  i n  t h e  c u r r e n t  v e r s i o n  o f  t h e  IB .
No va r t i s Con f iden t ia l Page  46
Amended  P ro toco l  Ve rs ion  01  (C lean ) P ro toco l  No .  CACZ885X2205
N ew  u n e x p e c t e d  s e r i o u s  a d v e r s e  e v e n t s  c o n s i d e r e d  r e l a t e d  t o  c a n a k i n um a b  i n  m o r e  t h a n
3i n d i v i d u a l s  o n  a c t i v e  t h e r a p y .
7 .6  Ea r ly  s tudy te rm ina t ion  by  [CONTACT_343843] r
T h e  i n v e s t i g a t o r  mu s t  c o n t a c t  t h e  IR T  to  r e g i s t e r  t h e  s u b j e c t ’ s  d i s c o n t i n u a t i o n  f r om  t h e  s tudy  
a n d / o r  i n v e s t i g a t i o n a l  t r e a tm e n t .  Th e  s tudy  c an  b e  t e rm i n a t e d  by  N ov a r t i s  a t  a n y  t im e  fo r  
m e d i c a l  o r  e t h i c a l  r e a son s ,  a n d / o r  in  a c c o r d a n c e  w i th  t h e  r e s p e c t iv e  c o n t r a c t u a l  t e rm s .  
Shou ldth i s  b e  n e c e s s a r y ,  t h e  sub j e c t  s h o u l d  b e  s e e n  a s  s o o n  a s  p o s s i b l e  and  t r e a t e d  a s  a  
p r em a t u r e ly  w i t h d r aw n  su b j e c t  a s  d e s c r i b e d  i n  S e c t ion  7.  Th e  inv e s t ig a to r  m ay  b e  in fo rm ed  o f  
add i t ion a l  p ro c edu r e s  to  b e  f o l l ow e d  in  o rd e r  to  en su r e  th a t  ad equ a t e  con s id e r a t ion  i s  g i v e n  to  
t h e  p r o t e c t i o n  o f  t h e  s u b j e c t ’ s  i n t e r e s t s .  T h e  i n v e s t i g a t o r  w i l l  b e  r e s p o n s i b l e  f o r  i n f o rm i n g  
in s t i tu t ion a l  r e v i ew  bo a rd s  ( IRB s )  and /o r  e th i c  comm i t t e e s  (EC s )  o f  t h e  e a r l y  t e rm in a t ion  o f  
t h e  t r i a l .
Co rpo ra te  Con f iden t ia l  In fo rma t ionCo rpo ra te  Con f iden t ia l  In fo rma t ion
No va r t i s Con f iden t ia l Page  49
Amended  P ro toco l  Ve rs ion  01  (C lean ) P ro toco l  No .  CACZ885X2205
1V i s i t  s t ru c tu re  g i ven  fo r  in te rna l  p rog ramm ing  pu rpo se  on l y
2A  w indow  o f  ±[ADDRESS_426688]  exam  shou lda lso  be  inc luded  as  
assessed  on  a  case- by- ca se  ba s i s  b y  the  Spon so r
4L im i ted  to  fema le s  o f  ch i ldbea r ing  age .  Se rum  te s t ing  i s  done  a t  s c reen ing  and  u r ine  te s t  i s  done  p redo se  a t  Da y  1  and  a t  theEOS
5I f  the  d ip s t i c k  re su l t  i s  po s i t i ve  fo r  p ro te in ,  n i t r i te ,  leu ko c y te s  and /o r  b lood ,  the  samp le  shou ld  be  sen t  fo r  m i c ro s cop i c  ana l y s i s  o f  W BC ,  red  b lood  ce l l  coun t  (RBC )  and  
cas ts
6V i ta l  s ign s  ta ken  a f te r  re s t ing  in  a  s i t t ing  po s i t ion  fo r  a t  lea s t  3  m inu te s
7Fo r  sub je c t s  a t  ba se l ine  who  a re  unab le  to  gene ra te  rep rodu c ib le  sp i rome t r y  maneu ve r s ,  an  add i t iona l  5  da y s  be yond  the  40  da y  s c reen ing  w indow  w i l l  be  a l lowed  fo r  
the  sub je c t s  to  re tu rn  fo r  repea t  sp i rome t r y .
8Oxygen  sa tu ra t ion  % ,  pu l se  ra te ,  and  Bo rg  Que s t ionna i re  s co re  w i l l  be  re co rded  be fo re  the  te s t .O x ygen  sa tu ra t ion  % ,  pu l se  ra te ,  Bo rg  Que s t ionna i re  s co re ,  and  
d i s tan ce  wa l ked  w i l l  be  re co rded  a t  the  end  o f  the  te s t .  6MWT shou ld  o c cu r  a f te r  ECG s  ha ve  been  comp le ted .  Pu l se  ra te  shou ld  be  ta ken  a f te r  s i t t ing  fo r  a t  lea s t  [ADDRESS_426689]  ev idence  o fpa ren ch yma l  in vo l vemen t  o f  d i sea se  f rom  h is to r ica l
rad io log i ca l  e v iden ce  (e .g .  CT ,  MR I  o r  x - ra y ) ,  then  ba se l ine  HRCT  can  be  pe r fo rmed  a t  same  t ime  as  the  [F - 18 ]FDG- PET /CT.  A t  each  t imepo in t ,  two  s can s  w i l l  be  
co l le c ted :  [ADDRESS_426690]  s can .  
10The  [F- 18 ]FDG- PET /CT  requ i re s  a  b lood  g lu co se  le ve l  be low  11  mmo l /L .  The  mea su remen t  i s  pe r fo rmed  b y  f inge r  p r i c k  a t  s i te  the  same  da y  [F -18 ]FDG- PET /CT  i s  
pe r fo rmed
11Fo r  base l ine ,  [F- 18 ]FDG- PET /CT  re su l t s  ob ta ined  w i th in  8  wee k s  o f  random i za t ion  w i l l  be  a c cep ted .  The  [F- 18 ]FDG- PET /CT  a t  ba se l ine  shou ld  a lwa y s  be  condu c ted  
a f te r  a l l  o the r  a s se s smen t s  a re  done  and  pa t ien t  found  e l ig ib le  unle s s  a  p re v iou s  re su l t  wa s  u sedo r  spon so r  ag reemen twas  ob ta ined.  I t  shou ld  no t  be  done  po s t -
random iza t ion .  
12A l l  a s se s smen t s  fo r  a  g i ven  v i s i t  shou ld  be  comp le ted  be fo re  s tud y  d rug  i s  adm in i s te red
Co rpo ra te  Con f iden t ia l  In fo rma t ion
No va r t i s Con f iden t ia l Page  50
Amended  P ro toco l  Ve rs ion  01  (C lean ) P ro toco l  No .  CACZ885X2205
8 .2  In fo rmed  consen t  p ro cedu res
E l i g i b l e  s u b j e c t s  m ay o n ly  b e  i n c l u d e d  in  t h e  s tudy  a f t e r  p r o v i d i n g  w r i t t en  (w i t n e s s e d ,  w h e r e  
r e q u i r e d  by  l aw  o r  r egu l a t ion ) ,  IR B / IEC- app rov ed  i n f o rm e d  c o n s e n t .  I f  th e  s u b j e c t  i s  c a p a b l e  
o f  d o i n g  s o ,  h e / s h e  shou ld  i n d i c a t e  a s s e n t  by  p e r s o n a l l y  s ign ing  and  d a t i n g  th e  w r i t t en  
i n f o rm e d  c o n s e n t  d o c um e n t .
I n f o rm e d  con s en t  mu s t  b e  o b t a i n e d  b e f o r e  c o n d u c t i n g  a n y  s tudy - s p e c i f i c  p r o c e d u r e s  ( i . e . ,  a l l  
o f  t h e  p r o c e d u r e s  d e s c r ib ed  in  t h e  p r o t o c o l ) .  Th e  p r o c e s s  o f  ob t a in ing  i n f o rm e d  con s en t  
s h o u l d  b e  d o c um e n t e di n  t h e  s u b j e c t  s o u r c e  d o c um e n t s .
N o v a r t i s  w i l l  p r o v i d e  t o  i n v e s t i g a t o r s  in  a  s e p a r a t e  d o c um e n t  a  p r o p o s e d  i n f o rm e d  c o n s e n t  
f o rm  t h a t  c om p l i e s  w i t h  t h e  IC H  GCP  g u i d e l i n e  a n d  r egu l a to ry  r e q u i r em e n t s  a n d  i s  
c o n s i d e r e d  app rop r i a t e  fo r  th i s  s tudy .  Any  ch ang e s  to  th e  p ropo s ed  con s en t  fo rm  sugg e s t ed  by  
t h e  i n v e s t i g a t o r  mu s t  b e  a g r e e d  to  by  N ov a r t i s  b e f o r e  subm i s s ion  to  t h e  IRB / IEC ,  a n d  a  c o p y  
o f  t h e  a p p r o v e d  v e r s i o n  m u s t  b e  p r o v i d e d  t o  t h e  N o v a r t i s  m o n i t o r  a f t e r  IR B / IEC  a p p r o v a l .
I n  th e  ev en t  t h a t  Nov a r t i s  w a n t s  to  p e r f o rm  t e s t i n g  o n  th e  s am p l e s  t h a t  a r e  no t  d e s c r i b e d  in  
th i s  p ro to co l ,  add i t ion a l  In s t i tu t ion a l  R ev i ew  Bo a rd  and /o r  E th i c s  Comm i t t e e  app rov a l  w i l l  b e  
o b t a i n e d .
8 .3  Sub jec t  sc reen ing
I n  g e n e r a l ,  i t  i s  p e rm i s s i b l e  to  r e - s c r e e n  a  sub j e c t ;  h ow e v e r ,  e a c h  c a s e  mu s t  b e  d i s c u s s e d  a n d  
a g r e e d  w i t h  t h e  S p o n s o r ’ s  m e d i c a l  l e a d  o n  a  c a s e - by - c a s e  b a s i s .
P a t i e n t  r e - s c r e e n i n g  w i l l  b e  a l l ow e d  in  t h e  s tudy  i n  t h e  e v e n t  o f  a  d e l ay  i n  t r e a tm e n t ,  e . g . ,  in  
t h e  e v e n t  o f  a  w a s h o u t  p e r iod  o f  mo r e  tha n  [ADDRESS_426691]  c a n n o t  b e  
r e p e a t e d  a n d  r e - s c r e e n i n g  m ay n o t  o c c u r  i f  p l a n n e d  d o s in g  w i l l  no t  t a k e  p l a c e  w i th in  8w e e k s  
o f  t h e s e  s c r e e n i n g  im a g i n g  a s s e s sm e n t s .Co rpo ra te  Con f iden t ia l  In fo rma t ion
No va r t i s Con f iden t ia l Page  51
Amended  P ro toco l  Ve rs ion  01  (C lean ) P ro toco l  No .  CACZ885X2205
8 .4  Sub jec t  demog raph ics /o the r  base l ine  cha rac te r is t ics
S u b j e c t  d em o g r a p h i c  and  b a s e l i n e  c h a r a c t e r i s t i c  d a t a  to  b e  c o l l e c t e d  o n  a l l  s u b j e c t s  in c lud e :  
d a t e  o f  b i r t h ,  a g e ,  s e x ,  r a c e ,  p r e d om i n a n t  e t h n i c i t y .
R e l e v a n t  m e d i c a l  h i s to ry / cu r r en t  m ed i c a l  cond i t ion s  d a t a  i n c l u d e s  d a t a  un t i l  s i g n a t u r e  o f  
i n f o rm e d  c o n s e n t .  W h e r e  p o s s i b l e ,  d i a g n o s e s,and  no t  sy mp tom s, w i l l  b e  r e c o r d e d .
T h e  f o l l ow i n g  s h o u l d  b e  r e c o r d e d  o n  t h e  r e s p e c t i v e  CRF  p a g e :
R e l e v a n t  m e d i c a l  h i s t o r y / c u r r e n t  m e d i c a l  c o n d i t i o n s
P r i o r  a n d  c u r r e n t  m e d i c a t i o n s  /  s i g n i f i c a n t  n o n- d r u g  t h e r a p i e s
R e s p o n s e  t o  t r e a tm e n t  w i thp r e v i o u s  d r u g  t h e r a p i e s  ( e . g . ,  c o r t i c o s t e r o i d s ,  m e t h o t r e x a t e ,
a z a t h i o p r i n e ,  TNF - α  b l o c k e r s )
8 .4 .1 Hepa t i t is  sc reen ,  H IV  sc reen ,  t ube rcu los is  sc reen
A l l  s u b j e c t s  w i l l  b e  s c r e e n e d  f o r  H IV ,  h e p a t i t i s  B  a n d  C,  a n d  t u b e r c u l o s i s .  S e e  t h e  S i t e
O p e r a t i o n s  M a n u a l  f o r  d e t a i l s .
8 .4 .2 A lcoho l  tes t ,  drug  sc reen ,  u r ine  co t in ine
A l l  s u b j e c t s  w i l l  b e  s c r e e n e d  f o r  s u b s t a n c e s  o f  a b u s e  a n d  c o t i n i n e .  S e e  t h e  S i t eO p e r a t i o n s  
M a n u a l  f o r  d e t a i l s .
8 .5  E f f icacy/Pha rmacody nam ics
P h a rm a c o dy n am i c  a s s e s sm en t s  a r e  s p e c i f i e d  b e low ,  w i th  t h e  m e t h o d s  fo r  a s s e s sm e n t  and  
r e c o r d i n g  s p e c i f i e d  in  th e  S tudy O p e r a t i o n s  M anu a l .  A s s e s sm e n t s  w i l l  b e  p e r f o rm e d / s am p l e s  
c o l l e c t e d  a t  t h e  t im e p o i n t sd e f i n e d  i n  t h e  A s s e s sm e n t  S c h e d u l e.
I n  o r d e r  to  b e t t e r  d e f in e  t h e  PD  p r o f i l e ,  t h e  t im i n g  o f  t h e  s am p l e  co l l e c t ion  m ay b e  a l t e r ed  
b a s e d  o n  em e r g e n t  d a t a .  T h e  n um b e r  o f  s amp l e s /b lood  d r aw s  a n d  to t a l  b l o o d  v o l um e  
c o l l e c t e d  w i l l  n o t  e x c e e d  t h o s e  s t a t e d  i n  t h e  p r o t o c o l .
8 .5 .1 C l in ica l  Ou tcome  Assessmen ts  (COAs )
Co rpo ra te  Con f iden t ia l  In fo rma t ion
No va r t i s Con f iden t ia l Page  52
Amended  P ro toco l  Ve rs ion  01  (C lean ) P ro toco l  No .  CACZ885X2205
Co rpo ra te  Con f iden t ia l  In fo rma t ion
No va r t i s Con f iden t ia l Page  53
Amended  P ro toco l  Ve rs ion  01  (C lean ) P ro toco l  No .  CACZ885X2205
[ADDRESS_426692]  a n d  [F - 1 8 ]FDG- PET /CT  im a g i n g  a r e  d e s c r i b e d  in  th e  P a r e xe l  Im a g i n g  
I n v e s t i g a t o r  SOM .
T o  a v o i d  u n n e c e s s a r y  r ad i a t ion ,a l l  s c r e e n i n g  a c t iv i t i e s  e x c e p t  im a g i n g  n e ed s  to  b e  c om p l e t e d  
p r i o r  to  HRCT  s c an  fo r  e l i g i b i l i t y .  Ev a lu a t ion  by  H RCT  fo r  e l ig ib i l i ty  m u s t  b e  comp l e t ed  
p r i o r  to  t h e  p a t i e n t  und e rgo ing  b a s e l i n e  [F - 1 8 ]FDG - PET /CT.  P a t i e n t s  w i thh i s t o r i c a l  
r a d i o l o g i c  e v i d e n c e  o f  p a r en chy m a l  d i s e a s e  invo lv em en t  ( e i t h e r  HRCT  o r  h i s t o r i c a l  c h e s t  x -
r ay )  c an  b e  u s ed  fo r  e l ig ib i l i ty ,  a l low ing  th e  HRCT  b a s e l in e  a s s e s sm en t  to  b e  p e r fo rm ed  a long  
w i th  [F - 1 8 ]FDG - PET /CTo n  s am e  v is i t  d ay  w i t h o u t  w a i t i n g  f o r  HRCT  s c r e e n i n g  r e su l t .
8 .5 .2 .1 [F - 18 ]  FDG- PET /CT
I n  t h i s  s tudy ,  [F - 1 8 ]FDG- PET /CT  im a g i n g  w i l l  p r o v i d e  e a r l y  e v i d e n c e  fo r  a n t i - i n f l amm a t o r y  
e f f e c t s  o f  IL - 1β  b l o c k a d e  by  A CZ8 8 5o n  t h e  s a r co ido s i s  p r o c e s s .  [F - 1 8 ]FDG - PET /CT  h a s  
b e e n  shown  to  d e t e c t  l u n g  p a r en chy m a l  invo lv em en t  a t  a n y  ch e s t  x - r ay  ( CXR )  s t ag e ,  
i n c l u d i n g  t h e r a p y -r e s i s t an t  d i s e a s e ,  a n d  c a n  a l so  p r o v i d e  i n f o rm a t i o n  o n  ex t r a - p u lm o n a r y  
d i s e a s e .  L u n g  f luo rod eoxy g l u c o s e  ( FDG)up t ak e  in  s a r c o i d o s i s  h a s  b ee n  s h ow n  by  P ET  
im a g i n g  to  c o r r e l a t e  w i th  im p o r t a n t  s a r c o i d o s i s  BAL  b i om a r k e r s ,  in c lud ing  p e r c en t ag e  
n e u t r o p h i l s  a n d  CD4 :CD8  r a t i o .  I n  t w o  p r ev iou s  s a r c o i d o s i s  t r i a l s ,  th e  [F1 8 ]FDG - PET /CT  
e n d p o i n t  w a s  s h ow n  to  b e  d e c r e a s e d  by  5 3 - 5 5%  o n  t r e a tm e n t  ( K e i j s e r se ta l2 0 0 8;  
M i lm ane ta l2 0 1 2 ) .  Im p r o v em e n t s  in  FVC  ov e r  a  2 4  w e e k  p e r iod  h av e  b e en  c o r r e l a t e d  w i th  
d e c r e a s e s  in  [F - 1 8 ]FDG- PET /CT  c om p a r e d  to  b a s e l i n e ,  w i th  e v i d e n c e  o f  imp r o v em e n t  b y  
s e r i a l  [F - 1 8 ]FDG- PET /CT  d e t e c t e d  in  s a r c o i d  p a t i e n t s  r e p o r t e d  a s  e a r l y  a s  1 - 2  mon th s  
( B r u d i ne ta l1 9 9 4 ;  B r a u ne ta l2 0 0 8 ;  Im p e r i a l ee ta l2 0 1 3 ) .  F u r t h e rm o r e ,  [F - 1 8 ]FDG- PET /CT  
im a g i n g  w a s  ab l e  to  p r e d i c t  s u b s e q u e n t  d e c r e a s e s  in  FVC  a n d  DL co  
( Sob i c- S a r a n o v i ce ta l2013;V o r s e l a a r se ta l2 0 1 5) .
I nth i s  s tudy ,  a l l  p a t i en t s  w i l l  u n d e r g o  w h o l e -body  h e ad  to  m id- t h i g h  [F - 1 8 ]FDG- PET /CT  
im a g i n g  on  a  s t a t e - o f - th e - a r t ,  3D  PET /CT  s c ann e r  w i th  a  r e c o n s t r u c t e d  r e so lu t ion  o f  ≤5mm .  
Sub j e c t s  w i th  g lu co s e  l ev e l s  abov e  11  mmo l /L ( 200  mg /dL )  shou ld  h av e  th e i r  s c an  d e l ay ed  o r  
b e  r e s c h e d u l e d  a s  a p p r o p r i a t e .  Th e  b l o o d  g l u c o s e  l e v e l  m e a su r ed  p r io r  to  t h e  r ad io t r a c e r  
a dm i n i s t r a t i o n  s h o u l d  b e  r e c o r d e d  in  t h e  im ag e  t r an sm i t t a l  f o rm  ( I TF ) .  Sub j e c t s  w i l l  h av e  th e  
r a d i o t r a c e r  a dm i n i s t e r e d  t h r o u g h  a n  i .v .  l i n e ,  w h e r e a f t e r  th eyw i l l  b e  p o s i t i o n e d  c om f o r t a b l y  
in  a  sup in e  po s i t ion  to  r e s t  fo r  [ADDRESS_426693]  w i l l  b e  a c q u i r e d  w i th  a  w h o l e  
body  e f f e c t iv e  d o s e  o f  1 . 5  mSv .  M a x im um  i n j e c t e d  r a d i o a c t i v i t y  do s e  2 0 0  MB q  w i l l  r e s u l t  in  
a  who l e  body  e f f e c t i v e  d o s e  o f  4  mSv  ( ICRP2 0 0 8 ) .  H i g h e r[F - 18 ]FDG  a c t i v i t i e s  m ay b e  
r e q u i r e d  in  l a r g e  o r  ob e s e  p a t i e n t s  to  e n s u r e  s u f f i c i e n t  im a g i n g  qu a l i ty ,bu t  i t  w i l l  no t  e x c e e d  
[ADDRESS_426694] ing  to  t h e  s ch edu l e  
o n  e n r o l l e d  p a t i en t s  w i th  r e s u l t s  q u a n t i ta t iv e ly  c om p a r e d  to  b a s e l in e  f i n d i n g s  u s ing  
c e n t r a l i z e dqu an t i t a t iv e  r e ad ing .  D e t a i l edin fo rm a t ion  w i l l  b e  p rov id ed  in  th e  P a r ex e l  Im ag ing  
I n v e s t i g a t o r  SOM.  To t a li n j e c t e d  a c t i v i t y  and  body  w e i g h t  w i l l  b e  r e c o r d e d  and  u s e d  to  Co rpo ra te  Con f iden t ia l  In fo rma t ion
No va r t i s Con f iden t ia l Page  54
Amended  P ro toco l  Ve rs ion  01  (C lean ) P ro toco l  No .  CACZ885X2205
c om p u t e  s t a n d a r d i z e d  up t ak e  v a l u e s .  T h e  to t a l  d o s e  f o r  a l l  PET /CT  s c a n n i n g  ( e x c l u d i n g  
HRCT )  in  th i s  p r o t o c o l  w i l l  b e  m ax im a l ly 1 1mSv,o r  1 6mSvin  l a r g e r  o r  ob e s e  p a t i en t s  
r e q u i r i n g  a  h i g h e r[F - 1 8 ]FDG  i n j e c t e d  d o s e .
[ADDRESS_426695]  s c ann ing  ( ex c lud ing  [F  18 ]F DG- PET /CT )  w i l l  b e  m ax im a l ly [ADDRESS_426696]  s c an  shou ld  b e  p e r fo rm ed  wh e r e  po s s ib l e  on  
t h e  s am e  s c a n n e r ,  a l t h o u g h  s c a n s  o n  t h e  PET /CT  s c a n n e r  m ay b e  u s e d  i f  th ey  a r e  d e t e rm in ed  
t o  b e  c om p a r a b l e  w i t h  f o l l ow - u p  s c a n s  o n  a  d i f f e r e n t  s c a n n e r .
8 .5 .3 S ix- m inu te  wa lk  tes t  (6MWT )
T h e  6 - m i n u t e  w a l k  t e s t  ( 6MWT )  i s  a  s im p l e ,  e c o n om i c a l  a n d  r e p r o d u c i b l e  t e s t  t h a t  m e a s u r e s  
h ow  m a ny  m e t e r s  a  p e r son  c an  w a lk  in  6  m inu t e s .  R e p e a t e d  m e a su r em en t  o f  t h e  6MWT  ov e r  
t im e  h a s  b e e n  u s e d  in  s tudy ing  n um e r o u s  m u s c u l o s k e l e t a l ,  pu lmon a ry ,  a n d  c a r d i o v a s c u l a r  
c o n d i t i o n s  a n d  i s  a  v a l i d a t e d  o u t c om e  i n  i n v e s t i g a t i o n a l  d r u g  t r i a l s .
P a t i e n t s  w i l l  b e  in s t ru c t ed  by  t h e  t e s t  a dm i n i s t r a t o r  u s ing  a  s c r i p t  a n d  e s t a b l i s h e d  t e s t ing  
p r o t o c o l .  T h e  t e s t i n g  shou ld  b e  c o n d u c t e d  o n  a n  i n d i v i d u a l  b a s i s  ( p a t i e n t  a n d  t e s t e r s )  w i th  n o  
add i t ion a l  aud i en c e  o r  suppo r t  o th e r  th an  th a t  o f  th e  t r a in ed  p e r sonn e l  condu c t ing  th e  t e s t .  I f  a  
w a l k i n g  a i d  i s  r equ i r ed  a t  b a s e l in e ,  p a t i en t s  w i l l  b e  a sk ed  to  u s e  th e  l e a s t  a s s i s t iv e  w a lk ing  a id  
t h a t  in  t h e i r  op in ion  w i l l  e n a b l e  th em  to  comp l e t e  t h e  6MWT  s a f e l y .  P a t i e n t s  s h o u l d  b e  
e n c o u r a g e d  t o  u s et h e  s am e  w a l k i n g  a i d  w h e n  p e r f o rm i n g  a l l  t e s t s  t h r o u g h o u t  t h e  s t u d y .
A  c h a n g e  in  w a l k i n g  a id  to  p e r f o rm  t h e  t e s t  i s  p e rm i t t e d  i f  r e q u i r e d  f o r  s a f e t y  r e a son s  
( e . g . , d e t e r io r a t ion  o f  b a l an c e ) .  Th e  t e s t ing  shou ld  o c cu r  a t  app rox im a t e ly  th e  s am e  t im e  o f  th e  
d ay  a s  t h e  b a s e l i n e  a s s e s sm en t  to  p r e v e n t  a n y  p o s s i b l e  d i u r n a l  v a r i a t i o n s .  T h e  s am e  t e s t  
a dm i n i s t r a t o r  s h o u l d  p e r f o rm  a l l  r e p e a t  t e s t s  on  a  p a t i e n t  w h e n e v e r  p o s s i b l e  to  r edu c e  
t e c h n i c i a n - r e l a t e d  d i f f e r e n c e s  i n  t e s t  p e r f o rm a n c e .
I n  c i r c um s t a n c e s  w h e r e  t h e  t e s t  i s  i n t e r r u p t e d  fo r  r e a s o n s  o th e r  t h a n  p a t i en t  f a t i g u e  t h e  t e s t  
m ay b e  r e p e a t e d  o n c e ,  p r e f e r a b ly  on  th e  s am e  d ay  ( w i th  a  m inimum  6 0  m i n u t e  r e s t  p e r iod ) .  
I fr e - t e s t i n g  o n  th e  s am e  d ay  i s  no t  p o s s i b l e ,  t h e  t e s t  m ay b e  r e p e a t e d  a s  soon  a s  p o s s i b l e ,  bu t  
w i th in  2- 3  d ay s  o f  t h e  o r i g i n a l  a t t em p t .
P a t i e n t s  r e s t i n g  v a lu e s  o f  oxy g e n  s a tu r a t ion  (% ) ,  h e a r t  r a t e  ( b pm ) ,  a n d  B o r g  Qu e s t ionn a i r e  
s c o r e  w i l l  b e  r e c o r d e d  b e f o r e  t h e  t e s t .  O xy g e n  s a t u r a t i o n  (% ) ,  h e a r t  r a t e  ( b pm ) ,d i s t an c e  
w a l k e d  (m e t e r s ) ,  a n d  B o r g  Q u e s t i o n n a i r e  s co r ew i l l  b e  r e c o r d e d  a t  t h e  e n d  o f  t h e  6MWT .  
R e q u i r em e n t  o f  r e s c u e  m e d i c a t i o n s ,  i n c l u d i n g  supp l em en t a l  oxy g e n  th e r apy ,  a n d  a n y  adv e r s e  
e v e n t s  o c c u r r i n g  d u r i n g  th e  6MWT  w i l l  b e  r e co rd ed .  I f  a  p a t i e n t  i s  on  ch ron i c  oxy g e n  th e r apy ,  Co rpo ra te  Con f iden t ia l  In fo rma t ionCo rpo ra te  Con f iden t ia l  In fo rma t ion
No va r t i s Con f iden t ia l Page  55
Amended  P ro toco l  Ve rs ion  01  (C lean ) P ro toco l  No .  CACZ885X2205
s u p p l em e n t a l  oxy g en  w i l l  b e  a l low ed  d u r i n g  th e  6MWT ;  h ow e v e r ,  th e  s am e  l ev e l / r a t e  o f  
s u p p l em e n t a l  o x y g e n  s h o u l d  b e  m a i n t a i n e d  t h r o u g h  t h e  i n i t i a l  6MWT  a n d  a l l  s u b s e q u e n t  t r i a l s .  
Comp l e t e  d e t a i l s  o f  cou r s e  s e t- up ,  t e s t  adm in i s t r a t ion ,  equ ipm en t  and  r e co rd ing  in to  th e  eCRF  
a r e  d e s c r i b e d  i n  t h e  S i t e  O p e r a t i o n sM anu a l .
8 .5 .4 Se rum  IL- 1β
8 .5 .5 Pu lmona ry func t ion  tes t ing
F o r  d e t a i l s  o n  pu lmon a ry  f un c t ion  t e s t i n g  p l e a s e  r e f e r  to  b e l ow  s e c t i o n s  a n d  t h e  B i om e d i c a l  
Sys t em s  C e n t r a l i z e d  S p i r om e t r y ,  DL c o  a n d  L u n g  V o l um e s  P r o c e d u r e  M a n u a l.
8 .5 .5 .1 D i f fus ing  Capac i ty (DL CO)
D i f f u s i o n  c ap a c i ty  f o r  c a r b o n  monox id e  (DL CO)  w i l l  b e  d e t e rm i n e d  a c c o r d i n g  to  ATS  
g u i d e l i n e s  ( M a c I n ty ree ta l2 0 0 5 ) .  M e a su r em en t s  w i l l  in c lud e  DL COa n d  a l v e o l a r  v o l um e  (V A) .  
DLCOi s  d e t e rm i n e d  by  m e a s u r i n g  t h e  up t ak e  o f  c a r b o n  monox id e  f rom  t h e  lun g  ov e r  a  
b r e a t h- ho ld ing  p e r i o d .  V Ar e p r e s e n t s  a n  e s t im a t e  o f  lung  g a s  vo lum e  in to  w h i c h  CO  i s  
d i s t r i b u t e d  a n d  t h e n  t r a n s f e r r e d  a c r o s s  t h e  a l v e o l a r  c ap i l l a ry  m em b r a n e  m a k i n g  i t  c r i t i c a l  in  
t h e  m e a s u r em e n t  o f  DL CO.  VAi s  ty p i c a l ly  m e a su r ed  s imu l t an eou s ly  w i th  CO  u p t a k e  by  
c a l c u l a t i n g  t h e  d i lu t ion  o f  a n  i n e r t  t r a c e r  g a s  ( e .g . ,a rgon ,  m e t h a n e ,  o r  h e l i um) .  I n  n o rm a l  
s u b j e c t s ,  t h e  sum  o f  V Aa n d  VD( d e a d  s p a c e  vo lum e )c l o s e l y  m a t ch e s  t h e  to t a l  l u n g  c a p a c i t y  
(TL C )  d e t e rm in edby  p l e thy sm o g r a p h y . How ev e r ,  in  c a s e s  o f  poo r  g a s  m ix ing  in  p a t i en t s  w i th  
o b s t r u c t e d  a i rw ay s ,  t r a c e r  g a s  d i lu t ion  i s  m a rk ed ly r e d u c e d  l e a d i n g  to  V Av a l u e s  t h a t  a r e  
s i g n i f i c a n t l y  l e s s  t h a n  t h o s e  e x p e c t e d  b a s e d  o n  a c tu a l  to t a l  t h o r a c i c  g a s  vo lum e s .  Add i t iona l  
i n f o rm a t i o n  f o r  o b t a i n i n g  DL COi s  p rov id ed  in  th e  Pu lmon a ry  F u n c t i o n  T e s t s  M a n u a l .
8 .5 .5 .2 Lung  Vo lumes
A  body  p l e thy smog r aph  w i l l  b e  u s ed  to  m e a su r e  F u n c t i o n a l  R e s idu a l  C ap a c i ty ( FRC ) ,  
In sp i r a to ry  C a p a c i t y  ( IC ) ,  T o t a l  L u n g  C ap a c i ty ( TLC ),  and  R e s i d u a l  V o l um e  ( RV ) .  
A l lp l e thy sm o g r a p h y  ev a lu a t ion s  s h o u l d  f o l l ow  t h e  r e c omm e n d a t i o n s  o f  t h e  ATS /ERS  T a s k  
f o r c e :  S t a n d a r d i z a t i o n  o f  t h e  m e a s u r em e n t  o f  l u n g  v o l um e s  ( W a n g e re ta l2 0 0 5 ) .  A d d i t i o n a l  
i n f o rm a t i o n  f o r  condu c t  o f  p l e thy s mog r aphy w i l l  b e  p r o v i d e d  in  t h e  B i om e d i c a l  Sys t em s  
C en t r a l i z ed  Sp i rom e t ry,  DL c o  a n d  L u n g  V o l um e s  P r o c e d u r e  M a n u a l .Co rpo ra te  Con f iden t ia l  In fo rma t ion
No va r t i s Con f iden t ia l Page  56
Amended  P ro toco l  Ve rs ion  01  (C lean ) P ro toco l  No .  CACZ885X2205
[ADDRESS_426697] ing  to  t h e  Am e r i c an  Tho r a c i c  S o c i e ty  g u i d e l i n e s  
( M i l l e re ta l2 0 0 5 a ;  M i l l e re ta l2 0 0 5 b )  a t  s c r e en ing  to  a s s e s s  p a t i e n t s ’  e l ig ib i l i ty  f o r  t h e  s tudy  
a n d  a s  d e t a i l e d  in  t h e  a s s e s sm en t  s c h e d u l e .  E l ig ib i l i ty c r i t e r i a  a r e  b a s ed  on  FVC  in  p e r c e n t  o f  
p r e d i c t e d ,  s t r a t i f i e d  b y  g e n d e r ,  a g e ,  h e i g h t ,  a n d  r a c e  ( P e l l e g r i n oe ta l2 0 0 5) .
T h e  sp i rom e t ry  e qu ipm en t  u s e d  d u r i n g  t h e  t r i a l  mu s t  m e e t  o r  e x c e e d  th e  m in im a l  ATS /ERS  
r e c omm e n d a t i o n s  f o r  d i a g n o s t i c  sp i rom e t ry  e q u i pm e n t  a s  d e f in ed  i n  t h e  g u i d e l i n es
( M i l l e re ta l2 0 0 5 b ) .
T h e  s am e  sp i rom e t ry  e qu ipm en t  s h o u l d  b e  u s e d  f o r  a l l  a s s e s s m e n t s  p e r fo rm ed  by  a  s ub j e c t .  
Al im i t ed  n um b e r  o f  s t a f f ,  a s  d e s ign a t ed  by  t h e  inv e s t ig a to r ,  w i l l  ev a lu a t e  a l l  p a t i en t s  a t  a l l  
v i s i t s  t h r o u g h o u t  t h e  en t i r e  t r i a l .  W h e r e  po s s ib l e  t h e  s am e  t e c h n i c i a n  shou ld  p e r f o rm  a l l  
m a n e u v e r s  fo r  a n  i n d i v i d u a l  s u b j e c t .  A l l  s t a f f  c o n d u c t i n g  t h e  sp i rom e t ry  t e s t s  mu s t  h a v e  
r e c e i v e d  a p p r o p r i a t e  t r a i n i n g ,  w h i c h  m u s t  b e  d o c um e n t e d .
R e s ul t s  f r om  FVC ,  FEV 1,FEV 3a n d  FEV 6t e s t s  a r e  h igh ly  d ep end en t  o n  e f f o r t  and  
c o o p e r a t i o n  f r om  th e  sub j e c t .  T h u s ,  t h r o u g h o u t  t h e  m a n e u v e r ,  e n t h u s i a s t i c  c o a c h i n g  o f  th e  
s u b j e c t  i s  r e q u i r e d .
A l l  c l i n i c  v i s i t s  w i l l  s t a r t  in  t h e  m o r n i n g .  T h e  f o l l ow i n g  sp i rom e t ry  m e a s u r em e n t s  w i l l  b e  
t a k e n :  fo r c ed  v i t a l  c ap a c i ty  ( FVC ) ;  a b s o l u t e  a n d  FVC%  ( f o r c e d  v i t a l  c ap a c i ty ,  exp r e s s ed  a s  a  
p e r c en t ag e  o f  th e  no rm a l  exp e c t ed  v a lu e )  and  fo r c ed  exp i r a to ry  vo lum e  in  on e  s e cond  (FEV1 ) .  
A d d i t i o n a l  sp i rom e t ry  d a t a  to  b e  c ap tu r ed  in c lud e  FEF 2 5- 75 ,  FEV1 /FVC ,  FEV 3 /FVCand  
FEV 6.
F o r  a l l  c l i n i c  sp i rom e t ry  a s s e s sm e n t s ,  t h r e e  a c c e p t a b l e  m a n e u v e r s  shou ld  b e  p e r fo rm ed  fo r  
e a c h  t im e - po in t .  A l l  sp i rom e t ry  m a n e u v e r s  s h o u l d  b e  p e r f o rm e d  in  s i t t i n g  po s i t ion  wh i l s t  
w e a r i n g  n o s e  c l i p s .  Th e  FEV 1a n d  FVC  v a l u e s  r e c o r d e d  in  t h e  CRF  mu s t  b e  t h e  h i g h e s t  
v a l u e s  m e a s u r e d  i r r e sp e c t iv e  o f  wh e th e r  o r  no t  th ey  o c c u r  on  th e  s am e  cu rv e .  A l ld i s p l a c e a b l e  
v o l um e s  w i l l  b e  r e p o r t e d  in  l i t e r s  (L )  a t  t h e  f o l l ow i n g  cond i t ion s :  no rm a l  body  t emp e r a tu r e  
( 3 7 °  C ) ,  am b i e n t  p r e s s u r e ,  s a t u r a t e d  w i t h  w a t e r  v a p o r  (BTPS ) .
A d d i t i o n a l  i n f o rm a t i o n  f o r  c o n d u c t  o f  sp i rom e t ry  e v a lu a t ion s  i s  p rov id ed  in  t h e  B i om e d i c a l  
Sys t em s  C e n t r a l i z e d  S p i r om e t r y ,  DL c o  a n d  L u n g  V o l um e s  P r o c e d u r e  M a n u a l.
8 .5 .5 .4 Sp i rome t ry Rev e rs ib i l i ty Tes t
Tw o  sp i rom e t ry  e v a lu a t ion s  w i l l  b e  p e r fo rm ed  a t  V i s i t  101  and  V i s i t  107,  th e  f i r s t  p r io r  to  u s e  
o f  s a l b u t am o l / a l b u t e r o l ,  t h e  s e c o n d  p e r f o rm e d  a f t e r  in t a k e  o f  s a l b u t am o l / a l b u t e r o l .  T h ein i t i a l  
sp i rom e t ry  a s s e s sm en t  w i l l  b e  p e r fo rm ed  a f t e r  a  w a s h- ou t  p e r iod  o f  a t  l e a s t  6hou r s  f o ra  
s h o r t - a c t i n g  β - 2  a g o n i s t  a n d  a t  l e a s t  4 8  h o u r s  fo r  a  long  a c t ing  β - 2  agon i s t .  A f t e r  th e  in i t i a l  
sp i rom e t ry  a s s e s sm e n t  s a l b u t am o l / a l b u t e r o l  i s  a dm i n i s t e r e d ,  and  t h e  s e c o n d  s p i r om e t r y  
a s s e s sm e n t  i s  p e r f o rm e d  w i th in  3 0  m in  o f  a dm i n i s t r a t i o n .  I n v e s t i g a t o r s  s h o u l d  f o l l ow  th e
r ev e r s ib i l i ty  p r o c e d u r e s  c i t e din  t h e  ATS /ERS  g u i d e l i n e s  a b o v e  w i th  r eg a rd  to  b r o n c h o d i l a t o r  
u s e .  T h e  p r im a r y  sp i rom e t ry  r e a d o u t  w i l l  b e  t h e  p o s t - b r o n c h o d i l a t o r  FVC .
R ev e r s ib i l i ty (% )  w i l l  b e  c a l c u l a t e d  a s  f o l l ow s :
(FEV 1  ( p o s t  b r o n c h o d i l a t o r )  –FEV 1  ( p r e- b ron chod i l a to r )  x  1 0 0 ) /FEV 1  ( p r e - b r o n c h o d i l a t o r )
No va r t i s Con f iden t ia l Page  57
Amended  P ro toco l  Ve rs ion  01  (C lean ) P ro toco l  No .  CACZ885X2205
8 .6  Sa fe ty
S a f e ty  a s s e s sm e n t s  a r e  s p e c i f i e d  b e l ow ;  m e t h o d s  f o r  a s s e s sm e n t  a n d  r e c o r d i n g  a r e  s p e c i f i e d  i n  
t h e  S i t e  O p e r a t i o n s  M anu a l ,  w i th  t h e  A s se s sm en t  S c h e d u l ed e t a i l i n g  wh en  e a c h  a s s e s sm e n t  i s  
t o  b e  p e r f o rm e d .
8 .6 .1 Phys ica l  exam ina t ion
S e e  t h e  S i t e  O p e r a t i o n s  M a n u a l  f o r  d e t a i l s .
8 .6 .2 V i ta l  s igns
B l o o d  p r e s s u r e  (BP )
Pu l s e
Body  t em p e r a t u r e( s am e  m e t h o d  o f  m e a s u r em e n t  s h o u l d  b e  u s e d  t h r o u g h o u t  s t u d y )
8 .6 .3 He igh t  and  we igh t
H e i g h t
B o dy  w e i g h t
8 .6 .4 Labo ra to ry ev a lua t ions
I n  t h e  c a s e  w h e r e  a  l abo r a to ry  a s s e s sm e n t  t h a t  i s  l i s t ed  in  t h e  i n c l u s i o n / e x c l u s i o n  c r i t e r i a  i s  
o u t s i d e  o f  a  p r o t o c o l- s p e c i f i e d  r a n g e  a t  s c r e e n i n g  a n d / o r  a t  t h e  in i t i a l  b a s e l i n e ,  t h e  a s s e s sm e n t  
m ay b e  r e p e a t e d  on c e  p r i o r  to  r a n d om i z a t i o n .  I f  t h e  r ep e a t  v a lu e  r em a i n s  o u t s i d e  o f  
p r o t o c o l- s p e c i f i e d  r a n g e s ,  t h e  s u b j e c t  i s  e x c l u d e d  f r om  t h e  s t u d y .
I n  t h e  c a s e  wh e r e  a  l abo r a to ry  r ang e  i s  no t  sp e c i f i ed  by  t h e  p ro to co l ,  bu t  i s  o u t s i d e  th e  
r e f e r e n c e  r ang e  f o r  th e  l abo r a to ry  a t  s c r e e n i n g  and /o r  in i t i a l  b a s e l i n e ,  a  d e c i s i o n  r e g a r d i n g  
w h e t h e r  th e  r e su l t  i s  o f  c l in i c a l  s i g n i f i c a n c e  o r  no t  s h a l l  b e  m ad e  by  t h e  i nv e s t ig a to r  a n d  sh a l l  
b e  b a s ed ,  in  p a r t ,  u p o n  t h e  n a t u r e  a n d  d eg r e e  o f  t h e  o b s e r v e d  abno rm a l i ty .  Th ea s s e s sm e n t  
m ay b e  r e p e a t e d  o n c e  p r i o r  t o  r a n d om i z a t i o n .
I n  a l l  c a s e s ,  t h e  i n v e s t i g a t o r  mu s t  d o c um e n t  in  t h e  s o u r c e  d o c um e n t s  t h e  c l i n i c a l  
c o n s i d e r a t i o n s  ( i . e . ,  r e su l t  w a s /w a s  no t  c l in i c a l ly  s ig n i f i c a n t  a n d / o r  m ed i c a l ly r e l e v a n t )  in  
a l l ow i n g  o r  d i s a l l ow i n g  t h e  s u b j e c t  to  con t inu e  in  th e  s tudy .
C l in i c a l ly r e l e v a n t  d ev i a t ion s  o f  l a b o r a t o r y  t e s t  r e su l t s  o c c u r r i n g  d u r i n g  o r  a t  c om p l e t i o n  o f  
t h e  s tudy  m u s t  b e  r e p o r t e d  a n d  d i s c u s s e d  w i th  N o v a r t i s  p e r s o n n e l .  Th e  r e s u l t s  s h o u l d  b e  
e v a l u a t e d  f o r  c r i t e r i a  d e f in ing  an  a d v e r s e  e v e n t  and  r e p o r t e d  a s  su ch  i f  th e  c r i t e r i a  a r e  m e t .  
R e p e a t e d  ev a lu a t ion s  a r e  m and a to ry u n t i l  no rm a l i z a t ion  o f  t h e  r e s u l t ( s )  o r  un t i l  t h e  c h a n g e  i s  
n o  l o n g e r  c l i n i c a l ly  r e l e v a n t .  I n  c a s e  o f  d o u b t ,  N o v a r t i s  p e r s o n n e l  s h o u l d  a g a i n  b e  c o n t a c t e d .
Hema to logy
H em og l o b i n ,  h em a to c r i t ,  r e d  b l o o d  c e l l  coun t ,  w h i t e  b l o o d  c e l l  coun t  w i th  d i f f e r e n t i a l s  
( e . g . ,n e u t r o p h i l s ,  b a soph i l s ,  e o s i n o p h i l s ,  mono cyt e s ,  ly mpho cyt e s )  a n d  p l a t e l e t  c o u n t  w i l l  b e  
m e a s u r e d .
No va r t i s Con f iden t ia l Page  58
Amended  P ro toco l  Ve rs ion  01  (C lean ) P ro toco l  No .  CACZ885X2205
C l in ica l  chem is t ry
A lbum in ,  a l k a l i n e  p h o s p h a t a s e  (AL P ) ,  to t a l  b i l i r u b i n ,  b i c a r b o n a t e /CO [ADDRESS_426698] ,  ALT ,  sod ium ,  t r i g l y ce r i d e s ,  u r e a /BUN  a n d  u r i c  
a c i d .
I f  t h e  to t a l  b i l i rub in  c o n c e n t r a t ion  i s  i n c r e a s e d  a b o v e  1 . 5  t im e s  t h e  upp e r  l im i t  o f  n o rm a l ,  
d i r e c t  a n d  i n d i r e c t  r e a c t i n g  b i l i r u b i n  s h o u l d  b e  d i f f e r e n t i a t e d .
U r ina lys is
A  s em i - q u a n t i t a t i v e  " d i p s t i c k "  e v a l u a t i o n  fo r  t h e  f o l l ow i n g  p a r am e t e r s  w i l l  b e  p e r fo rm ed :  
sp e c i f i c  g r av i ty ,  pH ,  g l u c o s e ,  p r o t e i n ,  b i l i r u b i n ,  k e t o n e s ,  n i t r i t e ,  l e u k o c y t e s  and  b lood .
M i c r o s c o py ,  WBC ,  RBC  a n d  c a s t s  w i l l  a l s o  b e  a s s e s s e d  i n  c a s e  o f  a n  a b n o rm a l  d i p s t i c k  t e s t .
[ADDRESS_426699] iog ram  (ECG )
F u l l  d e t a i l s  o f  a l l  p r o c e d u r e s  r e l a t i n g  to  t h e  ECG  c o l l e c t i o n  a n d  r e p o r t i n g  a r e  c o n t a i n e d  in  th e  
S i t e  O p e r a t i o n s  M a n u a l .
PR  i n t e r v a l ,  QRS  d u r a t i o n ,  h e a r t  r a t e ,  RR ,  QT ,  QT c
T h e  F r i d e r i c i a  QT  co r r e c t ion  f o rm u l a  (QT cF )  c a l cu l a t ed  w i th  t h e  RR  i n t e r v a l  e x p r e s s e d  in  
s e c o n d s  s h o u l d  b e  u s e d  f o r  c l i n i c a l  d e c i s i o n s .
C l in i c a l ly s ign i f i c a n t  abno rm a l i t i e s  shou ld  b e  r e co rd ed  on  th e  r e l ev an t  m ed i c a l  h i s to ry / cu r r en t  
m e d i c a l  c o n d i t i o n s  CRF  p a g e  p r i o r  to  in fo rm ed  con s en t  s i g n a t u r e  a n d  o n  th e  A d v e r s e  Ev en t s  
p a g e  t h e r e a f t e r .  C l i n i c a l l y  s i g n i f i c a n t  f i n d i n g s  m u s t  b e  d i s c u s s e d  w i t h  t h e  S p o n s o r .
8 .6 .6 P regnancy and  assessmen ts  o f  fe r t i l i ty
A l l  p r e- m e n o p a u s a l  wom en  who  a r e  no t  su rg i c a l ly  s t e r i l e  wi l l  h av e  p r egn an cy  t e s t ing .  S e e th e  
A s s e s sm e n t  S c h e d u l ef o r  t im i n g  o f  t h e  p r o t o c o l  r e q u i r e d  p r egn an cy  t e s t i n g ;  a d d i t i o n a l  
p r egn an cy  t e s t i n g  m ay b e  p e r f o rm e d  to  m e e t  lo c a l  r e q u i r em e n t s .  A  p o s i t i v e  u r i n e  p r egn an cy  
t e s t  r e q u i r e s  imm e d i a t e  in t e r rup t ion  o f  s tudy  t r e a tm en t  un t i l  s e r um  β -hCG  i s  p e r f o rm e d  and  
f o u n d  t o  b e  n e g a t i v e .
I f  a d d i t i o n a l  p r egn an cy  t e s t i n g  i s  n e ed ed  p e r  l o c a l  r e q u i r em e n t s ,  t h o s e  add i t ion a l  r e s u l t s  w i l l  
b e  k e p t  a s  s o u r c e  d o c um e n t a t i o n  o n l y .
8 .6 .7 Immunogen ic i ty  (A n t i- ACZ885  An t ibod ies )
T o  a s s e s s  po t en t i a l  imm u n o g e n i c i t y ,  s e rum  s amp l e s  f o r  d e t e rm in a t ion  o f  a n t i - ACZ885  
a n t i b o d i e s  (ADA )  w i l l  b e  c o l l e c t e d  d u r i n g  t h e  s tu dy  ( s e e  A s s e s sm en t  S ch edu l e) .
F o l l ow  i n s t r u c t i o n s  o u t l i n e d  in  t h e  C e n t r a l  L a b o r a t o r y M a n u a l  r eg a rd ing  s am p l e  c o l l e c t i o n ,  
n um b e r i n g ,  p r o c e s s i n g ,  a n d  s h i pm e n t .
I n  t h e  c a s e  o f  an  an aphy l a c t i c  r e a c t i o n  o c c u r r ing  a f t e r  i n j e c t i o n ,  a  s amp l e  w i l l  b e  t ak en  a t  th e  
t im e  o f  th e  ev en t  and  8  w e e k s  l a t e r .  An  immunog en i c i ty  p o s i t i v e  sub j e c t  a t  th e  end  o f  th e  
s tudy  w i l l  b e  f o l l ow e d  u p  f o r  t h r e e  m o n t h s .
No va r t i s Con f iden t ia l Page  59
Amended  P ro toco l  Ve rs ion  01  (C lean ) P ro toco l  No .  CACZ885X2205
Immunogen ic i ty  ana ly t ica l  me thod
A n  EL ISA  b a s ed  m e thod  w i l l  b e  u s e d  fo rth e  d e t e c t ion  o f  po t en t i a l  ADA  fo rm a t ion .
T h ed e t a i l e d  m e thod  d e s c r ip t ion  to  a s s e s s  imm u n o g e n i c i t y  w i l l  b e  d e s c r i b e d  in  th e  
b io an a ly t i c a l  r aw  d a t a  o f  th e  s tudy  a n d  i n  t h e  r e s p e c t i v e  B i o a n a l y ti c a l  D a t a  R e p o r t  (BDR ) .
8 .6 .8 Loca l  to le rab i l i ty (subcu taneous  in jec t i ons )
L oc a l  to l e r ab i l i ty  a t  t h e  s i t e s  o f  s . c .  in j e c t ion s  w i l l  b e  ev a lu a t ed  by  t h e  inv e s t ig a to r .  A nylo c a l  
r e a c t i o n s  s h o u l d  b e  o b s e r v e d  un t i l  th ey  h av e  d i s a p p e a r e d .  An  a s s e s sm en t  o f  s ev e r i ty  ( i . e . ,  
n o n e ,  m i ld ,  m o d e r a t e ,  s ev e r e )  o f  t h e  f o l l ow i n g  s i g n s  a n d  sy mp tom s :  p a in ,  r e d n e s s ,  sw e l l ing ,  
i n d u r a t i o n ,  h em o r r h a g e  and  i t c h ,  a n d  t h e  e x a c t  l o c a t i o n  o f  a n y  lo c a l  r e a c t ion  w i l l  b e  r e co rd ed  
i n  t h e  eCRF .
[ADDRESS_426700] e r  to  b e t t e r  d e f in e  th e  PK  p ro f i l e ,  th e  t im ing  o f  th e  PK  s amp l e  co l l e c t ion  m ay  b e  a l t e r ed  
b a s e d  o n  em e r g e n t  d a t a .  Th e  n um b e r  o f  s amp l e s /b lood  d r aw s  a n d  to t a l  b l o o d  v o l um e  
c o l l e c t e d  w i l l  n o t  e x c e e d  t h o s e  s t a t e d  i n  t h e  p r o to co l .
Pha rmacok ine t ic  pa rame te rs
Con c en t r a t ion s  w i l l  b e  exp r e s s ed  in  m a s s  p e r  vo lum e  un i t s .  M i s s ing  v a lu e s  o r  tho s e  b e low  th e  
l im i t  o f  q u a n t i f i c a t i o n  w i l l  b e  i n d i c a t e d  in  th e  d a t a  l i s t i n g s  a n d  t r e a t ed  a s  z e r o  in  d a t a  
p r e s e n t a t i o n s  a n d  c a l c u l a t i o n s .
F o r  s t a n d a r d  p h a rm a c o k i n e t i c  a b b r e v i a t i o n s  and  d e f i n i t i o n s  s e e  th e  l i s t  p r o v i d e d  a t  th e  
b e g i n n i n g  o f  t h i s  p r o t o c o l .
A  p r ev iou s ly  u t i l i z ed  a n d  v a l i d a t e d  m i x e d  e f f e c t s  m o d e l i n g  a p p r o a c h  m ay b e  u s e d  to  
c h a r a c t e r i z e  t h e  expo su r e - r e l a t e d  PK  p a r am e t e r s  ( i . e . ,  AUC  a n d  CL)  o f  c a n a k i n um a b .  
T h e s er e su l t s  m ay b e  r e p o r t e d  in  a  s e p a r a t e  r epo r t  f r om  t h e  f i n a l  CACZ 8 8 5X 2 2 0 5  c l in i c a l  
s tudy  r e p o r t .Co rpo ra te  Con f iden t ia l  In fo rma t ion
No va r t i s Con f iden t ia l Page  60
Amended  P ro toco l  Ve rs ion  01  (C lean ) P ro toco l  No .  CACZ885X2205
8 .8  O the r  assessmen ts
Co rpo ra te  Con f iden t ia l  In fo rma t ion
No va r t i s Con f iden t ia l Page  61
Amended  P ro toco l  Ve rs ion  01  (C lean ) P ro toco l  No .  CACZ885X2205
8 .9  Use  o f  res idua l  b io log ica l  samp les
R e s i d u a l  b l o o d  a n d  l e s i o n a l  b iop sy  s am p l e s  m ay b e  u s e d  fo r  a n o t h e r  p r o t o c o l- sp e c i f i ed  
e n d p o i n t .Co rpo ra te  Con f iden t ia l  In fo rma t ion
Co rpo ra te  Con f iden t ia l  In fo rma t ion
No va r t i s Con f iden t ia l Page  62
Amended  P ro toco l  Ve rs ion  01  (C lean ) P ro toco l  No .  CACZ885X2205
9  Sa fe ty mon i to r ing
9 .1  Adve rse  even ts
A n  a d v e r s e  ev en t  (AE )  i s  any  u n t ow a r d  m ed i c a l  o c c u r r e n c e  ( i . e . ,  any  u n f a v o r a b l e  and  
u n i n t e n d e d  s ign  i n c l u d i n g  a b n o rm a l  l abo r a to ry  f ind ing s ,  sy mp tom  o rd i s e a s e )  in  a  sub j e c t  o r  
c l i n i c a l  i n v e s t i g a t i o n  sub j e c t  a f t e r  p r o v i d i n g  w r i t t e n  i n f o rm e d  c o n s e n tfo r  p a r t i c i p a t i o n  in  th e  
s tudy  u n t i l  t h e  end  o f  s tudy  v i s i t .  T h e r e f o r e ,  a n  AE  m ay o r  m ay n o t  b e  t empo r a l ly  o r  c a u s a l l y  
a s s o c i a t e d  w i t h  t h e  u s e  o f  a  m e d i c i n a l  ( i n v e s t i g a t i o n a l )  p r o d u c t .
I n  a d d i t i o n ,  a l l  r e p o r t s  o f  i n t e n t i o n a l  m i s u s e  a n d  a b u s e  o f  t h e  s tudy  t r e a tm e n t  a r e  a l s o  
c o n s i d e r e d  a n  a d v e r s e  ev en t  i r r e s p e c t i v e  i f  a  c l i n i c a l  ev en t  h a s  o c cu r r ed .  S e e  S e c t i o n9 . 5fo r  
a n  o v e r v i ew  o f  t h e  r e p o r t i n g  r e q u i r em e n t s .
T h e  o c c u r r e n c e  o f  a d v e r s e  e v e n t s  mu s t  b e  s o u g h t  by  n o n - d i r e c t i v e  q u e s t i o n i n g  o f  t h e  sub j e c t  
a t  e a c h  v i s i t  du r ing  th e  s tudy .  Adv e r s e  ev en t s  a l so  m ay  b e  d e t e c t ed  wh en  th ey  a r e  vo lun t e e r ed  
by  t h e  sub j e c t  d u r in g  o r  b e tw e e n  v i s i t s  o r  t h r o u g h  phy s i c a l  ex am in a t ion  f i n d i n g ,  l abo r a to ry  
t e s t  f i n d i n g ,  o r  o t h e r  a s s e s sm e n t s .
A b n o rm a l  l abo r a to ry  v a lu e s  o r  t e s t  r e s u l t s  c o n s t i t u t e  a d v e r s e  e v e n t s  on ly  i f  t h ey  f u l f i l l  a t  l e a s t  
o n e  o f  t h e  f o l l ow i n g  c r i t e r i a :
th ey  i n d u c e  c l i n i c a l  s ign s  o r  sy mp tom s ,
th ey  a r e  con s id e r ed  c l in i c a l ly  s ign i f i c an t ,
th ey  r equ i r e  th e r apy .
C l in i c a l ly s ig n i f i c an t  a b n o rm a l  l abo r a to ry  v a l u e s  o r  t e s t  r e su l t s  s h o u l d  b e  id en t i f i ed  t h r o u g h  a  
r e v i ew  o f  v a lu e s  o u t s i d e  o f  n o rm a l  r ang e s / c l in i c a l ly  n o t a b l e  r a n g e s ,  s i g n i f i c a n t  c h a n g e s  f rom  
b a s e l i n e  o r  t h e  p r e v i o u s  v i s i t ,  o r  v a l u e s  w h i c h  a r e  c o n s i d e r e d  t o  b e  n o n- ty p i c a l  in  p a t i en t s  w i th  
u n d e r ly in g  d i s e a s e .  I n v e s t i g a t o r s  h av e  t h e  r e spon s ib i l i ty  f o r  m a n a g i n g  t h e  s a f e t y  o f  i n d i v i d u a l  
s u b j e c t  a n d  id en t i fy ing  a d v e r s eev en t s .  A l e r t  r a n g e s  f o r  l i v e r -a n d  k idn ey - r e l a t e d  e v e n t s  a r e  
i n c l u d e d  i n  App end ix  1a n d  App end ix  2,  r e s p e c t i v e l y .
P r e- e x i s t i n g  m e d i c a l  cond i t ion s /d i s e a s e s  ( i . e . ,  M e d i c a l  H i s to ry( i e s ) )  a r e  c o n s i d e r e d  AE s  i f  
th ey  w o r s e n  a f t e r  p r o v i d i n g  w r i t t e n  i n f o rm e d  c o n s e n t .
A d v e r s e  e v e n t s  mu s t  b e  r e c o r d e d  o n  th e  Adv e r s e  E v e n t s  CRF  und e r  t h e  s ign s ,  sy mp tom s  o r  
d i a g n o s i s  a s s o c i a t e d  w i t h  t h em ,  a n d  a c c om p a n i e d  b y  th e  fo l low ing  in fo rm a t ion :
1 .T h e  s ev e r i ty  g r ad e :
m i ld :  u su a l ly t r a n s i e n t  i n  n a t u r e  a n d  g e n e r a l l y  no t  in t e r f e r ing  w i th  no rm a l  a c t iv i t i e s
m o d e r a t e :  s u f f i c i e n t l y d i s c om f o r t i n g  t o  i n t e r f e r e  w i t h  n o rm a l  a c t i v i t i e s
s e v e r e :  p r e v e n t s  n o rm a l  a c t i v i t i e s
2 .I t s  r e l a t ion sh ip  to  s tudy  t r e a tm en t
3 .I t s  d u r a t i o n  ( s t a r t  a n d  e n d  d a t e s )  o r  i f  t h e  e v e n t  i s  o n g o i n g  a n  o u t c om e  o f  n o t  r e c o v e r e d / n o t
r e s o l v e d  m u s t  b e  r e p o r t e d .
4 .W h e t h e r  i t  c o n s t i t u t e s  a  SAE  ( s e e  S e c t ion  9 .2f o r  d e f i n i t i o n  o f  SAE )  a n d  w h i c h  s e r i o u s n e s s
c r i t e r i a  h a v e  b e e n  m e t
5 .A c t i o n  t a k e n  r e g a r d i n g  i n v e s t i g a t i o n a l  t r e a tm e n t .
No va r t i s Con f iden t ia l Page  63
Amended  P ro toco l  Ve rs ion  01  (C lean ) P ro toco l  No .  CACZ885X2205
A l l  a d v e r s e  ev en t s  mu s t  b e  t r e a t e d  a p p r o p r i a t e l y .  T r e a tm e n t  m ay i n c l u d e  o n e  o r  m o r e  o f  th e  
f o l l ow i n g :
n o  a c t i o n  t a k e n  ( e . g . , f u r t h e r  o b s e rv a t ion  on ly )
i n v e s t i g a t i o n a l  t r e a tm e n t  d o s a g e  i n c r e a s e d / r e d u c e d
i n v e s t i g a t i o n a l  t r e a tm e n t  i n t e r r u p t e d /w i t h d r aw n
c o n c om i t a n t  m e d i c a t i o n  o r  n o n - d r u g  t h e r a py  g i v e n
h o s p i t a l i z a t i o n / p r o l o n g e d  h o s p i t a l i z a t i o n  ( s e e  S e c t i o n  9 . 2f o r  d e f i n i t i o n  o f  SAE )
6 .I t s  o u t c om e  ( n o t  r e c o v e r e d / n o t  r e s o l v e d ;  r e c o v e r e d / r e s o l v e d ;  r e c o v e r i n g / r e s o l v i n g ,
r e c o v e r e d / r e s o l v e d  w i t h  s e q u e l a e ;  f a t a l ;  o r  u n k n ow n ) .
I n f o rm a t i o n  a b o u t  c omm o n  s i d e  e f f e c t s  a l r e a d y  known  a b o u t  t h e  i n v e s t i g a t i o n a l  d r u g  c a n  b e  
f o u n d  in  th e  IB .   O n c e  an  a d v e r s e  ev en t  i s  d e t e c t ed ,  i t  mu s t  b e  fo l low ed  un t i l  i t s  r e s o l u t i o n  o r  
un t i l  i t  i s  j u d g e d  to  b e  p e rm a n e n t ,  a n d  a s s e s sm en t  s h o u l d  b e  m a d e  a t  e a c h  v i s i t  ( o r  mo r e  
f r e q u e n t l y ,  i f  n e c e s s a ry )  o f  a n y  c h a n g e s  in  s e v e r i t y ,  th e  s u s p e c t e d  r e l a t i o n s h i p  to  th e  
i n v e s t i g a t i o n a l  d r u g ,  t h e  i n t e r v e n t i o n s  r e q u i r e d  t o  t r e a t  i t ,  a n d  t h e  o u t c om e .
T h e  i n v e s t i g a t o r  mu s t  a l so  i n s t r u c t  e a c h  sub j e c t  to  r e p o r t  a n y  n ew  a d v e r s e  e v e n t  (b ey o n d  th e  
p r o t o c o l  o b s e r v a t i o n  p e r i o d )  t h a t  t h e  s u b j e c t ,  o r  t h e  s u b j e c t ’ s  p e r s o n a l  phy s i c i a n ,  b e l i ev e s  
m i g h t  r e a s o n a b l y  b e  r e l a t e d  to  s tudy  t r e a tm e n t .  Th i s  i n f o rm a t i o n  mu s t  b e  r e c o r d e d  in  t h e  
i n v e s t i g a t o r ’ s  s o u r c e  do cum en t s ;  h ow e v e r ,  i f  t h e  AE  m e e t s  t h e  c r i t e r i a  o f  a n  SAE ,  i t  mu s t  b e  
r e p o r t e d  t o  N o v a r t i s .
9 .2  Se r iousadve rse  even t  repo r t ing
9 .2 .1 De f in i t ion  o f  SAE
A n  SAE  i s  d e f i n e d  a s  any  a dv e r s e  e v e n t  ( a p p e a r a n c e  o f  (o r  w o r s e n i n g  o f  a n y  p r e - ex i s t ing )  
u n d e s i r a b l e  s i g n ( s ) ,  sy m p t om ( s )  o r  m ed i c a l  c o n d i t i o n s ( s ) )  wh i ch  m e e t s  a n y  on e  o f  th e  
f o l l ow i n g  c r i t e r i a :
i s  f a t a l  o r  l i f e - th r e a t e n i ng
r e s u l t s  i n  p e r s i s t e n t  o r  s i g n i f i c a n t  d i s a b i l i t y / in c ap a c i ty
c o n s t i t u t e s  a  c o n g e n i t a l  a n om a l y / b i r t h  d e f e c t
r e q u i r e s  i n p a t i e n t  h o s p i t a l i z a t i o n  o r  p r o l o n g a t i o n  o f  e x i s t i n g  h o s p i t a l i z a t i o n ,  u n l e s s
h o s p i t a l i z a t i o n  i s  f o r :
r o u t i n e  t r e a tm e n t  o r  m o n i t o r i n g  o f  t h e  s t u d i e d  i n d i c a t i o n ,  n o t  a s s o c i a t e d  w i t h  a n y
d e t e r i o r a t i o n  i n  cond i t ion ,  in c lud ingp l a n n e d  im a g i n g  p r o c e d u r e s .
e l e c t i v e  o r  p r e - p l a n n e d  t r e a tm e n t  f o r  a  p r e- e x i s t i n g  c o n d i t i o n  t h a t  i s  u n r e l a t e d  t o  t h e
i n d i c a t i o n  u n d e r  s t udy  a n d  h a s  n o t  w o r s e n e d  s i n c e  s i g n i n g  t h e  i n f o rm e d  c o n s e n t  f o rm
t r e a tm e n t  o n  a n  em e r g e n c y  o u t p a t i e n t  b a s i s  f o r  a n  e v e n t  n o t  f u l f i l l i n g  a n y  o f  th e
d e f i n i t i o n s  o f  a n  SAE  g i v e n  a b o v e  a n d  n o t  r e s u l t i n g  i n  h o s p i t a l  a dm i s s i o n
s o c i a l  r e a s o n s  a n d  r e s p i t e  c a r e  i n  t h e  a b s e n c e  o f  a n y  d e t e r io r a t ion  in  th e  sub j e c t ’ s
g e n e r a l  c o n d i t i o n
i s  m ed i c a l ly  s i g n i f i c a n t ,  e . g . ,  d e f i n e d  a s  a n  e v e n t  t h a t  j e o p a r d i z e s  t h e  p a t i e n t  o r  m a y
r e q u i r e  m e d i c a l  o r  s u r g i c a l  i n t e r v e n t i o n  t o  p r e v e n t  o n e  o f  t h e  o u t c om e s  l i s t e d  a b o v e .
No va r t i s Con f iden t ia l Page  64
Amended  P ro toco l  Ve rs ion  01  (C lean ) P ro toco l  No .  CACZ885X2205
A l l  m a l i g n a n t  n eop l a sm s  w i l l  b e  a s s e s s e d  a s  s e r iou s  u n d e r  “m ed i c a l ly  s i g n i f i c a n t ”  i f  o th e r  
s e r i o u s n e s s  c r i t e r i a  a r e  n o t  m e t .
L i f e- th r e a t en ing  in  th e  con t ex t  o f  a  SAE  r e f e r s  to  a  r e a c t ion  in  wh i ch  th e  sub j e c t  w a s  a t  r i sk  o f  
d e a t h  a t  th e  t im e  o f  th e  r e a c t i o n ;  i t  d o e s  no t  r e f e r  to  a  r e a c t i o n  t h a t  hy po th e t i c a l ly  m ig h t  h av e  
c a u s e d  d e a t h  i f  i t  w e r e  m o r e  s e v e r e  ( s e e  A n n e x  I V ,  ICH-E 2D  G u i d e l i n e ) .
M e d i c a l  a n d  s c i e n t i f i c  j u d gm e n t  s h o u l d  b e  e x e r c i s e d  in  d e c i d i n g  wh e th e r  o t h e r  s i tu a t ion s  
s h o u l d  b e  c o n s i d e r e d  s e r i o u s  r e a c t i o n s ,  s u c h  a s  im p o r t a n t  m e d i c a l  e v e n t s  t h a t  m i g h t  n o t  b e  
imm ed i a t e ly  l i f e - t h r e a t e n i n g  o r  r e s u l t  in  d e a t h  o r  ho sp i t a l i z a t ion  bu t  m i g h t  j eop a rd i z e  th e  
s u b j e c t  o r  m i g h t  r e q u i r e  i n t e r v e n t i o n  to  p r e v e n t  o n e  o f  t h e  o t h e r  o u t c om e s  l i s t ed  a b o v e .  
Ex amp l e s  o f  su ch  ev en t s  a r e  in t en s iv e  t r e a tm en t  in  an  em e rg en cy  r oom  o r  a t  hom e  fo r  a l l e rg i c  
b r o n c h o s p a sm ,  b l o o d  dy s c r a s i a s  o r  c o n v u l s i o n s  t h a t  d o  no t  r e s u l t  in  ho sp i t a l i z a t ion  o r  
d e v e l o pm e n t  o f  d e p e n d e n c y  o r  a b u s e  ( s e e  A n n e x  IV ,  ICH-E 2D  G u i d e l i n e ) .
Any su sp e c t ed  t r an sm i s s ion  v i a  a  m e d i c in a l  p rodu c t  o f  an  in f e c t iou s  ag en t  i s  a l so  con s id e r ed  a  
s e r i o u s  a d v e r s e  r e a c t i o n .
A l l  AE s  ( s e r i o u s  a n d  n o n - s e r i o u s )  a r e  c ap tu r ed  o n  t h e  CRF ;  SAE s  a l s o  r e q u i r e  i n d i v i d u a l  
r e p o r t i n g  t o  N o v a r t i s  D r u g  S a f e t y  &  E p i d em i o l o g y  (DS&E )  a s  p e r  S e c t ion  [ADDRESS_426701] l e s s  o f  c a u s a l i t y ,  o c c u r r i n g  a f t e r  t h e  sub j e c t  h a s  
p r o v i d e d  i n f o rm e d  con s en t  a n d  un t i l  3 0  d ay s  a f t e r  t h e  l a s t  s tudy  v i s i t  mu s t  b e  r e p o r t e d  to  
N o v a r t i s  w i th in  2 4  h o u r s  o f  l e a r n i n g  o f  i t s  o c c u r r e n c e  a s  d e s c r i b e d  b e l ow .  Any S AE s  
e x p e r i e n c e d  a f t e r  th i s  shou ld  on ly  b e  r e p o r t e d  to  N o v a r t i s  i f  th e  inv e s t ig a to r  s u s p e c t s  a  c a u s a l  
r e l a t ion sh ip  to  s tudy  t r e a tm e n t .
N o t e :  SAE s  r e p o r t e d  by  s u b j e c t s  d e em e d  to  b e  s c r e e n  f a i lu r e s  mu s t  b e  r e p o r t e d  to  N o v a r t i s  a s  
o u t l i n e d  h e r e  w i th  a p p r o p r i a t e  i n f o rm a t i o n  a l s o  c a p t u r e d  in  t h e  CRF s  a s  s p e c i f i e d  in  t h e  S i t e  
O p e r a t i o n s  M a n u a l .
A l l  f o l l ow- u p  i n f o rm a t i o n  f o r  t h e  SAE  i n c l u d i n g  i n f o rm a t i o n  o n  c om p l i c a t i o n s ,  p r o g r e s s i o n  o f  
t h e  in i t i a l  SAE  a n d  r e c u r r e n t  e p i s o d e s  mu s t  b e  r e p o r t e d  a s  f o l l ow - u p  to  th e  o r i g i n a l  ep i sod e  
w i th in  2 4  h o u r s  o f  t h e  i n v e s t i g a t o r  r e c e i v i n g  t h e  fo l low - u p  i n f o rm a t i o n .  An  SAE  o c c u r r i n g  a t  
a  d i f f e r en t  t im e  in t e rv a l  o r  o th e rw i s e  con s id e r ed  comp l e t e ly  un r e l a t ed  to  a  p r ev iou s ly r epo r t ed  
o n e  m u s t  b e  r e p o r t e d  s e p a r a t e ly  a s  a  n ew  e v e n t .
F o l l ow-u p  i n f o rm a t i o n  p r o v i d e d  m u s t  d e s c r i b e  w h e t h e r  t h e  e v e n t  h a s  r e s o l v e d  o r  c o n t i n u e s ,  i f  
a n d  h ow  i t  w a s  t r e a t e d ,  w h e t h e r  t h e  b l ind  w a s  b r o k e n  o r  no t  ( i f  a p p l i c a b l e )  a n d  w h e t h e r  th e  
s u b j e c t  c o n t i n u e d  o r  w i t h d r ew  f r om  s tudy  p a r t i c i p a t i o n .  E a c h  r e - o c c u r r e n c e ,  c om p l i c a t i o n ,  o r  
p r o g r e s s i o n  o f  t h e  o r ig in a l  e v e n t  mu s t  b e  r e p o r t e d  a s  a  f o l l ow - u p  to  t h a t  e v e n t  r e g a r d l e s s  o f  
w h e n  i t  o c c u r s .
No va r t i s Con f iden t ia l Page  65
Amended  P ro toco l  Ve rs ion  01  (C lean ) P ro toco l  No .  CACZ885X2205
I f  t h e  SAE  i s  no t  p r ev iou s ly  d o c um e n t e d  in  th e  IBo r  p a ck ag e  i n s e r t  ( n ew  o c c u r r e n c e )  a n d  i s  
t h o u g h t  to  b e  r e l a t e d  to  t h e  s tudy  t r e a tm e n t ,a  D r u g  S a f e ty  a n d  Ep id em io logy D e p a r tm e n t  
a s s o c i a t e  m ay u rg en t l y  r e q u i r e  f u r t h e r  in fo rm a t ion  f r om  t h e  i n v e s t i g a t o r  fo r  H e a l t h  A u t h o r i ty  
r e p o r t i n g .  N o v a r t i s  m ay n e e d  to  i s s u e  a n  IN  t o  i n f o rm  a l l  i n v e s t i g a t o r s  i n v o l v e d  in  any  s tud y  
w i th  th e  s am e  s tudy t r e a tm en t  th a t  th i s  SAE  h a s  b e en  r epo r t ed .  Su sp e c t ed  Un exp e c t ed  S e r iou s  
A d v e r s e  R e a c t ion s  (S[LOCATION_003]R s )  w i l l  b e  c o l l e c t e d  and  r e p o r t e d  to  t h e  comp e t en t  a u t h o r i t i e s  a n d  
r e l e v a n t  e t h i c s  c omm i t t e e sin  a c c o r d a n c e  w i th  EU  G u i d a n c e  2011 /C  1 7 2 / 0 1  o r  a s  p e r  n a t i o n a l  
r egu l a to ry  r e q u i r em e n t s  i n  p a r t i c i p a t i n g  c o u n t r i e s .
F o l l ow  t h e  d e t a i l ed  in s t ru c t ion s  o u t l i n e d  in  t h e  S i t e  O p e r a t i o n s  M anu a l  r e g a r d i n g  th e  
subm i s s ion  p r o c e s s  f o r  r e p o r t i n g  SAE s  to  Nov a r t i s .  N ot e :  SAE s  mu s t  b e  r e p o r t e d  to  Nov a r t i s  
w i t h i n  2 4  h o u r s  o f  t h e  i n v e s t i g a t o r  l e a r n i n g  o f  i t s  o c c u r r e n c e / r e c e i v i n g  f o l l ow- u p  i n f o rm a t i o n .
[ADDRESS_426702] i z ed  p r o c e s s  f o r  id en t i f i c a t ion ,  mon i to r ing  a n d  e v a l u a t i o n  o f  
l i v e r  e v e n t s  h a s  t o  b e  f o l l ow e d .
P l e a s e  r e f e r  t o  App end ix  1f o r  c om p l e t e  d e f i n i t i o n s  o f  l i v e r  e v e n t s .
Fo l low- upo f  l ive r  even ts
Ev e ry l i v e r  e v e n t  d e f in ed  in  App end ix  1s h o u l d  b e  f o l l ow e d  u p  by  t h e  i n v e s t i g a t o r  o r  
d e s i g n a t e d  p e r s o n n e l  a t  t h e  t r i a l  s i t e ,  a s  s umm a r i z e d  b e l ow .  A d d i t i o n a l  d e t a i l s  o n  a c t i o n s  
r e q u i r e d  i n  c a s e  o f  l i v e r  e v e n t s  a r e  o u t l i n e d  i n  App end ix  1.
R e p e a t i n g  l i v e r  ch em i s t ry  t e s t s  (ALT ,  AST ,  TBL ,  ALP  a n d  γGT )  to  c o n f i rm  e l ev a t ion
w i th in  48- 7 2  h o u r s
T h e s e  l i v e r  ch em i s t ry  r e p e a t s  s h o u l d  a lw ay s  b e  p e r f o rm ed  u s i n g  t h e  c e n t r a l  l abo r a to ry ,  w i th  
t h e  r e s u l t s  p r o v i d e d  v i a  t h e  s t a n d a r d  e l e c t r o n i c  t r a n s f e r .   I f  r e s u l t s  w i l l  no t  b e  a v a i l a b l e  f rom  
t h e  c e n t r a l  l abo r a to ry  w i th in  2 4  h o u r s ,  t h e n  th e  r e p e a t s  c a n  a l s o  b e  p e r fo rm ed  a t  a  lo c a l  
l abo r a to ry  t o  m o n i t o r  th e  s a f e t y  o f  th e  s u b j e c t .  I f  a  l i v e r  e v e n t  i s  sub s equ en t ly  r e p o r t e d ,  a n y  
l o c a l  l i v e r  ch em i s t ry  t e s t s  p r ev iou s ly  c ondu c t ed  t h a t  a r e  a s s o c i a t e d  w i th  th i s  e v e n t  s h o u l d  
h a v e  r e s u l t s  r e p o r t e d  i n  t h e  CRF .
I f  t h e  i n i t i a l  e l e v a t i o n  i s  c o n f i rm e d ,  c l o s e  o b s e r v a t i o n  o f  t h e  s u b j e c t  w i l l  b e  i n i t i a t e d ,
i n c l u d i n g  c o n s i d e r a t i o n  o f  t r e a tm e n t  i n t e r r u p t i o n  i f  d e em e d  a p p r o p r i a t e .
D i s c o n t i n u a t i o n  o f  t h e  i n v e s t i g a t i o n a l  d r u g  r e f e r  t o  S e c t i o n  7 . 2(D i s c o n t i n u a t i o n  o f  s t u d y
t r e a tm e n t ) ,  i f  a p p r o p r i a t e
H o s p i t a l i z a t i o n  o f  t h e  s u b j e c t  i f  a p p r o p r i a t e
C au s a l i ty a s s e s sm e n t  o f  t h e  l i v e r  e v e n t
T h o r o u g h  f o l l ow- u p  o f  t h e  l i v e r  e v e n t  s h o u l d  i n c l u d e :
No va r t i s Con f iden t ia l Page  66
Amended  P ro toco l  Ve rs ion  01  (C lean ) P ro toco l  No .  CACZ885X2205
R e p e a t i n g  l i v e r  c h em i s t r y  t e s t s  tw o  o r  t h r e e  t im e s  w e e k ly .  T e s t i n g  s h o u l d  i n c l u d e  ALT ,
AST ,  ALP ,  PT / INR ,  a n d  γGT .  I f  t o t a l  b i l i r u b i n  i s  e l e v a t e d  >  [ADDRESS_426703] ,  f r a c t ion a t ion  in to
d i r e c t  a n d  i n d i r e c t  b i l i r u b i n  i s  r e q u i r e d .  T o  r u l e  o u t  m u s c u l a r  o r i g i n  o f  t r a n s am i n a s e
e l e v a t i o n s ,  CPK  s h o u l d  b e  m e a s u r e d  a l o n g  w i t h  l i v e r  c h em i s t ry  t e s t s .  F r equ en cy  o f
r e - t e s t i n g  c a n  d e c r e a s e  t o  o n c e  a  w e e k  o r  l e s s  i f  a b n o rm a l i t i e s  s t a b i l i z e  o r  t h e  s t u d y  d r u g
h a s  b e e n  d i s c o n t i n u e d  a n d  t h e  s u b j e c t  i s  a symp tom a t i c .  R e - t e s t i n g  s h o u l d  b e  c o n t i n u e d  u p
t o  r e s o l u t i o n .
O b t a i n i n g  a  m o r e  d e t a i l e d  h i s t ory  o f  s ymp t om s  a n d  p r i o r  o r  c o n c u r r e n t  d i s e a s e s .
O b t a i n i n g  a  h i s t o r y o f  c o n c om i t a n t  d r u g  u s e  ( i n c l u d i n g  n o n p r e s c r i p t i o n  m e d i c a t i o n s  a n d
h e rb a l  and  d i e t a ry  s u p p l em e n t  p r e p a r a t i o n s ) ,  a l c o h o l  u s e ,  r e c r e a t i o n a l  d r u g  u s e ,  a n d
s p e c i a l  d i e t s .
Ex c lu s ion  o f  und e r lyi n g  l i v e r  d i s e a s e ,  a s  s p e c i f i e d  i n  T a b l e  1 5- 3 .
Im a g i n g  s u c h  a s  a b d om i n a l  US ,  CT  o r  MR I ,  a s  app rop r i a t e
O b t a i n i n g  a  h i s t o r y o f  e x p o s u r e  t o  e n v i r o nm e n t a l  c h em i c a l  a g e n t s .
C o n s i d e r i n g  g a s t r o e n t e r o l o g y o r  h e p a to logy  con su l t a t ion s .
A l l  f o l l ow - u p  in fo rm a t ion ,  a n d  th e  p r o c e d u r e s  p e r f o rm e d  mu s t  b e  r e co rd ed  a s  app rop r i a t e  in  
t h e  CRF .
9 .4  Rena l  sa fe ty mon i to r ing
Ev e ry r e n a l  l abo r a to ry  t r i g g e r  o r  r e n a l  e v e n t  mu s t  b e  f o l l ow e d  u p  by  t h e  i n v e s t i g a t o r  o r  
d e s i g n a t e d  p e r sonn e l  a t  t h e  t r i a l  s i t e .  R e c omm e n d e d  f o l l ow - u p  a s s e s sm en t s  a r e  l i s t ed  in  
A p p e n d i x2 .
9 .5  Repo r t ing  Med ica t ion  e r ro rs  inc lud ing  m isuse /abuse
M e d i c a t i o n  e r ro r s  a r e  un in t en t ion a l  e r r o r s  in  th e  p r e s c r i b i n g ,  d i s p e n s in g ,  a dm i n i s t r a t i o n  o r  
m o n i t o r i n g  o f  a  m e d i c i n e  w h i l e  u n d e r  t h e  c o n t r o l  o f  a  h e a l t h c a r e  p ro f e s s ion a l ,  p a t i e n t / s u b j e c t  
o r  c o n s um e r  (EMA  d e f i n i t i o n ) .
M i s u s e  r e f e r s  to  s i t u a t i o n s  w h e r e  t h e  m e d i c i n a l  p r o d u c t  i s  in t en t ion a l ly  a n d  i n a p p r o p r i a t e l y  
u s e d  n o t  i n  a c c ord an c e  w i th  th e  p ro to co l .
A b u s e  c o r r e s p o n d s  to  t h e  p e r s i s t e n t  o r  s p o r a d i c ,  i n t e n t i o n a l  e x c e s s i v e  u s e  o f  a  m e d i c i n a l  
p rodu c t ,  wh i ch  i s  a c comp an i ed  by  h a rm f u l  p h y si c a l  o r  p sy cho log i c a l  e f f e c t s .
A l l  s tudy  t r e a tm e n t  e r ro r s  and  u s e s  ou t s id e  o f  w h a t  i s  f o r e s e e n  in  th e  p ro to co l  w i l l  b e  
c o l l e c t e d  in  th e  do s e  adm in i s t r a t ion  r e co rd  (DAR )  CRF .   S tudy  t r e a tm en t  e r ro r s  a r e  on ly  to  b e  
r e p o r t e d  to  N o v a r t i s  D r u g  S a f e ty  a n d  Ep id em io logy d e p a r tm e n t  i f  t h e  t r e a tm e n t  e r r o r  i s  
a s s o c i a t e d  w i t h  a n  SAE .
A l l  i n s t a n c e s  o f  m i su s e  o r  a b u s e  mu s t  b e  do cum en t ed  in  t h e  AE  CRF  i r r e s p e c t i v e  o f  th e  
m i s u s e / a b u s e  b e i n g  a s s o c i a t e d  w i th  a n  AE /SAE .  I n  a dd i t ion ,  a l l  i n s t a n c e s  o f  m i su s e  o r  abu s e  
mu s t  b e  r epo r t ed  to  Nov a r t i s  D rug  S a f e ty  and  Ep id em io logy.  A s  su ch ,  i n s t a n c e s  o f  m i su s e  o r  
a b u s e  a r e  a l s oto  b e  r e p o r t e d  u s i n g  th e  SAE  fo rm /CRF .  T a b l e  9 - 1summ a r i z e s  t h e  r e p o r t i n g  
r e q u i r em e n t s .
No va r t i s Con f iden t ia l Page  67
Amended  P ro toco l  Ve rs ion  01  (C lean ) P ro toco l  No .  CACZ885X2205
Tab le  9 -1  Summa ry o f  repo r t ing  requ i remen ts  fo r  med ica t ion  e r ro rs
T rea tmen t  e r ro r  typeDocumen t  in  Dose
Adm in is t ra t ion  (DAR )  CRF  Documen t  in  AE  
CRFComp le te  SAE  
fo rm /CRF  
Un in ten t iona l  s tudy  
t rea tmen t  e r ro rYe s On ly  i f  assoc ia ted  
w i th  an  AEOn ly  i f  assoc ia ted  w i th  
an  SAE
M isuse /Abuse  Ye s Ye sYes ,  even  i f  no t  
assoc ia ted  w i th  a  SAE
F o r  mo r e  i n f o rm a t i o n  on  AE  a n d  SAE  d e f in i t ion  a n d  r e p o r t i n g  r e q u i r em e n t s ,  p l e a s e  s e e  
S e c t i o n  9 . 1a n dS e c t i o n  9 . 2,  r e s p e c t i v e l y .
9 .6  P regnancy repo r t ing
T o  e n s u r e  p a t i e n t  s a f e t y ,  e a c h  p r egn an cy  i n  a  sub j e c t  o n  s tudy  d r u g  mu s t  b e  r e p o r t e d  to  
N o v a r t i s  w i th in  2 4  hou r s  o f  l e a r n i n g  o f  i t s  o c c u r r e n c e .  Th e  p r egn an cy  s hou ld  b e  f o l l ow e d  up  
to  d e t e rm i n e  ou t com e ,  i n c l u d i n g  s p o n t an eou s  o r  vo lun t a ry  t e rm i n a t i o n ,  d e t a i l s  o f  t h e  b i r th ,  
a n d  t h e  p r e s en c e  o r  a b s e n c e  o f  a n y  b i r t h  d e f e c t s ,  c o n g e n i t a l  a b n o rm a l i t i e s ,  o r  m a t e r n a l  and /o r  
n ew b o r n  c om p l i c a t i o n s .  T h e  s tudy  d r u g  mu s t  b e  d i s c o n t i n u e d ,  t h o u g h  t h e  s u b j e c t  m ay s t ay  i n  
t h e  s tudy ,  i f  s h e  w i sh e s  to  d o  s o .  A l l  a s s e s sm en t s  t h a t  a r e  c o n s i d e r e d  a s  a  r i s k  d u r i ng  
p r egn an cy  m u s t  n o t  b e  p e r f o rm e d .  T h e  s u b j e c t  m a y  c o n t i n u e  a l l  o t h e r  p r o t o c o l  a s s e s sm e n t s .
P r egn an cy m u s t  b e  r e c o r d e d  o n  a  P h a rm a c o v i g i l a n c e  P r egn an cy F o rm  and  r e p o r t e d  by  t h e  
i n v e s t i g a t o r  to  t h e  lo c a l  N o v a r t i s  D rug  S a f e ty  a n d  Ep id em io logy D ep a r tm en t .  P r e g n a n cy  
f o l l ow - u p  s h o u l d  b e  r e c o r d e d  on  t h e  s am e  fo rm  a n d  s h o u l d  in c lud e  a n  a s s e s sm e n t  o f  th e  
p o s s i b l e  r e l a t i o n s h i p  t o  t h e  s t u d y  t r e a tm e n t s .
Any S AE  e x p e r i e n c e d  d u r i n g  p r egn an cy  a n d  un r e l a t e d  to  th e  p r egn an cy  m u s t  b e  r e p o r t e d  on  
a n  SAE  R e p o r t  F o rm .
P r egn an cy o u t com e s  shou ld  b e  c o l l e c t e d  fo r  th e  f em a l e  p a r tn e r s  o f  a n y  m a l e s  w h o  took  s tudy  
t r e a tm e n t  in  th i s  s tudy .  C o n s e n t  to  r e p o r t  i n f o rm a t i o n  r e g a r d i n g  t h e s e  p r egn an cy  o u t com e s  
s h o u l d  b e  o b t a i n e d  f r om  t h e  m o t h e r .
9 .7  Ea r ly  phase  sa fe ty m on i to r ing
T h e  Inv e s t ig a to r  w i l l  mon i to r  adv e r s e  ev en t s  in  an  ongo ing  m ann e r  and  in fo rm  th e  Spon so r  o f  
any  c l in i c a l ly  r e l e v a n t  o b s e r v a t i o n s .  A ny  r e q u i r e d  s a f e t y  r e v i ew s  w i l l  b e  m ad e  jo in t ly  
b e tw e e n  m ed i c a l ly  qu a l if i e d  p e r s o n n e l  r e p r e s e n t i n g  th eSpon so r  a n d  I n v e s t i g a t o r .  
S u c he v a l u a t i o n s  m ay o c c u r  v e r b a l ly ,  bu t  t h e  o u t c om e  a n d  k ey  d i s cu s s ion  po in t s  wi l l  b e  
s umm a r i z e d  in  w r i t i n g  ( e - m a i l )  a n d  m ad e  a v a i l a b l e  to  bo th  S p o n s o r  and  a l l  I n v e s t i g a t o r ( s ) .  
C r i t e r i a  p e r t a i n i n g  to  s topp ing  t h e  s tudy / t r e a tm en t  o r  a d a p t i n g  t h e  s tudy  d e s i g n  a r e  p r e s en t ed  
a b o v e .
Wh en  tw o  o r  m o r e  c l i n i c a l  s i t e ( s )  a r e  p a r t i c i p a t i n g  in  t h e  c l i n i c a l  s t u d y ,  t h e  S p o n s o r  w i l l  
a d v i s e  t h e  I n v e s t i g a t o r ( s )  a t  a l l  s i t e s  in  w r i t i n g  ( e - m a i l )  ( a n d  by  t e l e p h o n e  i f  p o s s i b l e )  o f  a n y  
n ew ,  c l in i c a l ly  r e l e v a n t  s a f e t y  in fo rm a t ion  r e p o r t e d  f r om  a n o t h e r  s i t e  d u r i n g  t h e  c o n d u c t  o f  
th e  s tudy  i n  a  t im e l y  m a n n e r .
No va r t i s Con f iden t ia l Page  68
Amended  P ro toco l  Ve rs ion  01  (C lean ) P ro toco l  No .  CACZ885X2205
10  Da ta  rev iew  and  da tabase  managemen t
10 .1 S i te  mon i to r ing
B e f o r e  s tudy  i n i t i a t ion ,  a t  a  s i t e  in i t i a t ion  v i s i t  o r  a t  a n  inv e s t i g a t o r ’ s  m e e t i n g ,  a  Nov a r t i s  
r e p r e s e n t a t i v e  w i l l  r ev i ew  t h e  p r o t o c o l  a n d  CRF s  w i th  t h e  i n v e s t ig a to r s  a n d  t h e i r  s t a f f .  
D u r i n gth e  s tudy  N ov a r t i s  emp loy s  s ev e r a l  m e t h o d s  o f  e n s u r i n g  p r o t o c o l  a n d  GCP  
c om p l i a n c e  a n d  t h e  qu a l i ty / i n t e g r i t y  o f  t h e  s i t e s ’  d a t a .  T h e  m o n i t o r  w i l l  v i s i t  t h e  s i t e  to  c h e c k  
t h e  c om p l e t e n e s s  o f  sub j e c t  r e co rd s ,  th e  a c cu r a cy  o f  e n t r i e s  on  th e  CRF s ,  th e  adh e r en c e  to  th e  
p r o t o c o l  a n d  to  G o o d  C l i n i c a l  P r a c t i c e ,  t h e  p rog r e s s  o f  e n r o l lm e n t  a n d  to  e n s u r e  t h a t  s tudy  
d r u g  i s  b e i n g  s t o r e d ,  d i sp en s e d ,  a n d  a c c o u n t e d  f o r  a c c o r d i n g  to  s p e c i f i c a t i o n s .  K ey s tudy  
p e r s o n n e l  m u s t  b e  a v a i l a b l e  t o  a s s i s t  t h e  m o n i t o r  d u r i n g  t h e s e  v i s i t s .
T h e  i n v e s t i g a t o r  mu s t  m a i n t a i n  s o u r c e  do cum en t s  f o r  e a c h  sub j e c t  in  t h e  s tudy ,  c o n s i s t i n g  o f  
c a s e  a n d  v i s i t  n o t e s  ( h o s p i t a lo r  c l i n i c  m e d i c a l  r e c o r d s )  c o n t a i n i n g  d em o g r a p h i c  a n d  m ed i c a l  
i n f o rm a t i o n ,  l abo r a to ry  d a t a ,  e l e c t r o c a r d i o g r am s  a n d  t h e  r e s u l t s  o f  a n y  o th e r  t e s t s  o r  
a s s e s sm e n t s .  A l l  in fo rm a t ion  o n  CRF s  mu s t  b e  t r a c e a b l e  to  t h e s e  sou r c e  d o c um e n t s  in  th e  
s u b j e c t ' s  f i l e .  T he  i n v e s t i g a t o r  mu s t  a l s o  k e e p  th e  o r i g i n a l  i n f o rm e d  con s en t  f o rm  s i g n e d  by  
t h e  s u b j e c t  ( a  s i g n e d  c o p y  i s  g iv en  to  th e  sub j e c t ) .
T h e  i n v e s t i g a t o r  mu s t  g iv e  t h e  m o n i t o r  a c c e s s  to  a l l  r e l e v a n t  s o u r c e  do cum en t s  to  c o n f i rm  
t h e i r  con s i s t en cy  w i th  t h e  CRF  e n t r i e s .  N o v a r t i s  m o n i t o r i n g  s t a n d a r d s  r e q u i r e  f u l l  v e r i f i c a t i o n  
f o r  t h e  p r e s en c e  o f  in fo rm ed  c o n s e n t ,  a d h e r e n c e  to  t h e  e l ig ib i l i ty  c r i t e r i a ,  d o c um e n t a t i o n  o f  
SAE s ,  a n d  t h e  r e c o r d i n g  o f  d a t a  t h a t  w i l l  b e  u s e d  f o r  a l l  p r im a ry  a nd  s a f e t y  v a r i ab l e s .  
A d d i t i o n a l  c h e c k s  o f  th e  con s i s t en cy  o f  t h e  s o u r c e  d a t a  w i th  t h e  CRF s  a r e  p e r fo rm ed  
a c c o r d i n g  to  t h e  s tudy - s p e c i f i c  mon i to r ing  p l an .  N o  i n f o rm a t i o n  in  sou r c e  d o c um e n t s  a b o u t  
th e  id en t i ty  o f  t h e  s u b j e c t s  w i l l  b e  d i s c l o s e d .
[ADDRESS_426704]  wi l l  b e  d e f in ed  in  th e  S i t e  Op e r a t ion s  M anu a l  and  
A s s e s sm e n t  s c h e d u l eand  c a n  b e  r e c o r d e d  d i r e c t ly  o n  th e  CRF s .  A l l  o th e r  d a t a  c a p t u r e d  fo r  
th i s  s tudy  w i l l  h a v e  a n  ex t e rn a l  o r i g i n a t i n g  s o u r c e  ( e i t h e r  w r i t t en  o r  e l e c t r o n i c )  w i th  t h e  CRF  
n o t  b e i n g  c o n s i d e r e d  a s  s o u r c e .
A l l  d a t a  s h o u l d  b e  r e c o r d e d ,  h and l ed  a n d  s to r ed  in  a  w ay t h a t  a l l ow s  i t s  a c c u r a t e  r epo r t ing ,  
i n t e r p r e t a t i o n  a n d  v e r i f i c a t i o n .
No va r t i s Con f iden t ia l Page  69
Amended  P ro toco l  Ve rs ion  01  (C lean ) P ro toco l  No .  CACZ885X2205
[ADDRESS_426705] em  i s  no t  u s e d ,  a  p a p e r  D a t a  Qu e ry  
F o rm  w i l l  b e  f ax ed  to  th e  s i t e .  S i t e  p e r sonn e l  w i l l  comp l e t e  and  s ign  th e  f ax ed  cop y  and  f ax  i t  
b a c k  t o  t h e  CRO  w o r k i n g  o n  b e h a l f  o f  N o v a r t i s  w h o  w i l l  m a k e  t h e  c o r r e c t i o n  t o  t h e  d a t a b a s e .
C o n c om i t a n t  m e d i c a t i o n s  e n t e r e d  in to  t h e  d a t a b a s e  w i l l  b e  c o d e d  u s i n g  t h e  WHO  D rug  
R e f e r e n c e  L is t ,  w h i c h  emp loy s  t h e  A n a t om i c a l  T h e r a p e u t i c  C h em i c a l  c l a s s i f i c a t i o n  sy s t em .  
M e d i c a l  h i s to ry / cu r r en t  m e d i c a l  c o n d i t i o n s  a n d  a d v e r s e  ev en t s  w i l l  b e  c o d e d  u s i n g  th e  
M ed i c a l  d i c t ion a ry fo r  r egu l a to ry  a c t iv i t i e s  (M edDRA )  t e rm ino logy .
L abo r a to ry s am p l e s  w i l l  b e  p r o c e s s e d  c e n t r a l l y  a n d  t h e  r e s u l t s  w i l l  b e  s e n t  e l e c t ron i c a l ly  t o  
N o v a r t i s  ( o r  a  d e s i g n a t e d  CRO ) .
Im a g i n g - r e l a t e d  d a t a  w i l l  b e  p r o c e s s e d  c en t r a l ly  a n d  t h e  r e s u l t s  w i l l  b e  s e n t  e l e c t ron i c a l ly  t o  
N o v a r t i s  ( o r  a  d e s i g n a t e d  CRO ) .
R andom i z a t ion  c o d e s  a n d  d a t a  in  r e f e r e n c e  to  d i s p e n s i n g  o f  s tudy  d r u g ( s )  to  t h e  su b j e c t  and  
a l l  IR T  r e c o r d e d  do s ag e  c h a n g e s  w i l l  b e  t r a c k e d  u s i n g  I n t e r a c t i v e  R e spon s e  T e c h n o l o g y  
( I RT ) .  T h e  sy s t em  w i l l  b e  s u p p l i e d  by  a  v endo r ,  w h o  w i ll  a l s o  m a n a g e  t h e  d a t ab a s e .  
T h ed a t a b a s e  w i l l  b e  s e n t  e l e c t r o n i c a l l y  t o  N o v a r t i s  ( o r  a  d e s i g n a t e d  CRO ) .
Ea c h  o c c u r r e n c e  o f  a  cod e  b r e a k  v i a  IRT  w i l l  b e  r e p o r t e d  to  t h e  c l in i c a l  t e am  a n d  mon i to r .  
T h e  cod e  b r e ak  fun c t ion a l i ty  w i l l  r em a in  a v a i l a b l e  un t i l  s tudy  s hu t  down  o r  upon  r e q u e s t  o f  
N o v a r t i s .
T h e  o c c u r r e n c e  o f  a n y  p ro to co l  d e v i a t i o n s  w i l l  b e  d e t e rm i n e d .  A ft e r  th e s e  a c t i o n s  h av e  b e en  
c om p l e t e d  a n d  th e  d a t a b a s e  h a s  b e en  d e c l a r e d  to  b e  comp l e t e  a n d  a c c u r a t e ,  i t  w i l l  b e  lo ck ed  
a n d  t h e  t r e a tm e n t  c o d e s  w i l l  b e  u n b l i n d e d  a n d  m a d e  a v a i l a b l e  f o r  d a t a  an a ly s i s .  A ny  ch ang e s  
to  t h e  d a t a b a s e  a f t e r  th a t  t im e  c a n  o n ly  b e  m ad e  by  j o in t  w r i t t e n  ag r e em en t  b e tw e e n  th e  
COAR  An a lyt i c s  N IBR  F r a n c h i s e  H e a d  a n d  t h e  r e l e v a n t  N IBR  TA  H e a d .
DNA samp les  (op t iona l ) :
T o  m ax im i z e  con f id en t i a l i ty ,  a l l  s am p l e s  a n d  t h e  i n f o rm a t i o n  a s s o c i a t e d  w i th  t h e s e  s am p l e s  
w i l l  b e  d o u b l e - c o d e d  to  p r e v e n tth e  e x p o s u r e  o f  t h e  sub j e c t ’ s  id en t i ty .  Th i s  d o u b l e - cod ing  
p r o c e s s  a l l ow s  Nov a r t i s  to  g o  b a c k  a n d  d e s t roy  t h e  s amp l e  a t  th e  s u b j e c t ’ s  r e q u e s t .   
I na d d i t i o n ,  s am p l e  in fo rm a t ion  i s  s t o r e d  in  on e  s e cu r ed  d a t ab a s e  wh i l e  g e n e t i c  d a t a  i s  s to r ed  
i n  a n  i n d e p e n d e n t ,  s e c u r e d  d a t a b a s e .
10 .4 Da ta  Mon i to r ing  Comm i t tee
N o t  r e q u i r e d .Co rpo ra te  Con f iden t ia l  In fo rma t ion
No va r t i s Con f iden t ia l Page  70
Amended  P ro toco l  Ve rs ion  01  (C lean ) P ro toco l  No .  CACZ885X2205
10 .5 Adjud ica t ion  Comm i t tee
10 .5 .1 In fec t i on  Ad jud ica t ion  Comm i t tee
A n  i n d e p e n d e n t  I n f e c t ion  Ad jud i c a t ion  Comm i t t e e  ( IAC )  h a s  b e en  fo rm ed  on  a  p rog r am  l ev e l  
a n d  w i l l  r e v i ew  p e r t i n e n t  d a t a  f r om  t h i s  t r i a l .
T h e  m i s s ion  o f  th e  IA C  i s  to  i n d e p e n d e n t l y  and  b l ind ly  r e v i ew ,  e v a l u a t e  and  c a t ego r i z e  
r e p o r t s  o f  s e r iou s  in f e c t ion  ev en t s  a c r o s s  a l l  po t en t i a l  i n d i c a t i o n s  and  t h e r a p e u t i c  a r e a s  in  th e  
c a n a k i n um a b  d e v e l o pm e n t  p r o g r am .
T h e  m em b e r s  a n d  p r o c e d u r e s  o f  t h e  IAC  a r e  d e t a i l e d  i n  t h e  IAC  C h a r t e r .
10 .5 .2 Ma l ignancy A d jud ica t ion  Comm i t tee
A n  i n d e p e n d e n t  M a l ign an cy A d j u d i c a t i o n  Comm i t t e e  (MAC )  h a s  b e en  f o rm e d  o n  a  p rog r am  
l e v e l  a n d  w i l l  r e v i ew  p e r t i n e n t  d a t a  f r om  t h i s  t r i a l .
T h e  m i s s ion  o f  t h e  MAC  i s  to  i n d e p e n d e n t l y  a n d  b l ind ly  r e v i ew ,  e v a l u a t e  a n d  c a t e g o r i z e  
r e p o r t s  o f  m a l ign an cy e v e n t s  a c r o s s  a l l  po t en t i a l  i n d i c a t ion s  and  th e r ap eu t i c  a r e a s  in  th e  
c a n a k i n um a b  d e v e l o pm e n t  p r o g r am .
T h e  m em b e r s  a n d  p r o c e d u r e s  o f  t h e  MAC  a r e  d e t a i l e d  i n  t h e  MAC  C h a r t e r .
11  Da ta  ana lys is
T h e  a n a l y si s  w i l l  b e  c o n d u c t e d  o n  a l l  s u b j e c t  d a t a  a t  t h e  t im e  t h e  t r i a l  e n d s .  Any d a t a  an a l y si s  
c a r r i e dou t  ind ep end en t ly  b y  th e  i n v e s t i g a t o r  s h o u l d  b e  subm i t t ed  to  N o v a r t i s  b e fo r e  
p u b l i c a t i o n  o r  p r e s e n t a t i o n .
11 .1 Ana lys is  se ts
F o r  a l l  a n a ly si s  s e t s ,  s u b j e c t s  w i l l  b e  a n a l y ze d  a c c o r d i n g  t o  t h e  s t u d y  t r e a tm e n t ( s )  r e c e i v e d .
Th e  s a f e ty an a l y si s  s e t  w i l l  in c lud e  a l ls u b j e c t s  t h a t  r e c e i v e d  a n y  s t u dy  d r u g .
T h e  PK  a n a l y si s  s e t  w i l l  i n c l u d e  a l l  s u b j e c t s  w i th  a v a i l a b l e  PK  d a t a  a n d  n o  p ro to co l  
d e v i a t i o n s  w i t h  r e l e v a n t  im p a c t  o n  PK  d a t a .
T h e  PD  an a ly s i s  s e t  w i l l  i n c l u d e  a l l  sub j e c t s  th a t  r e c e i v e d  a n y  s tudy  d r u g  a n d  t h a t  h av e  no  
p r o t o c o l  d e v i a t i o n s  w i t h  r e l e v a n t  im p a c t  o n  PD  d a t a .
11 .2 Sub jec t  demog raph ics  and  o the r  base l ine  cha rac te r is t ics
A l l  d a t a  f o r  b a ckg round  a n d  d emog r aph i c  v a r i ab l e s  w i l l  b e  l i s t ed  by  t r e a tm e n t  g r o u p  and  
sub j e c t .  Summ a ry  s t a t i s t i c s  w i l l  b e  p rov id ed  by  t r e a tm e n t  g r o u p .
R e l e v a n t  m e d i c a l  h i s to ry ,  c u r r e n t  m ed i c a l  c o n d i t i o n s ,  r e s u l t s  o f  l a b o r a t o r y  s c r e en s ,  a n d  a n y  
o t h e r  r e l e v a n t  i n f o rm a t i o n  w i l l  b e  l i s t e d  b y  t r e a tm e n t  g r o u p  a n d  s u b j e c t .
11 .3 T rea tmen ts
D a t a  fo r  s tudy  d r u g  adm in i s t r a t ion  ( r e s c u e  m ed i c a t ion )  a n d  c o n c o m i t an t  t h e r a p i e s  w i l l  b e  
l i s t ed  by  t r e a tm e n t  g r o u p  a n d  s u b j e c t .
No va r t i s Con f iden t ia l Page  71
Amended  P ro toco l  Ve rs ion  01  (C lean ) P ro toco l  No .  CACZ885X2205
11 .4 Ana lys is  o f  the  p r ima ry v a r iab le (s )
T h e  p r im a ry  a im  o f  th e  s tudy  i s  to  c om p a r e  th e  e f f e c t  o f  ACZ 8 8 5  v e r su s  p l a c e b o  o n  th e  
c l in i c a l  d i s e a s e  a c t iv i ty  o f  s a r co ido s i s  p a t i en t s  a s  m e a su r ed  by  [CONTACT_3433] e  c h ang e  f rom  b a s e l in e  in  th e  
p e r c e n t  p r e d i c t e d  FVC  a t  w e e k  2 4 .
11 .4 .1 Va r iab le (s )
T h e  p r im a ry  v a r i a b l e  w i l l  b e  t h e  c h a n g e  f rom  b a s e l i n e  inp e r c e n t  p r e d i c t e d  FVC  a f t e r  
2 4w e e k s  o f  t r e a tm e n t .
11 .4 .2 S ta t is t ica l  mode l ,  hypo thes is ,  and  me thod  o f  ana lys is
T h e  c h a n g e  f rom  b a s e lin e  in  p e r c e n t  p r e d i c t e d  FVC  w i l l  b e  an a ly z ed  u s i n g  a  B ay e s i a n  mod e l  
f o r  r e p e a t e d  m e a su r em en t s .  Th e  mod e l  w i l l  inv e s t ig a t e  e f f e c t s  f o r  t r e a tm en t  by  t im e  ( in c lud ed  
a s  a  c l a s s  v a r i a b l e )  i n t e r a c t i o n ,  b a s e l i n e  by  t im e  i n t e r a c t i o n  a n d  PET  po s i t iv i ty  ( y es / n o )  p r i o r  
t o  r a n d om i z a t i o n .  U n i n f o rm a t i v e  p r i o r s  w i l l  b e  u t i l i z e d  t o  o b t a i n  t h e  p o s t e r i o r  e s t im a t e s .
Th e  po s t e r io r  p rob ab i l i ty  th a t  ACZ885  i s  b e t t e r  th an  p l a c ebo  in  t e rm s  o f  ch ang e  f rom  b a s e l in e  
in  p e r c e n t  p r e d i c t e d  FVC  a t  2 4  w e e k s  w i l l  b e  c a l c u l a t e d .  I f  i t  i s  a t  l e a s t  9 0% ,  i t  w i l l  b e  
con s id e r ed  a  s ign  o f  e f f i c a cy  o f  ACZ 8 8 5  i n  i n c r e a s i n g  FVC  a f t e r  2 4  w e e k s  o f  t r e a tm e n t  i n  t h i s  
p a t i e n t  p o p u l a t i o n .
A t  t h e  i n t e r im  a n a l y si s ,  t h e  p o s t e r i o r  p rob ab i l i ty  t h a t  ACZ 8 8 5  i s  w o r s e  th an  p l a c e b o  in  t e rm s  
o f  c h a n g e  f rom  b a s e l i n e  in  p e r c e n t  p r e d i c t e d  FVC  a t  w e e k  1 2  w i l l  b e  c a l c u l a t e d .  I f  i t  i s  a t  
l e a s t  6 0% ,  t h e  s t u d y  m ay  b e  s t o p p e d  f o r  f u t i l i t y .
11 .4 .3 Hand l ing  o f  m iss ing  va lues /censo r ing /d iscon t inua t ions
T h e  p r im a ry  a n a ly s i s  w i l l  c o n s i d e r  p a t i e n t s  w i th  p a r t i a l  d a t a  ( f o r  i n s t a n c e  w i thou t  a  2 4  w e e k  
a s s e s sm e n t  bu t  w i th  a t  l e a s t  o n e  po s t  b a s e l i n e  a s s e s sm e n t  a v a i l a b l e ) .  E s t im a t e s  o f  t h e  m i s s i n g  
v a l u e s  w i l l  b e  d e r i v e d  by  t h e  m o d e l  t h a ta r e  v a l i d  u n d e r  t h e  m i s s ing  a t  r a n d om  (MAR )  
a s s um p t i o n .
11 .4 .4 Sens i t iv i ty  ana lyses
N o t  a p p l i c a b l e .
No va r t i s Con f iden t ia l Page  72
Amended  P ro toco l  Ve rs ion  01  (C lean ) P ro toco l  No .  CACZ885X2205
11 .5 Ana lys is  o f  seconda ry v a r iab le (s )
11 .5 .1 E f f icacy /  Pha rmacodynam ics
11 .5 .1 .1[F - 18 ]
T h e  [F - 1 8 ]FDG - PET /CT  im a g i n g  d a t a  w i l l  b e  a n a l y ze d  to  id en t i fy  t h e  m ax  s t a n d a r d i z e d  
u p t a k e  v a l u e s  i n  t h e  f o l l ow i n g  c a t e g o r i e s :
A  m a x im um  o f  5  f o c a l  n o d a l  u p t a k e  r e g i o n s  (m e d i a s t i n a l ,  h i l a r )
A  m ax imum  o f  5f o c a l  r e g i o n s  o f  u p t a k e  i n  l u n g  p a r e n c h yma
A  m a x im um  o f  5  e x t r a- t h o r a c i c  f o c a l  u p t a k e  r e g i o n s  o n  t h e  w h o l e  b o d y  s c a n
[F - 1 8 ]FDG - PET /CT  m e an
A  r e g i o n  o f  l u n g  p a r e n c h ym a ,  u n a f f e c t e d  by  f o c a l  l e s i o n  u p t a k e
T h e  m e an  o f  th e  SUVm ax  ( r e s p .  SUVm e an )  fo r  e a c h  c a t ego ry  w i l l  b e  t ak en  to  o b t a i n  on e  
SUVm a x  v a l u e  ( r e s p .  SUVm e a n )  p e r  p a t i e n t  /  t im e  p o i n t  /  c a t e g o r y.
T h e  m e a n  p e r c e n t  c h a n g e  f rom  b a s e l i n e  in  SUVm ax  in  t h e  n o d u l e s  a f t e r  1 2w e e k s  o f  
t r e a tm e n t  w i l l  b e  an a l y z e d  u s i n g  ANCOVA  w i th  b a s e l i n e  SUVm ax  a s  a  c o v a r i a t e  and  
t r e a tm en t  and  PET  po s i t iv i ty  (y e s / n o )  a s  f a c t o r s .
T h e  s am e  a n a l y si s  a s  fo r  t h e  p e r c e n t  c h a n g e  f rom  b a s e l i n e  in  SUVm ax  in  t h e  n o d u l e s  w i l l  b e  
p e r f o rm e d  f o r  t h e  p e r c en t  c h a n g e  f r om  b a s e l i n e  in  SUVm ax  in  t h e  l u n g  p a r e n c hyma  a n d  t h e  
ex t r a - t h o r a c i c  r e g i o n s ,  w h e r e  a v a i l a b l e .  I t  w i l l  a l s o  b e  r e p e a t e d  fo r  SUVm e a n  in  th e  
p a r e n c hyma .
T h e  p e r c e n t a g e  o f  p a t i en t s  w i th  a t  l e a s t  5 0%  r e d u c t i o n  o f  SUVm ax  in  n o d u l e s  w i l l  b e  
a n a l y ze d  v i a  log i s t i c  r e g r e s s i o n  w i th  b a s e l i n e  SUVm a x  a s  a  c o v a r i a t e  and  t r e a tm e n t  a n d  PET  
p o si t iv i ty  (y e s /no )  a s  f a c to r s .
A l s o  t h e  c h a n g e  in  th e  ind iv idu a l  l u n g  nodu l e s  w i l l  b e  e x am i n e d ,  u s ing  a  d i s c r e t i z ed  s c a l e  o f  
c om p l e t e  r e s p o n s e  (CR ) ,  p a r t i a l  r e s p o n s e  (PR ) ,  s t a b l e  d i s e a s e  (SD )  a n d  p r o g r e s s i v e  d i s e a s e  
(PD )  a s  in  th e  on co logy  E u r o p e a n  O r g a n i za t ion  fo r  R e s e a r ch  and  T r e a tm en t  o f  C an c e r  c r i t e r i a  
f o r  [F - 1 8 ]FDG - PET /CT .  T h e  p r o p o r t i o n  o f  ind iv idu a l  r e s p o n d e r s  a n d  n o n - r e s p o n d e r s  w i l l  b e  
d e t e rm i n e d ,  b a s e d  o n  PET .  P a t i e n t s  w h o  d i s c o n t i n u e  f o r  l a c k  o f  e f f i c a cy  w i l l  b e  t r e a t e d  a s  a  
s ep a r a t e  c a t ego ry  in  t h i s  summ a ry .
T h e  co r r e l a t ion  b e tw e en  c h a n g e s  f rom  in i t i a l  FDG- PET  s c an  in  SUVm ax  a n d  c h a n g e s  f rom  
b a s e l i n e  i n  FVC ,  FEV 1 ,  COA s,  6MWT  d i s t a n c e  w i l l  b e  a s s e s s e d  w i t h  g r a p h i c a l  m e t h o d s .
11 .5 .1 .2H igh  reso lu t ion  compu ted  tomog raphy  (HRCT )
C h a n g e  in  HRCT  s c o r i n g  f r om  in i t i a l  s c a n  to  [ADDRESS_426706]  s c o r e  a s  a  cov a r i a t e  a n d  t r e a tm e n t  a n d  PET  po s i t iv i ty  ( y e s / n o )  a s  
f a c t o r s .  T h e  HRCT  s c an s  w i l l  b e  ev a lu a t ed  u s ing  a n  HRCT  s co r ing  sy s t em  qu an t i fy ing  
v a r i o u s  f e a t u r e s  su ch  a s :  BVB :  t h i c k e n i n g  o r  i r r egu l a r i ty  o f  t h e  b r o n c h o v a s c u l a r  bund l e ;  PC :  
p a r e n c hyma l  con so l id a t ion  ( i n c l u d i n g  g r o u n d- g la s s  o p a c i f i c a t i o n s ) ;  ND :  i n t r a p a r e n c h yma l  
n o d u l e s ;  LS:  s e p t a l  a n d  n o n s e p t a l  l in e s ;  PL:  fo c a l  p l e u r a l  t h i c k e n i n g ;  LN :  e n l a r g em e n t  o f  th e  
m e d ia s t i n a l  ly mph  nod e s .  T h e  s c o r e  f o r  th e  lung  w i l l  b e  d e t e rm i n e d  u s ing  a  s co r ing  sy s t em  
s im i l a r  t o  p r e v i o u s  p u b l i s h e d  l i t e r a t u r e  ( O b e r s t e i ne ta l1 9 9 7 ;  O r se ta l2 0 1 3) .
No va r t i s Con f iden t ia l Page  73
Amended  P ro toco l  Ve rs ion  01  (C lean ) P ro toco l  No .  CACZ885X2205
I n  a d d i t ion ,  HRCT  r e su l t s  w i l l  b e  e v a l u a t e d  f o r  w o r s e n i n g ,  imp rov em en t ,  o r  s t a b l e  ou t com e  
by  2  b l i n d e d  a s s e s s o r s  i n  s i d e - by - s i d e  c om p a r i s o n .  R e s u l t s  w i l l  b e  s umm a r i z e d  i n  a  s h i f t  t a b l e .
11 .5 .1 .3O the r  seconda ry v a r iab les
D a t a  f rom  o th e r  pu lmon a ry  f un c t ion  t e s t s  and  6MWT  w i l l  b e  l i s t ed  a n d  summ a r i z ed .  
G r a p h i c a l  r e p r e s e n t a t i o n s  o f  t h e  pu lmon a ry  f un c t ion  t e s t  e n d p o i n t s  o v e r  t im e  w i l l  b e  
p r e s e n t e d .
11 .5 .2 Sa fe ty
11 .5 .2 .1V i ta l  s igns
A l l  v i t a l  s i g n s  d a t a  w i l l  b e  l i s t ed  by  t r e a tm e n t ,  s u b j e c t ,  a n d  v i s i t  a n d  i f  r a n g e s  a r e  av a i l ab l e  
a b n o rm a l i t i e s  ( a n d  r e l ev an t  o r t h o s t a t i c  c h a n g e s )  w i l l  b e  f l a g g e d .  Summ a ry s t a t i s t i c s  w i l l  b e  
p r o v i d e d  by  t r e a tm e n t  a n d  v i s i t .
11 .5 .2 .2ECG  eva lua t ions
A l l  ECG  d a t a  w i l l  b e  l i s t ed  by t r e a tm en t ,  sub j e c t  and  v i s i t / t im e ,  abno rm a l i t i e s  w i l l  b e  f l agg ed .  
Summ a ry s t a t i s t i c s  w i l l  b e  p rov id ed  by  t r e a tm en t  and  v i s i t .
11 .5 .2 .3C l in ica l  labo ra to ry eva lua t ions
A l l  l abo r a to ry d a t a  w i l l  b e  l i s t ed  by  t r e a tm en t ,  sub j e c t ,  and  v i s i t / t im e  and  i f  no rm a l  r ang e s  a r e  
a v a i l a b l e  abno rm a l i t i e s  w i l l  b e  f l a g g e d .  Summ a ry s t a t i s t i c s  w i l l  b e  p r o v i d e d  by  t r e a tm e n t  a n d  
v i s i t / t im e .
[ADDRESS_426707] s  th e  to t a l  o f  th i s  body  s y s t em .
11 .5 .3 Pha rmacok ine t ics
Co rpo ra te  Con f iden t ia l  In fo rma t ionCo rpo ra te  Con f iden t ia l  In fo rma t ion
No va r t i s Con f iden t ia l Page  74
Amended  P ro toco l  Ve rs ion  01  (C lean ) P ro toco l  No .  CACZ885X2205
11 .5 .4 Pha rmacok ine t ic /pha rmacodynam ic  in te rac t ions
T h e  r e l a t i o n s h i p  b e tw e en  PK  and  e f f i c a cy /PD  p a r am e t e r s  m ay  b e  inv e s t ig a t ed  u s ing  g r a p h i c a l  
m e t h o d s  a n d  s im p l e  r e g r e s s i o n  m o d e l s .
[ADDRESS_426708] i c a b l e .
11 .6 Ana lys is  o f  exp lo ra to ry v a r iab les
S t a t i s t i c a l  an a lys i s  fo r  exp lo r a to ry  v a r i a b l e s  w i l l  b e  d e s c r i b e d  i n  t h e  s t a t i s t i c a l  a n a l y si s  p l a n .
11 .6 .1 Exp lo ra to ry b ioma rke rs
11 .7 Samp le  s ize  ca lcu la t ion
T h e  s am p l e  s i z e  i s  d e t e rm i n e d  by  c a l cu l a t ion s  w i th  r e s p e c t  to  t h e  B ay e s i a n  a n a l y se s
( F i s c he ta l  2 0 1 4 )( b a s e d  o n  u n i n f o rm a t i v e  p r io r s )  o f  th e  c h a n g e  f r om  b a s e l in e  in  th ep e r c en t  
p r e d i c t e d  FVC  a f t e r  24w e e k s  o ft r e a tm en t .  W i th  15  p a t i en t s  p e r  g roup  p rov id ing  d a t a  a t  w e ek  
2 4  a n d  a s s um i n g  a  s t a n d a r d  d e v i a t i o n  o f  9%  ( J u d s o ne ta l2 0 1 4 ) ,  t h e r e  i s  app rox im a t e ly  8 0%  
p ow e r  to  m e e t  th e  e f f i c a cy  c r i t e r ion ,  i f  th e  t ru e  e f f e c t  o f  ACZ8 8 5  ov e r  p l a c ebo  i s  7% .  Co rpo ra te  Con f iden t ia l  In fo rma t ion
No va r t i s Con f iden t ia l Page  75
Amended  P ro toco l  Ve rs ion  01  (C lean ) P ro toco l  No .  CACZ885X2205
U n d e rth e  s am e  a s sump t ion  fo r  th e  s t and a rd  d ev i a t ion ,  th e r e  i s  l0%  p rob ab i l i ty  o f  m e e t ing  th e  
e f f i c a cy  c r i t e r i o n  i f  t h e  t r u e  t r e a tm e n t  d i f f e r e n c e  i s  0 %( ty p e  I  e r ro r  r a t e ) .
11 .8 Powe r  fo r  ana lys is  o f  key  seconda ry va r iab les
N o t  a p p l i c ab l e .
11 .9 In te r im  ana ly ses
12  E th ica l  cons ide ra t ions
12 .1 Regu la to ry and  e th ica l  comp l iance
Th i s  c l i n i c a l  s tudy  w a s  d e s i g n e d  and  s h a l l  b e  im p l em e n t e d ,  ex e cu t ed  a n d  r e p o r t e d  in  
a c c o r d a n c e  w i th  th e  IC H  H a rm o n i z e d  T r ip a r t i t e  G u i d e l i n e s  fo r  G o o d  C l in i c a l  P r a c t i c e ,  w i th  
a p p l i c a b l e  l o c a l  r egu l a t ion s  ( i n c l u d i n g  Eu rop e an  D i r e c t i v e  2001 /20 /EC ,  US  C o d e  o f  F e d e r a l  
R e g u l a t i o n s  T i t l e  2 1 ,  a n d  J a p a n e s e  M in i s t ry o f  H e a l t h ,  L a b o r ,  a n d  W e l f a r e ) ,  a n d  w i th  t h e  
e t h i c a l  p r i n c i p l e s  l a i d  d ow n  i n  th e  D e c l a r a t i o n  o f  H e l s i n k i .
12 .2 Respons ib i l i t ies  o f  the  inves t iga to r  and  IRB / IEC
B e f o r e  i n i t i a t i n g  a  t r i a l ,  t h e  i n v e s t i g a t o r / i n s t i t u t i o n  mu s t  o b t a i n  a p p r o v a l / f a v o r a b l e  op in ion  
f r om  t h e  I n s t i tu t ion a l  R e v i ew  B o a r d / I n d e p e n d e n t  E t h i c s  C omm i t t e e  ( I RB / IEC )  f o r  t h e  t r i a l  
p r o t o c o l ,  w r i t t e n  in fo rm ed  c o n s e n t  fo rm ,  con s en t  f o rm  upd a t e s ,  sub j e c t  r e c ru i tm en t  
p ro c edu r e s  ( e .g . ,  adv e r t i s em en t s )  and  any  o th e r  w r i t t en  in fo rm a t ion  to  b e  p rov id ed  to  sub j e c t s .  
P r i o r  to  s tudy  s t a r t ,  t h e  i n v e s t i g a t o r  i s  r e q u i r e d  to  s i g n  a  p ro to co l  s i g n a t u r e  p ag e  con f i rm ing  Co rpo ra te  Con f iden t ia l  In fo rma t ion
No va r t i s Con f iden t ia l Page  76
Amended  P ro toco l  Ve rs ion  01  (C lean ) P ro toco l  No .  CACZ885X2205
h i s / h e r  a g r e em e n t  to  c o n d u c t  t h e  s tudy  i n  a c c o r d a n c e  w i th  t h e s e  do cum en t s  a n d  a l l  o f  t h e  
i n s t r u c t i o n s  a n d  p r o c e d u r e s  found  in  th i s  p ro to co l  a n d  to  g i v e  a c c e s s  to  a l l  r e l e v a n t  d a t a  and  
r e c o r d s  t o  N o v a r t i s  m o n i t o r s ,  a u d i t o r s ,  N o v a r t i sQu a l i ty A s s u r a n c e  r e p r e s e n t a t i v e s ,  d e s i g n a t e d  
a g e n t s  o f  Nov a r t i s ,  IR B s / IEC s ,  a n d  r egu l a to ry  a u tho r i t i e s  a s  r equ i r ed .  I f  an  i n s p e c t i o n  o f  th e  
c l i n i c a l  s i t e  i s  r equ e s t ed  by  a  r egu l a to ry  a u tho r i ty ,  t h e  inv e s t ig a to r  mu s t  i n f o rm  Nov a r t i s  
imm ed i a t e ly  th a t  th i s  r e q u e s t  h a s  b e e n  m a d e .
F o r  mu l t i- c e n t e r  t r i a l s ,  a  C o o r d i n a t i n g  I n v e s t i g a t o r  w i l l  b e  s e l e c t e d  by  N o v a r t i s  a r o u n d  t h e  
t im e  o f  L a s t  P a t i e n t  L a s t  V i s i t  t o  b e  a  r e v i ew e r  a n d  s i g n a t o r yfo r  th e  c l in i c a l  s tudy  r e p o r t .
12 .3 Pub l ica t ion  o f  s tudy p ro toco l  and  resu l ts
T h e  k ey  d e s i g n  e l em en t s  o f  t h i s  p r o t o c o l  w i l l  b e  p o s t e d  in  a  pub l i c ly  a c c e s s ib l e  d a t a b a s e  su ch  
a s  c l i n i c a l t r i a l s . g o v .  I n  add i t ion ,  u p o n  s tudy  c omp l e t ion  a n d  f in a l i z a t ion  o f  t h e  s tudy  r epo r t  
t h e  r e s u l t s  o f  th i s  t r i a l  w i l l  b e  e i th e r  subm i t t ed  fo r  p u b l i c a t i o n  a n d /o r  p o s t e d  in  a  p u b l i c ly  
a c c e s s i b l e  d a t a b a s e  o f  c l i n i c a l  t r i a l  r e s u l t s .
13  P ro toco l  adhe rence
Th i s  p r o t o c o l  d e f i n e s  t h e  s tudy  o b j e c t iv e s ,  t h e  s tudy  p r o c e d u r e s  a n d  t h e  d a t a  to  b e  c o l l e c t e d  
o n  s tudy  p a r t i c i p a n t s .  Add i t ion a l  a s s e s sm e n t s  r e q u i r e d  to  e n s u r e  s a f e tyo f  s u b j e c t s  s h o u l d  b e  
a dm i n i s t e r e d  a s  d e em ed  n e c e s s a ry  o n  a  c a s e  by  c a s e  b a s i s .  U n d e r  n o  c i r c um s t a n c e s  i s  an  
i n v e s t i g a t o r  a l low ed  to  c o l l e c t  a d d i t i o n a l  d a t a  o r  c o n d u c t  a n y  a d d i t i o n a l  p r o c e d u r e s  f o r  a n y  
r e s e a r c h  r e l a t e d  p u r p o s e  i n v o l v i n g  a n y  i n v e s t i g a t i o n a l  d r u g s  u n d e r  t h e  p r o t o c o l .
I n v e s t i g a t o r s  a s c e r t a i n  th ey  w i l l  a p p l y  d u e  d i l i g e n c e  to  a v o i d  p ro to co l  d e v i a t i o n s .  I f  an  
i n v e s t i g a t o r  f e e l s  a  p ro to co l  d e v i a t i o n  w o u l d  im p r o v e  th e  condu c t  o f  t h e  s tudy  t h i s  mu s t  b e  
c o n s i d e r e d  a  p r o t o c o l  am e n dm e n t ,  a n d  u n l e s s  su ch  a n  am endm en t  i s  ag r e ed  u p o n  by  N o v a r t i s  
a n d  a p p r o v e d  b y  t h e  IRB / I EC /REB  i t  c a n n o t  b e  im p l em e n t e d .
13 .1 P ro toco l  Amendmen ts
Any c h a n g e  to  t h e  p ro to co l  c a n  on ly  b e  m ad e  in  a  w r i t t e n  p r o t o c o l  am endm en t  t h a t  mu s t  b e  
a p p r o v e d  by  N ov a r t i s ,  H e a l t h  Au tho r i t i e s  w h e r er e q u i r e d ,  and  th e  IR B / IEC  p r io r  to  
im p l em e n t a t i o n .
Am e n dm e n t s  t h a t  a r e  i n t e n d e d  to  e l im i n a t e  an  a p p a r e n t  imm e d i a t e  h a z a rd  to  s u b j e c t s  m ay b e  
im p l em e n t e d  imm ed i a t e ly ,  p rov id ed  t h e  H e a l th  A u t h o r i t i e s  a r e  sub s equ en t ly  n o t i f i ed  by  
p r o t o c o l  am e n dm e n t  a n d  t h e  r e v i ew i n g  IRB / IEC  i s  n o t i f i e d .
N o tw i t h s t a n d i n g  th e  n e ed  f o r  a p p r o v a l  o f  fo rm a l  p r o t o c o l  am endm en t s ,  t h e  i n v e s t i g a t o r  i s  
e x p e c t e d  to  t ak e  a n y  imm ed i a t e  a c t ion  r e q u i r e d  f o r  th e  s a f e ty  o f  a n y  sub j e c t  in c lud ed  in  th i s  
s tudy ,  e v e n  i f  th i s  a c t i o n  r e p r e s e n t s  a  d e v i a t i o n  f rom  t h e  p r o t o c o l .  I n  s u c h  c a s e s ,  t h e  r e p o r t i n g  
r e q u i r em e n t s  i d e n t i f i e d  i n  S e c t i o n  9(S a f e t y  Mon i to r ing )  mu s t  b e  fo l low ed  and  th e  S tudy  L e ad  
i n f o rm e d .
No va r t i s Con f iden t ia l Page  77
Amended  P ro toco l  Ve rs ion  01  (C lean ) P ro toco l  No .  CACZ885X2205
14  Re fe rences
R e f e r e n c e s  a r e  a v a i l a b l e  u p o n  r e q u e s t .
A d am s  H ,  K e i j s e r s  RG ,  K o r e n r om p  IHE ,  e t  a l  ( 2 0 1 4 )  FDG  PET  f o r  g a u g i n g  o f  s a r c o i d  
d i s e a s e  a c t iv i ty .  S em i n  R e s p i r  C r i t  C a r e  M e d ;  3 5 : 3 5 2 - 3 6 1 .
B a r t h  J ,  K r e i p e  H ,  R a d z u n  H J ,  e t  a l  ( 1 9 8 9 )  S p o n t a n e  I n t e r l e u k i n- 1 - s e k r e t i o n  a u s  
A l v e o l a rm a k r o p h a g e n  d e r  b r o n c h o a l v e o la r e n  L a v a g e  v o n  P a t i e n t e n  m i t  a k t i v e r  S a r k o i d o s e .  
Imm u n e  I n f e c k t ;  1 7 : 1 4 1 - 1 4 4 .
B a t r a  P  ( 1 9 9 3 )  R o l e  o f  h i g h- r e s o l u t i o n  CT  i n  t h e  d i a g n o s i s  a n d  e v a l u a t i o n  o f  p u lm o n a r y  
s a r c o i d o s i s .  S a r c o i d o s i s ;  1 0 : 9 5 - 9 7 .
B a u g hm a n  RP ,  D r e n t  M ,  C u l v e r  DA ,  e t  a l  ( 2 0 1 2 )  E n d p o i n t sf o r  c l i n i c a l  t r i a l s  o f  s a r c o i d o s i s .  
S a r c o i d  V a s c  D i f f  L u n g  D i s ;  2 9 : 9 0- 9 8 .
B a u g hm a n  RP ,  L ow e r  EE  ( 2 0 1 1 )  Am  J  R e s p i r  C r i t  C a r e  M e d ;  1 8 3 : 1 4 4 6- 1447 .
B a u g hm a n  RP ,  N u n e s  H  ( 2 0 1 2 )  T h e r a py  f o r  s a r c o i d o s i s :  e v i d e n c e- b a s e d  r e c omm e n d a t i o n s .  
Exp e r t  R ev  C l in  Immuno l ;  8 :95 - 1 0 3 .
B a u g hm a n  RP ,  N u n e s ,  Sw e i s s  N J ,  e t  a l( 2 0 1 3 )  E s t a b l i s h e d  a n d  e x p e r im e n t a l  m e d i c a l  t h e r a p y  
o f  pu lmon a ry  s a r c o i d o s i s .  E u r  R e s p i r  J ;  4 1 ( 6 ) : 1 4 2 4 - 3 8
B a u g hm a n  RP ,  S p a r km a n  BK ,  L ow e r  EE  ( 2 0 0 7 )  S i x -m i n u t e  w a l k  t e s t  a n d  h e a l t h  s t a t u s  
a s s e s sm e n t  i n  s a r c o i d o s i s .  Ch e s t  132 ;  207 - 2 1 3
B e s t a l l  JC ,  P a u l  EA ,  G a r r o d  R ,  e t  a l  ( 1 9 9 9 )  U s e f u l n e s s  o f  t h e  M e d i c a l  R e s e a r c h  C o u n c i l  
(MRC )  dy spn e a  s c a l e  a s  a  m e a su r e  o f  d i s ab i l i ty  i n  p a t i e n t s  w i t h  c h r o n i c  o b s t r u c t i v e  
pu lmon a ry  d i s e a s e .  Tho r ax ;  54 :581 - 5 8 6 .
B r a u n  J J ,  K e s s l e r  R ,  C o n s t a n t i n e s c o  A ,  e t  a l  ( 2 0 0 8 )  1 8F -FDG  PET /CT  i n  s a r c o i d o s i s  
m a n a g em e n t :  r e v i ew  a n d  r e p o r t  o f  2 0  c a s e s .  E u r  J  N u c  M e d  M o l  Im a g i n g ;  3 5 : 1 5 3 7- 1 5 4 3 .
B r u d i n  LH ,  V a l i n d  S- O ,  R h o d e s  CG ,  e t  a l  ( 1 9 9 4 )  F l u o r i n e- 18  d eoxy g l u c o s e  u p t a k e  i n  
s a r c o i d o s i s  m e a s u r e d  w i t h  p o s i t r o n  em i s s i o n  t om o g r a p h y .  E u r  J  N u c  M e d ;  2 1 : [ADDRESS_426709] in  A ,  Ch an e z  P ,  e t  a l  ( 2 0 1 1 )  U p d a t e  o n  t h e  r o l e s  o f  d i s t a l  a i rw a y s  in  COPD .  
E u r  R e s p i r  R e v ;  2 0 ( 1 1 9 ) : 7- 2 2 .
C a r  BD ,  M e l o n i  F ,  L u i s e t t i  M ,  e t  a l  ( 1 9 9 4 )  E l e v a t e d  IL- 8  and  MCP- 1  i n  t h e  b r o n c h o a l v e o l a r  
l a v a g e  f l u i d  o f  p a t i e n t s  w i t h  i d i o p a t h i c  p u lm o n a r y  f ib ro s i s  and  pu lmon a ry  s a r co ido s i s .  Am  J  
R e s p i r  C r i t  C a r e  M e d ;  1 4 9 : [ADDRESS_426710]  ( 2 0 1 1 )  S a r c o i d o s i s- s c i e n t i f i c  p r o g r e s s  a n d  c l i n i c a l  c h a l l e n g e s .  N a t  R e v  
R h e um a t o l ;  7 : 4 5 7- 4 6 7 .Co rpo ra te  Con f iden t ia l  In fo rma t ion
No va r t i s Con f iden t ia l Page  78
Amended  P ro toco l  Ve rs ion  01  (C lean ) P ro toco l  No .  CACZ885X2205
C h i l o s i  M ,  M e n e s t r i n a  F ,  C a p e l l i  P ,  e t  a l  (1988 )  Immunoh i s to ch em i c a l  an a ly s i s  o f  s a r c o i d  
g r a n u l om a s :  E v a l u a t i o n  o f  K i 6 7+  a n d  i n t e r l e u k i n - 1+  c e l l s .  Am  J  P a t h o l ;  1 3 1 : 1 9 1- 1 9 8 .
D e v e r g n e  O ,  Em i l i e  D ,  P e u c hm a u r  M ,  e ta l  (1992 )  P rodu c t ion  o f  cy tok in e s  in  s a r co id  ly mph  
n o d e s :p r e f e r e n t i a l  e x p r e s s i o n  o f  i n t e r l e u k i n - 1β  a n d  i n t e r f e r o n - γ  g en e s .  Hum  P a tho l ;  
2 3 : 3 1 7- 3 2 3 .
D i n a r e l l o  CA ,  S imon  A ,  v a n  d e r  M e e r  JW  ( 2 0 1 2 )  T r e a t i n g  in f l amm a t ion  by  b lo ck ing  
i n t e r l e u k i n - 1  i n  a  b r o a d  s p e c t r um  o f  d i s e a s e s . N a t  R e v  D r u g  D i s c o v;  11 :633 - 5 2 .
D r en t  M ,  D e  V r i e s  J ,  L en t e r s  M ,  e t  a l  (2003 )  S a r co ido s i s :  a s s e s sm en t  o f  d i s e a s e  s ev e r i ty  u s ing  
HRCT .  E u r  R a d i o l ;  1 3 : 2 4 6 2- 2 4 7 1 .
D r e n t  M ,  J a c o b s  JA ,  d e  V r i e s  J ,  e t  a l  ( 1 9 9 9 )  D o e s  t h e  c e l l u l a r  b r o n c h o a l v e o l a r  l a v a g e  f l u i d  
p r o f i l e  r e f l e c t  t h e  s e v e r i t y  o f  s a r co ido s i s ?  Eu r  R e sp i r  J ;  13 :[ADDRESS_426711]  ( 2 0 0 3 )  T h e  s i x-m i n u t e  w a l k  t e s t .  R e s p i r  C a r e ;  4 8 : 7 8 3- 7 8 5 .
F i sc h  R ,  Jon e s  I ,  Jon e s  J ,  e t  a l  ( 2 0 1 4 )  B ay e s i a n  D e s i g n  o f  P r o o f - o f - C o n c e p t  T r i a l s.  
T h e r a p e u t i c  I n n o v a t i o n  &  R e g u l a t o r y S c i e n c e ;  4 9 ( 1 ) :  1 5 5 - 1 6 2 .  
H e r o nH ,  S l i e k e r  WAT ,  Z a n e n  P ,  e t  a l  ( 2 0 0 8 )  E v a l u a t i o n  o f  CD 1 0 3  a s  a  c e l l u l a r  m a r k e r  f o r  
t h e  d i a g n o s i s  o f  p u lm o n a r y  s a r c o i d o s i s .  C l inIm muno l;  1 2 6 : 3 3 8- 3 4 4 .
H ind  CRK ,  La t c hm a n  YE ,  B r o s t o f f  J  ( 1 9 8 8 )  C i r c u l a t i n g  h um a n  l e u k o c y t e  e l a s t a s e  l ev e l s  in  
p a t i e n t s  w i t h  p u lmon a ry s a r c o i d o s i s .  S a r c o i d o s i s ;  5 : 3 8 - 4 2 .
H u n n i n g h a k e  GW  ( 1 9 8 4 )  R e l e a s e  o f  i n t e r l e u k i n- 1  by  a l v e o l a r  m a c r o p h a g e s  o f  p a t i e n t s  w i t h  
a c t iv e  pu lmon a ry  s a r c o i d o s i s .  Am  R e v  R e s p i r  D i s ;  1 2 9 : 5 6 9 - 5 7 2 .
ICRP  ( 2 0 0 8 )  R a d i a t i o n  d o s e  t o  p a t i e n t s  f r om  r a d i o p h a rm a c e u t i c a l s .  Add endum  to  I CRP  
pub l i c a t ion  53 .  I CRP  Pub l i c a t ion  106 .  App rov ed  by [CONTACT_3433] e  Comm i s s ion  in  O c t  2007 .  Ann  I CRP ;  
38 :1 - 1 9 7 .
Im p e r i a l e  A ,  R i e hm  S ,  B r a u n  J - J  (2013 )  I n t e r e s t  o f  [ 1 8F ]FDG  PET /CT  f o r  t r e a tm e n t  e f f i c a c y 
a s s e s sm e n t  i n  a g g r e s s i v e  p h e n o t y p e  o f  s a r co ido s i sw i t h  s p e c i a l  em p h a s i s  o n  s i n o n a s a l  
i n v o l v em e n t .  Q  J  N u c l  M e d  M o l  I m a g i n g ;  5 7 : 1 7 7-1 8 6 .
J u d s o n  MA ,  B a u g hm a n  RP ,  C o s t a b e l  U ,  e t  a l( 2 0 1 4 )  S a f e t y  a n d  e f f i c a c y  o f  u s t e k i n um a b  o r  
g o l im um a b  i n  p a t i e n t s  w i t h  c h r o n i c  s a r c o i d o s i s .  E u r  R e s p i r  J .  2 0 1 4  N o v ; 4 4 ( 5 ) : 1 2 9 6 - 3 0 7 .
K a s ah a r a  K ,  Kob aya s h i  K ,  S h i k am a  Y  ( 1 9 8 9 )  T h e  r o l e  o f  m o n o k i n e s  i n  g r a n u l om a  f o rm a t i o n  
in  m i c e :  th e  ab i l i ty  o f  i n t e r l e u k i n  1  a n d  t um o r  n e c r o s i s  f a c t o r - a  t o  i n d u c e  l u n g  g r a n u l om a s .  
C l in  Immuno l  Immunop a tho l ;  51 :419- 4 2 5 .
K e i j s e r s  RGM ,  V e r z i j l b e r g e n  JF ,  v a n  D i e p e n  DM ,  e t  a l  ( 2 0 0 8 )  1 8F-FDG  PET  i n  s a r c o i d o s i s :  
a n  o b s e r v a t i o n a l  s t u d y  i n  1 2  p a t i e n t s  t r e a t e d  w i t h  i n f l i x im a b .  S a r c o i d  V a s c  D i f f  L u n g  D i s ;  
2 5 : 1 4 3- 1 5 0 .Co rpo ra te  Con f iden t ia l  In fo rma t ion
No va r t i s Con f iden t ia l Page  79
Amended  P ro toco l  Ve rs ion  01  (C lean ) P ro toco l  No .  CACZ885X2205
Kob aya s h i  K ,  A l l r e d  C ,  C a s t r i o t t a  R ,  e t  a l  ( 1 9 8 5 )  S t r a i n  v a r i a t i o n  o f  B a c i l lu s  C a lm e t t e -
G u e r i n- indu c ed  pu lmon a ry  g r anu lom a  fo rm a t ion  i s  co r r e l a t ed  w i th  an e rgy  a n d  t h e  l o c a l  
p r o d u c t i o n  o f  m i g r a t i o n  i n h i b i t i o n  f a c t o r  a n d  i n t e r l e u k i n - 1 .  Am  J  P a t h o l ;  1 1 9 : 2 2 3- 2 3 5 .
L o z a  M J ,  B r o dm e r k e l  C ,  D u  B o i s  RM ,  e t  a l  (2011 )  I n f l amm a to ry  p r o f i l e  a n d  r e s p o n s e  t o  
a n t i - t um o r  n e c r o s i s  f a c t o r  t h e r a p y  i n  p a t i e n t s  w i t h  c h r o n i c  p u lm o n a r y  s a r co ido s i s .  C l i n  V a c  
Imm u n o l ;  1 8 : 9 3 1 - 9 3 9 .
M a c I n ty re  N ,  C r a p o  RO ,  V i e g i  G ,  e t  a l  ( 2 0 0 5 )  S e r i e s  “ATS /ERS  T a s k  F o r c e :  S t a n d a r d i z a t i o n  
o f  L u n g  F u n c t i o n  T e s t i n g ”  S t a n d a r d i s a t i on  o f  t h e  s i n g l e - b r e a t h  d e t e rm i n a t i o n  o f  c a r b o n  
m o n o x i d e  u p t a k e  i n  t h e  l u n g .  E u r  R e s p i r  J ;  2 6 : 7 2 0 - 7 3 5 .
M a h l e r  DA ,  W e l l s  CK  ( 1 9 8 8 )  E v a l u a t i o n  o f  c l i n i c a l  m e t h o d s  f o r  r a t i n g  dy sp n e a .  C h e s t ;  
9 3 : 5 8 0- 5 8 6 .
M i l l e r  MR ,  H a n k i n s o n  J ,  B r u s a s c o  V ,  e t  a l  ( 2 0 0 5 a )  S e r i e s  “ATS /ERS  T a s k  F o r c e :  
S t and a rd i z a t ion  o f  Lu n g  F u n c t i o n  T e s t i n g ”  G e n e r a l  c o n s i d e r a t i o n s  f o r  l u n g  f u n c t i o n  t e s t i n g .  
Eu r  R e sp i r  J ;  26 :153- 1 6 1 .
M i l l e r  MR ,  H a n k i n s o n  J ,  B r u s a s c o  V ,  e t  a l  ( 2 0 0 5 b )  S e r i e s  “ATS /ERS  T a s k  F o r c e :  
S t and a rd i z a t ion  o f  Lu n g  F u n c t i o n  T e s t i ng ”  S t a n d a r d i s a t i o n  o f  s p i r om e t r y .  Eu r  R e sp i r  J ;  
2 6 : 3 1 9- 3 3 8 .
M i lm a n  N ,  G r a u d a l  N ,  L o f t  A ,  e t  a l  ( 2 0 1 2 )  E f f e c t  o f  t h e  TNF - a  i n h i b i t o r  a d a l im um a b  i n  
p a t i e n t s  w i t h  r e c a l c i t r a n t  s a r c o i d o s i s :  a  p r o s p e c t i v e  o b s e r v a t i o n a l  s t u dy  u s i n g  FDG - PET .  C l in  
R e sp  J ;  6 :238- 2 4 7 .
N u n e s  H ,  U z u n h a n  Y ,  G i l l e  T ,  e t  a l  ( 2 0 1 2 )  Im a g i n g  o f  s a r c o i d o s i s  o f  t h e  a i rw a ys  a n d  l u n g  
p a r e n c hyma  a n d  c o r r e l a t i o n  w i t h  l u n g  f u n c t i o n .  Eu r  R e sp i r  J ;  40 :750- 7 6 5 .
O b e r s t e i n  A ,  v o n  Z i t z ew i t z  H ,  S c hw e d e n  F ,  e t  a l  ( 1 9 9 7 )  N o n - i n v a s i v e  e v a l u a t i o n  o f  t h e  
i n f l a mm a to ry a c t iv i ty  i n  s a r c o i d o s i s  w i t h  h i g h  r e s o l u t i o n  HRCT .  S a r c o i d  V a s c  D i f f u s e  L u n g  
D i s ;  14 :65- 7 2 .
O r s  F ,  G um u s  S ,  A yd o g a n  M ,  e t  a l  ( 2 0 1 3 )  HRCT  f i n d i n g s  o f  p u lm o n a r y  s a r c o i d o s i s ;  r e l a t i o n  t o  
p u lm o n a r y  f u n c t i o n  t e s t s .  M u l t i d i s c i p  R e s p i r  M e d ;  8 :  o p e n  a c c e s s d o i : 1 0 . 1 1 8 6 / 2 0 4 9 - 6 9 5 8 - 8 - 8 .
P a n s e l i n a s  E  a n d  J u d s o n  MA  ( 2 0 1 2 )  A c u t e  p u lm o n a r y e x a c e r b a t i o n s  o f  s a r c o i d o s i s .  C h e s t ;  
1 4 2 : 8 2 7- 8 3 6 .
P a r amo th ayan  NS ,  L a s s e r son  T J ,  W a l t e r s  EH  (2008 )  I mmuno supp r e s s iv e  and  cyto tox i c  
t h e r a p y  f o r  p u lm o n a r y  s a r c o i d o s i s  (R e v i ew ) .  C o c h r a n e  d a t a b a s e  Sy st em a t i c  R ev ;  3 :  
CD 0 0 3 5 3 6 .Co rpo ra te  Con f iden t ia l  In fo rma t ion
No va r t i s Con f iden t ia l Page  80
Amended  P ro toco l  Ve rs ion  01  (C lean ) P ro toco l  No .  CACZ885X2205
P e l l eg r ino  R ,  V i eg i  G ,  B ru s a s co  V ,  e t  a l( 2 0 0 5 )  I n t e rp r e t a t ion  s t r a t eg i e s  fo r  lung  fun c t ion  t e s t s .  
E u r  R e s p i r  J :  2 6  ( 5 ) : 9 4 8- 9 6 8 .
S h a h  DK  a n d  B e t t s  AM  ( 2 0 1 2 )  T ow a r d s  a  p l a t f o rm  PBPK  m o d e l  t o  c h a r a c t e r i z e  t h e  p l a sm a  
a n d  t i s s u e  d i s p o s i t i o n  o f  m o n o c l o n a l  a n t i b o d i e s  i n  p r e c l i n i c a l  s p e c i d s  a n d  h um a n .  J  
Ph a rm a cok in e t  Ph a rm a codyn ;  39 :67 - 8 6 .
S h a h  DK  a n dB e t t s  AM  ( 2 0 1 3 )  A n t i b o d y b i o d i s t r i b u t i o n  c o e f f i c i e n t s .  I n f e r r i n g  t i s s u e  
c o n c e n t r a t i o n s  o f  m o n o c l o n a l  a n t i b o d i e s  b a s e d  o n  t h e  p l a sm a  c o n c e n t r a t i o n s  i n  s e v e r a l  
p r e c l i n i c a l  s p e c i e s  a n d  h um a n .  mA b s ;  5 : 1 - 9 .
S c hm e k e l  B ,  H a k a n s s o n  L ,  H a l l g r e n  R ,  e t  a l  (1985 )  N eu t roph i l  ph ago cy to s i s  in  s a r co ido s i s .  
R e d u c e d  C 3 b  r e c e p t o r- m ed i a t ed  ph ago cyt o s i s  i n  a c t i v e  a n d  s i l e n t  s a r c o i d o s i s .  C l i n  E x p  
Imm u n o l ;  6 0 : 1 9 1 - 1 9 5 .
Sob i c- S a r anov i c  DP ,  G ro zd i c  IT ,  V id enov i c- I v a n o v  J ,  e t  a l  ( 2 0 1 3 )  R e s p o n s i v e n e s s  o f  FDG  
PET /CT  t o  t r e a tm e n t  o f  p a t i e n t s  w i t h  a c t i v e  c h r o n i c  s a r c o i d o s i s .  C l i n  N u c l  M e d ;  3 8 : 5 1 6- 5 2 1 .
S t e f f e n  M ,  P e t e r s e n  J ,  O l d i g s  M ,  e t  a l  ( 1 9 9 3 )  I n c r e a s e d  s e c r e t i o n  o f  t um o r  n e c r o s i s  
f a c t o r a l p h a ,  i n t e r l e u k i n - 1 - b e t a  a n d  i n t e r l e u k i n - 6  by  a lv eo l a r  m a c roph ag e s  f rom  p a t i en t s  w i th  
s a r co ido s i s .  J  A l l e rgy  C l in  I mmuno l ;  91 :939- 9 4 9 .
Sw i g r i s  J J ,  O l s o n  AL,  H u i e  T J ,  e t  a l  ( 2 0 1 1 )  S a r c o i d o s i s - r e l a t e d  m o r t a l i t y  i n  t h e  U n i t e d  S t a t e s  
f r om  1 9 8 8  t o  2 0 0 7 .  Am  J  R e s p i r  C r i t  C a r e  M e d ;  1 8 3 : 1 5 2 4 - 1 5 3 0 .
T e r a o  I ,  H a s h im o t o  S ,  H o r i e  T  ( 1 9 9 3 )  E f f e c t  o f  GM - CSF  o n  TNF- a l p h a  a n d  IL -1 - b e t a  
p rodu c t ion  by  a l v e o l a r  m a c r o p h a g e s  a n d  p e r iph e r a l  b lood  mono cy t e s  f r om  p a t i e n t s  w i t h  
s a r c o i d o s i s .  I n t  A r c h  A l l e r g y  I mmuno l ;  102 :242- 2 4 8 .
T u t o r- U r e t a  P ,  C i t o r e s  M J ,  C a s t e j o n  R ,  e t  a l  ( 2 0 0 6 )  P r o g n o s t i c  v a l u e  o f  n e u t r o p h i l s  a n d  NK  
c e l l s  i n  b r o n c h o a l v e o l a r  l a v a g e  o f  s a r c o i d o s i s .  C y tom e t ryP t  B  (C l in  Cytom e t ry ) ;  
7 0B : 4 1 6- 4 2 2 .
V o r s e l a a r s  ADM ,  C r omm e l i n  HA ,  D e n e e r  VHM ,  e t  a l  ( 2 0 1 5 )  E f f e c t i v e n e s s  o f  i n f l i x im a b  i n  
r e f r a c to ry  FDG  PET - p o s i t i v e  s a r c o i d o s i s .  Eu r  R e sp  J ;  46 :175- 8 5 .
W a n g  W ,  W a n g  EQ ,  B a l t h a s a r  JP  ( 2 0 0 8 )  M o n o c l o n a l  a n t i b o d y p h a rm a c o k i n e t i c s  a n d  
p h a rm a c o dy nam i c s .  C l i n  P h a rm a c o l  T h e r ;  8 4 : 5 4 8- 5 5 8 .
W ang e r  J ,  C l au s en  JL,  C o a t e s  A ,  e t  a l  ( 2 0 0 5 )  S e r i e s  “ATS /ERS  T a s k  F o r c e :  S t a n d a r d i s a t i o n  
o f  l u n g  f u n c t i o n  t e s t i n g ”  S t a n d a r d i s a t i o n  o f  t h e  m e a s u r em e n t  o f  l u n g  v o l um e s .  E u r  R e s p i r  J ;  
2 6 : 5 1 1- 5 2 2 .Co rpo ra te  Con f iden t ia l  In fo rma t ionCo rpo ra te  Con f iden t ia l  In fo rma t ion
Co rpo ra te  Con f iden t ia l  In fo rma t ion
No va r t i s Con f iden t ia l Page  81
Amended  P ro toco l  Ve rs ion  01  (C lean ) P ro toco l  No .  CACZ885X2205
Y am a g u c h i  E ,  O k a z a k i  N ,  T s u n e t a  Y ,  e t  a l  ( 1 9 8 8 )  I n t e r l e u k i n s  i n  p u lm o n a r y  s a r c o i d o s i s .  Am  
R e v  R e s p i r  D i s ;  1 3 8 : 6 4 5- 6 5 1 .
Z i e g e n h a g e n  MW ,  R o t h e  ME ,  S c h l a a k  M ,  e t  a l  ( 2 0 0 3 )  B r o n c h o a l v e o l a r  a n d  s e r o l o g i c a l  
p a r am e t e r s  r e f l e c t i n g  t h e  s e v e r i ty  o f  s a r c o i d o s i s .  E u r  R e s p i r  J ;  2 1 : 4 0 7 - 4 1 3 .Co rpo ra te  Con f iden t ia l  In fo rma t ion
No va r t i s Con f iden t ia l Page  82
Amended  P ro toco l  Ve rs ion  01  (C lean ) P ro toco l  No .  CACZ885X2205
15  Append ix  1 :  L ive r  Even t  de f in i t ions  and  fo l lo w -up  
requ i remen ts
Tab le  15-1  L ive r  Even t  de f in i t ions
De f in i t ion Th resho lds
Po ten t ia l  Hy ’s  law  cases ALT  o r  AST  >  3  ×  ULN  and  TBL  >  2  ×  ULN  w i thou t  in i t ia l  inc rease
in  ALP  to  >  2  ×  ULN
ALT  o r  AST  e leva t ion  w i th  
coagu lopa thy ALT  o r  AST  >  3  ×  ULN  and  INR  >  1 .5  ( in  the  absence  o f
an t icoagu la t ion )
ALT  o r  AST  e leva t ion  
accompan ied  by  [CONTACT_23805] ALT  o r  AST  >  3  ×  ULN  accompan ied  by  (gene ra l )  ma la ise ,
fa t igue ,  abdom ina l  pa in ,  nausea ,  o r  vom i t ing ,  o r  rash ,  o r
eos inoph i l ia
Iso la ted  ALT  o r  AST  e leva t ion  ALT  o r  AST  >  8  ×  ULN
 [ADDRESS_426712]  <  ALT /AST  ≤[ADDRESS_426713]
 [ADDRESS_426714]  <  ALT /AST  ≤[ADDRESS_426715]
Iso la ted  ALP  e leva t ion  ALP  >  2  ×  ULN  ( in  the  absence  o f  known  bone  pa tho logy )
O the rs Any  c l in i ca l  e v en t  o f  jaund ice  (o r  equ iva len t  te rm )
 Any  adve rse  even t  po ten t ia l ly  ind ica t ive  o f  l ive r  tox ic i ty
Tab le  15-[ADDRESS_426716] ions  requ i red  fo r  L ive r  Even ts
C r i te r ia Ac t ions  requ i red
Po ten t ia l  Hy ’s  Law  case  D iscon t inue  the  s tudy  t rea tmen t  immed ia te ly
 Hosp i ta l ize ,  i f  c l in ica l ly  app rop r ia te
 Es tab l ish  causa l i ty
 Comp le te  CRFs  pe r  l ive r  even t  gu idance
ALT  o r  AST  e leva t ion  w i th  coagu lopa thy
ALT  o r  AST  e leva t ion  accompan ied  by  
[CONTACT_343844]  o r  AST  e leva t ion  >  8  ×  ULN
Jaund ice
Iso la ted  ALT  o r  AST  e leva t ion  >  5  to  ≤  8  
×  ULN I f  con f i rmed ,  cons ide r  in te r rup t ion  o r  d iscon t inua t ion
o f  s tudy  d rug
 I f  e leva t ion  pe rs is ts  fo r  mo re  than  2  weeks ,
d iscon t inue  the  s tudy  d rug
 Es tab l ish  causa l ity
 Comp le te  CRFs  pe r  l ive r  even t  gu idance
Iso la tedALT  o r  AST  e leva t ion  >  3  to  
≤5×  ULN  (pa t ien t  is  asymptoma t ic ) Mon i to r  l ive r  chem is t ry  tes ts  two  o r  th ree  t imes  week ly
No va r t i s Con f iden t ia l Page  83
Amended  P ro toco l  Ve rs ion  01  (C lean ) P ro toco l  No .  CACZ885X2205
C r i te r ia Ac t ions  requ i red
Iso la ted  ALP  e leva t ion  Repea t  l ive r  chem is t ry tes ts  w i th in  48 - 72  hou rs
 I f  e leva t ionis  con f i rmed ,  measu re  f rac t iona ted  ALP ;  i f
>50%  is  o f  l ive r  o r ig in ,  es tab l ish  hepa t ic  causa l i ty
 Comp le te  CRFs  pe r  l ive r  even t  gu idance
Any  AE  po ten t ia l ly  ind ica t ive  o f  l ive r  
tox ic i ty Cons ide r  s tudy  t rea tmen t  in te r rup t ion  o r
d iscon t inua t ion
 Ho sp i ta l i ze  i fc l in ica l ly  app rop r ia te
 Comp le te  CRFs  pe r  l ive r  even t  gu idance
Tab le  15-3  Exc lus ion  o f  unde r lying  l ive r  d isease
D isease Assessmen t
Hepa t i t is  A ,  B ,  C ,  E  IgM  an t i - HAV ;  HBSAg ,  IgM  an t i- HBc ,  HBV  DNA ;  an t i- HCV ,  HCV  RNA ,
IgM  &  IgG  an t i - HEV ,  HEV  RNA
CMV ,  HSV ,  EBV  
in fe c t ion IgM  &  IgG  an t i - CMV ,  IgM  &  IgG  an t i- HSV ;  IgM  &  IgG  an t i- EBV
Au to immune  hepa t i t is  ANA  &  ASMA  t i te rs ,  to ta l  IgM ,  IgG ,  IgE ,  IgA
A lcoho l ic  hepa t i t is  E thano l  h is to ry ,  gGT ,  MCV ,  CD- t rans fe r r in
Nona lcoho l ic  
s tea tohepa t i t is U l t rasound  o r  MR I
Hypox ic / ischem ic  
hepa topa thy Med ica l  h is to ry :  acu te  o r  ch ron ic  CHF ,  hypo tens ion ,  hypox ia ,  hepa t ic
venous  occ lus ion .  U l t rasound  o r  MR I .
B i l ia ry  t ra c t  d i sea se  U l t rasound  o r  MR I ,  ERCP  as  app rop r ia te .
W il son  d i sea se  Cae ru lop lasm in
Hemoch roma tos is  Fe r r i t in ,  t rans fe r r in
A lpha-1 - an t i t ryp s in  
de f i c ien cy A lpha-1 - an t i t ryp s in
No va r t i s Con f iden t ia l Page  84
Amended  P ro toco l  Ve rs ion  01  (C lean ) P ro toco l  No .  CACZ885X2205
16  Append ix  2 :  Spec i f ic  Rena l  a le r t  c r i te r ia  and  ac t ions
Tab le  16-1  Spec i f ic  Rena l  a le r t  c r i te r ia  and  ac t ions
C r i te r ia Ac t ion  requ i red
Se rum  c rea t in ine  (sC r )  inc rease
25  –49%  compa red  to  base l ine Cons ide r  causes  and  poss ib le  in te rven t ions
 Fo l low  up  w i th in  2- 5  days
Se rum  c rea t in ine  inc rease  >50%  Cons ide r  causes  and  poss ib le  in te rven t ions
 Repea t  assessmen t  w i th in  24- 48h  i f  poss ib le
 Cons ide r  d rug  in te r rup t ion  o r  d iscon t inua t ion  
un less  o the r  causes  a re  d iagnosed  and  
co r rec ted
 Cons ide r  hosp i ta l iza t ion  and  spec ia l ized  
t r ea tmen t
P ro te in- c rea t in ine  o r  a lbum in- c rea t in ine  ra t io  
in c rea se  ≥  2- fo ld
o r
new  onse t  d ips t ick  p ro te inu r ia  ≥  1+
o r
A lbum in- c rea t in ine  ra t io  (ACR )  ≥  30  mg /g  o r  ≥  
3  mg /mmo l ;
o r
P ro te in- c rea t in ine  ra t io  (PCR  )≥  150  mg /g  o r  
>15  mg /mmo l Cons ide r  causes  and  poss ib le  in te rven t ions
 Assess  se rum  a lbum in  &  se rum  p ro te in
 Repea t  assessmen t  to  con f i rm
 Cons ide r  d rug  in te r rup t ion  o r  d iscon t inua t ion  
un less  o the r  causes  a re  d iagnosed  and  
co r rec ted
New  onse t  g lucosu r ia  on  u r ine  d ips t ick  (un less  
re la ted  to  concom i tan t  t r ea tmen t ,  d iabe tes )Assess  &  documen t :
 B lood  g lucose  ( fas t ing )
 Se rum  c rea t in ine
 U r ine  a lbum in- c rea t in ine  ra t io
New  hema tu r ia  on  d ips t ickAssess  &  documen t:
 U r ine  sed imen t  m ic roscopy
 Assess  sC r  and  u r ine  a lbum in- c rea t in ine  ra t io
 Exc lude  in fec t ion ,  t rauma ,  b leed ing  f rom  the  
d is ta l  u r ina ry  t rac t /b ladde r ,  mens t rua t ion
 Cons ide r  b leed ing  d iso rde r
A d d i t i o n a l  s p e c i a l i z e d  a s s e s sm e n t s  a r e  av a i l ab l e  to  a s s e s s  r e n a l  fun c t ion  o r  r e n a l  p a tho logy .  
(N o t e :  I n  e x c e p t i o n a l  c a s e s  w h e n  a  n eph ro log i s t  c o n s i d e r s  a  r e n a l  b iop sy ,i t  i s  s t r o n g l y  
r e c omm e n d e d  to  m a k e  s p e c im e n  s l i d e s  a v a i l a b l e  f o r  e v a l u a t i o n  by  N ov a r t i s  to  p o t e n t i a l ly  
id en t i fy  p r o j e c t - w id e  p a t t e rn s  o f  n eph ro tox i c i ty. )
No va r t i s Con f iden t ia l Page  85
Amended  P ro toco l  Ve rs ion  01  (C lean ) P ro toco l  No .  CACZ885X2205
W h e n e v e r  a  r e n a l  ev en t  i s  i d e n t i f i e d ,  a  d e t a i l e d  sub j e c t  h i s to ry  a n d  ex am in a t ion  a r e  ind i c a t ed  
to  id e n t i fy ,  d o c um e n t  a n d  p o t e n t i a l ly  e l im in a t e  r i s k  f a c t o r s  th a t  m ay  h a v e  in i t i a t ed  o r  
c o n t r i b u t e d  t o  t h e  e v e n t :
B l o o d  p r e s s u r e  a s s e s sm e n t  ( a f t e r  5  m i n  r e s t ,  w i t h  a n  a p p r o p r i a t e  c u f f  s i z e )
S i g n s  a n d  symp t om s  s u c h  a s  f e v e r ,  h e a d a c h e ,  s h o r t n e s s  o f  b r e a t h ,  b a c k  o ra b d om i n a l  p a i n ,
dy s u r i a ,  h em a t u r i a ,  d e p e n d e n t  o r  p e r i o r b i t a l  e d em a
C h a n g e s  i n  b l o o d  p r e s s u r e ,  b o d y w e i g h t ,  f l u i d  i n t a k e ,  v o i d i n g  p a t t e r n ,  o r  u r i n e  o u t p u t
C o n c om i t a n t  e v e n t s  o r  p r o c e d u r e s  s u c h  a s  t r a um a ,  s u r g i c a l  p r o c e d u r e s ,  c a r d i a c  o r  h e p a t i c
f a i l u r e ,  c o n t r a s t  m e d i a  o r  o t h e r  k n ow n  n e p h r o t o x i n  a dm i n i s t r a t i o n ,  o r  o t h e r  p o t e n t i a l
c a u s e s  o f  r e n a l  d y sfun c t ion ,  e .g . ,  d ehy d r a t i o n ,  h em o r r h a g e ,  t um o r  ly si s
Tab le  16-2  Fo l low -up  o f  rena l  even ts
Ac t ion Fo l low  up
Assess* ,  documen t  and  reco rd  in  the  Case  Repo r t  
Fo rm (CRF )  o r  v ia  e lec t ron ic  da ta  load .  Rev iew  and  
reco rd  poss ib le  con t r ibu t ing  fac to rs  to  the  rena l  even t  
(co - med ica t ions ,  o the r  co- morb id  cond i t ion s )  and  
add i t iona l  d iagnos t icp rocedu res  (MR I  e tc )  in  the  
CRF . U r ine  d ips t ick  and  sed imen t  m ic roscopy
 B lood  p ressu re  and  body  we igh t
 Se rum  c rea t in ine ,  e lec t ro ly tes  (sod ium ,
po tass ium ,  phospha te ,  ca lc ium ) ,
b ica rbona te  and  u r ic  ac id
 U r ine  ou tpu t
Mon i to r  sub jec t  regu la r ly  ( f requency  a t  inves t iga to r ’s  
d isc re t ion )  un t i l : Even t  reso lu t ion :  (sC r  w i th in  10%  o f
base l ine  o r  p ro te in- c rea t in ine  ra t io  w i th in
50%  o f  base l ine )
o r
 Even t  s tab i l iza t ion :  sC r  leve l  w i th  ±10%
va r iab i l i ty  ove r  las t  6  mon ths  o r  p ro te in -
c rea t in ine  ra t io  s tab i l iza t ion  a t  a  new  leve l
w i th  ±50%  va r iab i l i ty  ove r  las t  6  mon ths .
* U r ine  osmo la l i ty :  in  the  absence  o f  d iu re t ics  o r  ch ron ic  k idney  d isease  th is  can  be  a  ve ry  sens i t ive
met r ic  fo r  in teg ra ted  k idney  func t ion  tha t  requ i res  exce l len t  tubu la r  func t ion .  A  h igh  u r ina r y  o smo lal i t y
in  the  se t t ing  o f  an  inc rease  in  sC r  w i l l  po in t  towa rd  a  “p re - rena l ”  cause  ra the r  than  tubu la r  tox ic i ty .